IDEAS home Printed from https://ideas.repec.org/f/c/psc810.html
   My authors  Follow this author

Mark Sculpher

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.

    Mentioned in:

    1. Opportunity costs, marginal productivity, and cost-effectiveness thresholds: what are they and how are they related?
      by Rita Faria, Jessica Ochalek, jameslomas88 in The Academic Health Economists' Blog on 2020-09-23 06:00:00
  2. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.

    Mentioned in:

    1. Sofosbuvir: a fork in the road for NICE?
      by Chris Sampson in The Academic Health Economists' Blog on 2015-01-20 17:21:00
    2. Chris Sampson’s journal round-up for 22nd May 2017
      by Chris Sampson in The Academic Health Economists' Blog on 2017-05-22 16:00:45
    3. Rita Faria’s journal round-up for 18th June 2018
      by Rita Faria in The Academic Health Economists' Blog on 2018-06-18 11:00:47
  3. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.

    Mentioned in:

    1. Opportunity costs, marginal productivity, and cost-effectiveness thresholds: what are they and how are they related?
      by Rita Faria, Jessica Ochalek, jameslomas88 in The Academic Health Economists' Blog on 2020-09-23 06:00:00
  4. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.

    Mentioned in:

    1. Sam Watson’s journal round-up for 4th April 2016
      by Sam Watson in The Academic Health Economists' Blog on 2016-04-04 16:00:24
  5. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost‐effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787, December.

    Mentioned in:

    1. How to explain cost-effectiveness models for diagnostic tests to a lay audience
      by Rita Faria in The Academic Health Economists' Blog on 2019-06-12 06:00:28

RePEc Biblio mentions

As found on the RePEc Biblio, the curated bibliography of Economics:
  1. Elizabeth Fenwick & Karl Claxton & Mark Sculpher & Andrew Briggs, 2000. "Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling," Working Papers 179chedp, Centre for Health Economics, University of York.

    Mentioned in:

    1. > Economic Development Technological Change, and Growth > Technological Change: Choices and Consequences > Technology Assessment > Health Technology Assessment

Working papers

  1. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Caitlin M. Walsh & Takondwa Mwase & Manuela De Allegri, 2020. "How actors, processes, context and evidence influenced the development of Malawi's Health Sector Strategic Plan II," International Journal of Health Planning and Management, Wiley Blackwell, vol. 35(6), pages 1571-1592, November.
    2. Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong, 2018. "Cost-Effectiveness Thresholds: the Past, the Present and the Future," PharmacoEconomics, Springer, vol. 36(5), pages 509-522, May.
    3. Gesine Meyer-Rath & Craig van Rensburg & Bruce Larson & Lise Jamieson & Sydney Rosen, 2017. "Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-9, October.

  2. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Beth Woods & Claire Rothery & Paul Revill & Timothy Hallett & Andrew Phillips & Karl Claxton., 2018. "Setting research priorities in Global Health:Appraising the value of evidence generation activities to support decision-making in health care," Working Papers 155cherp, Centre for Health Economics, University of York.
    2. Dominic Byrne & Do Won Kwak & Kam Ki Tang & Myra Yazbeck, 2020. "Spillover Effects of Retirement: does health vulnerability matter?," Discussion Papers Series 620, School of Economics, University of Queensland, Australia.
    3. Niek Stadhouders & Xander Koolman & Christel van Dijk & Patrick Jeurissen & Eddy Adang, 2019. "The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function," Health Economics, John Wiley & Sons, Ltd., vol. 28(11), pages 1331-1344, November.
    4. Jan-Walter De Neve & Rija L Andriantavison & Kevin Croke & Johannes Krisam & Voahirana H Rajoela & Rary A Rakotoarivony & Valérie Rambeloson & Linda Schultz & Jumana Qamruddin & Stéphane Verguet, 2018. "Health, financial, and education gains of investing in preventive chemotherapy for schistosomiasis, soil-transmitted helminthiases, and lymphatic filariasis in Madagascar: A modeling study," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 12(12), pages 1-17, December.
    5. Anthony J Culyer, 2015. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Working Papers 121cherp, Centre for Health Economics, University of York.
    6. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
    7. Laia Cirera & Beatriz Galatas & Sergi Alonso & Krijn Paaijmans & Miler Mamuquele & Helena Martí-Soler & Caterina Guinovart & Humberto Munguambe & Fabião Luis & Hoticha Nhantumbo & Júlia Montañà & Quiq, 2020. "Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-17, July.
    8. Aidan Hollis, 2016. "Sustainable Financing of Innovative Therapies: A Review of Approaches," PharmacoEconomics, Springer, vol. 34(10), pages 971-980, October.
    9. Charles E Okafor & Obinna I Ekwunife, 2017. "Cost-effectiveness analysis of diarrhoea management approaches in Nigeria: A decision analytical model," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 11(12), pages 1-14, December.
    10. Yared Belete Belay & Eskinder Eshetu Ali & Karen Y. Chung & Gebremedhin Beedemariam Gebretekle & Beate Sander, 2021. "Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia," PharmacoEconomics - Open, Springer, vol. 5(4), pages 655-664, December.
    11. Maciel, Roberto Rodrigues Bandeira Tosta & Chiavegato, Luciana Dias & Marin, Luz Stella & Portella, Daniel Deivson Alves & de Souza, Marcio Costa & Camelier, Fernanda Warken Rosa & Padula, Rosimeire S, 2019. "Development of an e-health education program at the workplace using formative research – Technologies for improving quality of life," Evaluation and Program Planning, Elsevier, vol. 73(C), pages 129-137.
    12. William V. Padula & Hui-Han Chen & Charles E. Phelps, 2021. "Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 19(2), pages 155-162, March.
    13. Elisabeth PAUL & Fabienne FECHER & Céline DEVILLE & Youssoupha NDIAYE & Farba Lamine SALL & N’koué EmmanuelSAMBIÉNI & Remo MELONI & Denis PORIGNON, 2020. "Long Way to Universal Health Coverage (UHC): Are Policy Dialogue Processes Appropriate to Negotiate Trade-Offs in Africa? The Cases of Benin and Senegal," CIRIEC Working Papers 2005, CIRIEC - Université de Liège.
    14. Krishna P. Reddy & Kieran P. Fitzmaurice & Justine A. Scott & Guy Harling & Richard J. Lessells & Christopher Panella & Fatma M. Shebl & Kenneth A. Freedberg & Mark J. Siedner, 2021. "Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    15. Amani Thomas Mori & Ole Frithjof Norheim & Bjarne Robberstad, 2016. "Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania," PharmacoEconomics, Springer, vol. 34(3), pages 303-314, March.
    16. Amani Mori & Ole Norheim & Bjarne Robberstad, 2016. "Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania," PharmacoEconomics, Springer, vol. 34(3), pages 303-314, March.
    17. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
    18. Anuj Tiwari & David J Blok & Mohammad Arif & Jan Hendrik Richardus, 2020. "Leprosy post-exposure prophylaxis in the Indian health system: A cost-effectiveness analysis," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 14(8), pages 1-12, August.
    19. Morton, Alec & Arulselvan, Ashwin & Thomas, Ranjeeta, 2018. "Allocation rules for global donors," Journal of Health Economics, Elsevier, vol. 58(C), pages 67-75.
    20. Torbjørn Wisløff & Richard White & Olav Dalgard & Ellen J. Amundsen & Hinta Meijerink & Astrid Louise Løvlie & Hilde Kløvstad, 2018. "Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway," PharmacoEconomics, Springer, vol. 36(5), pages 591-601, May.
    21. Max J. Korman & Kjetil Retterstøl & Ivar Sønbø Kristiansen & Torbjørn Wisløff, 2018. "Are PCSK9 Inhibitors Cost Effective?," PharmacoEconomics, Springer, vol. 36(9), pages 1031-1041, September.
    22. Eda Ustaoglu & Brendan Williams, 2020. "Cost-Benefit Evaluation Tools on the Impacts of Transport Infrastructure Projects on Urban Form and Development," Chapters, in: Vito Bobek (ed.), Smart Urban Development, IntechOpen.
    23. Charles Ebuka Okafor, 2021. "Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications," PharmacoEconomics - Open, Springer, vol. 5(3), pages 545-557, September.
    24. Anita J. Brogan & Sandra E. Talbird & Ashley E. Davis & Elizabeth M. La & Princy N. Kumar, 2021. "The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States," PharmacoEconomics, Springer, vol. 39(4), pages 421-432, April.
    25. Halimatou Diawara & Patrick Walker & Matt Cairns & Laura C Steinhardt & Fatou Diawara & Beh Kamate & Laetitia Duval & Elisa Sicuri & Issaka Sagara & Aboubacar Sadou & Jules Mihigo & Erin Eckert & Alas, 2021. "Cost-effectiveness of district-wide seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali using fixed point distribution," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers) hal-03184961, HAL.
    26. Laura Catherine Edney & Hossein Haji Ali Afzali & Terence Chai Cheng & Jonathan Karnon, 2018. "Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System," PharmacoEconomics, Springer, vol. 36(2), pages 239-252, February.
    27. Jessica Ochalek & Haiyin Wang & Yuanyuan Gu & James Lomas & Henry Cutler & Chunlin Jin, 2020. "Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach," PharmacoEconomics, Springer, vol. 38(12), pages 1319-1331, December.
    28. James O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
    29. Caitlin M Dugdale & Tamsin K Phillips & Landon Myer & Emily P Hyle & Kirsty Brittain & Kenneth A Freedberg & Lucy Cunnama & Rochelle P Walensky & Allison Zerbe & Milton C Weinstein & Elaine J Abrams &, 2019. "Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-18, November.
    30. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
    31. Markiewicz Olimpia, 2021. "Value of Life Year and Cost-Effectiveness Thresholds: The Case of Poland," Central European Economic Journal, Sciendo, vol. 8(55), pages 256-268, January.
    32. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
    33. Samuel N. Frempong & Andrew J. Sutton & Clare Davenport & Pelham Barton, 2020. "Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana," PharmacoEconomics - Open, Springer, vol. 4(1), pages 143-157, March.
    34. Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for timing when assessing health-related policies," LSE Research Online Documents on Economics 100408, London School of Economics and Political Science, LSE Library.
    35. Sebastian Himmler & Jannis Stöckel & Job van Exel & Werner Brouwer, 2020. "The Value of Health - Empirical Issues when Estimating the Monetary Value of a QALY Based on Well-Being," SOEPpapers on Multidisciplinary Panel Data Research 1101, DIW Berlin, The German Socio-Economic Panel (SOEP).
    36. Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong, 2018. "Cost-Effectiveness Thresholds: the Past, the Present and the Future," PharmacoEconomics, Springer, vol. 36(5), pages 509-522, May.
    37. Marwân-Al-Qays Bousmah & Marie Libérée Nishimwe & Tamara Tovar-Sanchez & Martial Lantche Wandji & Mireille Mpoudi-Etame & Gwenaëlle Maradan & Pierrette Omgba Bassega & Marie Varloteaux & Alice Montoyo, 2021. "Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)," Post-Print hal-03174666, HAL.
    38. Morton, Alec & Arulselvan, Ashwin & Thomas, Ranjeeta, 2018. "Allocation rules for global donors," LSE Research Online Documents on Economics 101210, London School of Economics and Political Science, LSE Library.
    39. Pieter van Baal & Meg Perry‐Duxbury & Pieter Bakx & Matthijs Versteegh & Eddy van Doorslaer & Werner Brouwer, 2019. "A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 87-100, January.
    40. Philippe Grandjean & Martine Bellanger, 2017. "Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation," Post-Print hal-02464775, HAL.

  3. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Ryota Nakamura & James Lomas & Karl Claxton & Farasat Bokhari & Rodrigo Moreno Serra & Marc Suhrcke, 2016. "Assessing the impact of health care expenditures on mortality using cross-country data," Working Papers 128cherp, Centre for Health Economics, University of York.
    2. Tom L. Drake & Angela Devine & Shunmay Yeung & Nicholas P. J. Day & Lisa J. White & Yoel Lubell, 2016. "Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low‐ and Middle‐Income Countries: A Systematic Literature Review," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 124-139, February.
    3. Anthony J Culyer, 2015. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Working Papers 121cherp, Centre for Health Economics, University of York.
    4. Anthony J Culyer, 2015. "Efficiency, equity and equality in health and health care," Working Papers 120cherp, Centre for Health Economics, University of York.
    5. Jessica Ochalek & James Lomas & Karl Claxton, 2015. "Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data," Working Papers 122cherp, Centre for Health Economics, University of York.
    6. Matthew Franklin & Colin Angus & Tobias Welte & Guy Joos, 2023. "How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts," Applied Health Economics and Health Policy, Springer, vol. 21(4), pages 547-558, July.
    7. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
    8. Mujaheed Shaikh & Afschin Gandjour, 2019. "Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two‐step instrumental variables strategy," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 101-122, January.
    9. Jessica Ochalek & Miqdad Asaria & Pei Fen Chuar & James Lomas & Sumit Mazumdar & Karl Claxton, 2019. "Assessing health opportunity costs for the Indian health care systems," Working Papers 161cherp, Centre for Health Economics, University of York.
    10. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.

  4. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Mike Paulden & Christopher McCabe & Jonathan Karnon, 2014. "Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?," PharmacoEconomics, Springer, vol. 32(4), pages 315-318, April.
    2. Andrew J. Mirelman & Miqdad Asaria & Bryony Dawkins & Susan Griffin & Richard Cookson & Peter Berman, 2020. "Fairer Decisions, Better Health for All: Health Equity and Cost-Effectiveness Analysis," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 4, pages 99-132, World Scientific Publishing Co. Pte. Ltd..
    3. Eldon Spackman & Stewart Richmond & Mark Sculpher & Martin Bland & Stephen Brealey & Rhian Gabe & Ann Hopton & Ada Keding & Harriet Lansdown & Sara Perren & David Torgerson & Ian Watt & Hugh MacPherso, 2014. "Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-12, November.
    4. Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex, 2013. "Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold," Occasional Paper 000106, Office of Health Economics.
    5. Ulrikke J. V. Hernæs & Kjell A. Johansson & Trygve Ottersen & Ole F. Norheim, 2017. "Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss," PharmacoEconomics, Springer, vol. 35(9), pages 965-974, September.
    6. A. Newall & M. Jit & R. Hutubessy, 2014. "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines," PharmacoEconomics, Springer, vol. 32(6), pages 525-531, June.
    7. Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards, 2017. "Scoping review on social care economic evaluation methods," Working Papers 150cherp, Centre for Health Economics, University of York.
    8. Pieter van Baal & David Meltzer & Werner Brouwer, 2016. "Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost‐Effectiveness Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 237-248, February.
    9. Charles E Phelps & Chris Cinatl, 2021. "Estimating optimal willingness to pay thresholds for cost‐effectiveness analysis: A generalized method," Health Economics, John Wiley & Sons, Ltd., vol. 30(7), pages 1697-1702, July.
    10. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
    11. Hareth Al-Janabi & Job van Exel & Werner Brouwer & Joanna Coast, 2016. "A Framework for Including Family Health Spillovers in Economic Evaluation," Medical Decision Making, , vol. 36(2), pages 176-186, February.
    12. Linda Ryen & Mikael Svensson, 2015. "The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1289-1301, October.
    13. J. Jaime Caro & John E. Brazier & Jonathan Karnon & Peter Kolominsky-Rabas & Alistair J. McGuire & Erik Nord & Michael Schlander, 2019. "Determining Value in Health Technology Assessment: Stay the Course or Tack Away?," PharmacoEconomics, Springer, vol. 37(3), pages 293-299, March.
    14. Simon Eckermann & Brita Pekarsky, 2014. "Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room," PharmacoEconomics, Springer, vol. 32(4), pages 319-325, April.
    15. Sebastian Hinde & Eldon Spackman, 2015. "Bidirectional Citation Searching to Completion: An Exploration of Literature Searching Methods," PharmacoEconomics, Springer, vol. 33(1), pages 5-11, January.
    16. Iftekhar Khan & Mandy Maredza & Melina Dritsaki & Dipesh Mistry & Ranjit Lall & Sarah E. Lamb & Keith Couper & Simon Gates & Gavin D. Perkins & Stavros Petrou, 2020. "Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study," PharmacoEconomics - Open, Springer, vol. 4(4), pages 697-710, December.
    17. Alan Haycox, 2016. "Why Cancer?," PharmacoEconomics, Springer, vol. 34(7), pages 625-627, July.
    18. Mark Sculpher & Stephen Palmer, 2020. "After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?," PharmacoEconomics, Springer, vol. 38(3), pages 247-257, March.
    19. Ken Willis & Bob Crabtree & Liesl M. Osman & Kirsty Cathrine, 2016. "Green space and health benefits: a QALY and CEA of a mental health programme," Journal of Environmental Economics and Policy, Taylor & Francis Journals, vol. 5(2), pages 163-180, July.
    20. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
    21. Kinghorn, Philip & Afentou, Nafsika, 2021. "Eliciting a monetary threshold for a year of sufficient capability to inform resource allocation decisions in public health and social care," Social Science & Medicine, Elsevier, vol. 279(C).
    22. Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe, 2014. "Some Inconsistencies in NICE’s Consideration of Social Values," PharmacoEconomics, Springer, vol. 32(11), pages 1043-1053, November.
    23. J. Raftery, 2014. "NICE’s Cost-Effectiveness Range: Should it be Lowered?," PharmacoEconomics, Springer, vol. 32(7), pages 613-615, July.
    24. Stephen Martin & James Lomas & Karl Claxton & Francesco Longo, 2021. "How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 885-903, November.
    25. John Brazier & Aki Tsuchiya, 2015. "Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 557-565, December.
    26. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.
    27. Torbjørn Wisløff & Gunhild Hagen & Vida Hamidi & Espen Movik & Marianne Klemp & Jan Olsen, 2014. "Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010," PharmacoEconomics, Springer, vol. 32(4), pages 367-375, April.
    28. Alec Morton & Amanda I. Adler & David Bell & Andrew Briggs & Werner Brouwer & Karl Claxton & Neil Craig & Alastair Fischer & Peter McGregor & Pieter van Baal, 2016. "Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 933-938, August.
    29. Ryen, Linda & Svensson, Mikael, 2014. "The Willingness to Pay for a QALY: a Review of the Empirical Literature," Karlstad University Working Papers in Economics 12, Karlstad University, Department of Economics.
    30. Jessica Ochalek & Haiyin Wang & Yuanyuan Gu & James Lomas & Henry Cutler & Chunlin Jin, 2020. "Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach," PharmacoEconomics, Springer, vol. 38(12), pages 1319-1331, December.
    31. Wildman, John & McMeekin, Peter & Grieve, Eleanor & Briggs, Andrew, 2016. "Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators," Social Science & Medicine, Elsevier, vol. 169(C), pages 141-148.
    32. Doug Coyle & Matthew C. Cheung & Gerald A. Evans, 2014. "Opportunity Cost of Funding Drugs for Rare Diseases," Medical Decision Making, , vol. 34(8), pages 1016-1029, November.
    33. Asaria, Miqdad & Griffin, Susan & Cookson, Richard, 2016. "Distributional cost-effectiveness analysis: a tutorial," LSE Research Online Documents on Economics 101271, London School of Economics and Political Science, LSE Library.
    34. James F. O’Mahony & Mike Paulden & Chris McCabe, 2021. "NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests," PharmacoEconomics, Springer, vol. 39(2), pages 139-146, February.
    35. Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin, 2017. "A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 469-477, August.
    36. Mike Paulden & Christopher McCabe, 2021. "Modifying NICE’s Approach to Equity Weighting," PharmacoEconomics, Springer, vol. 39(2), pages 147-160, February.
    37. Mark Sculpher, 2013. "Methods Development for Health Technology Assessment," Medical Decision Making, , vol. 33(3), pages 313-315, April.
    38. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
    39. Bevan, Gwyn & Brown, Lawrence D., 2014. "The political economy of rationing health care in England and the US: the ‘accidental logics’ of political settlements," LSE Research Online Documents on Economics 57129, London School of Economics and Political Science, LSE Library.
    40. Miqdad Asaria & Susan Griffin & Richard Cookson, 2016. "Distributional Cost-Effectiveness Analysis," Medical Decision Making, , vol. 36(1), pages 8-19, January.
    41. Donna Rowen & John Brazier & Clara Mukuria & Anju Keetharuth & Arne Risa Hole & Aki Tsuchiya & Sophie Whyte & Phil Shackley, 2016. "Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life," Medical Decision Making, , vol. 36(2), pages 210-222, February.
    42. B. Rodríguez-Sánchez & L. M. Peña-Longobardo & A. J. Sinclair, 2020. "Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 335-349, April.
    43. Mike Paulden & Tania Stafinski & Devidas Menon & Christopher McCabe, 2015. "Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework," PharmacoEconomics, Springer, vol. 33(3), pages 255-269, March.
    44. Drew Carter & Arlene Vogan & Hossein Haji Ali Afzali, 2016. "Governments Need Better Guidance to Maximise Value for Money: The Case of Australia’s Pharmaceutical Benefits Advisory Committee," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 401-407, August.
    45. Pieter van Baal & Meg Perry‐Duxbury & Pieter Bakx & Matthijs Versteegh & Eddy van Doorslaer & Werner Brouwer, 2019. "A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 87-100, January.
    46. Karlsberg Schaffer, Sarah & Sussex, Jon & Devlin, Nancy & Walker, Andrew, 2015. "Local health care expenditure plans and their opportunity costs," Health Policy, Elsevier, vol. 119(9), pages 1237-1244.
    47. Brick, Aoife & Gorecki, Paul K. & Nolan, Anne, 2013. "Ireland: Pharmaceutical Prices, Prescribing Practices and Usage of Generics in a Comparative Context," Research Series, Economic and Social Research Institute (ESRI), number RS32.
    48. Luigi Siciliani & James Gaughan & Nils Gutacker & Hugh Gravelle & Martin Chalkley, 2021. "Paying for health gains," Working Papers 183cherp, Centre for Health Economics, University of York.
    49. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.

  5. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Sabine E. Grimm & Debra Fayter & Bram L. T. Ramaekers & Svenja Petersohn & Rob Riemsma & Nigel Armstrong & Xavier Pouwels & Willem Witlox & Caro Noake & Gillian Worthy & Jos Kleijnen & Manuela A. Joor, 2019. "Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 37(10), pages 1195-1207, October.
    2. Petrou, Panagiotis & Vandoros, Sotiris, 2015. "Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment," Health Policy, Elsevier, vol. 119(5), pages 563-568.
    3. Löblová, Olga & Csanádi, Marcell & Ozierański, Piotr & Kaló, Zoltán & King, Lawrence & McKee, Martin, 2019. "Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology," Health Policy, Elsevier, vol. 123(7), pages 630-634.
    4. Christopher McCabe & Mike Paulden & Isaac Awotwe & Andrew Sutton & Peter Hall, 2020. "One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit," PharmacoEconomics, Springer, vol. 38(2), pages 135-141, February.
    5. Claire Rothery & Karl Claxton & Stephen Palmer & David Epstein & Rosanna Tarricone & Mark Sculpher, 2017. "Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs," Health Economics, John Wiley & Sons, Ltd., vol. 26(S1), pages 109-123, February.
    6. Michael Drummond & Carlo Federici & Vivian Reckers‐Droog & Aleksandra Torbica & Carl Rudolf Blankart & Oriana Ciani & Zoltán Kaló & Sándor Kovács & Werner Brouwer, 2022. "Coverage with evidence development for medical devices in Europe: Can practice meet theory?," Health Economics, John Wiley & Sons, Ltd., vol. 31(S1), pages 179-194, September.
    7. Seung-Lai Yoo & Dae-Jung Kim & Seung-Mi Lee & Won-Gu Kang & Sang-Yoon Kim & Jong Hyuk Lee & Dong-Churl Suh, 2019. "Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System," IJERPH, MDPI, vol. 16(2), pages 1-15, January.
    8. Sabine E. Grimm & Simon Dixon & John W. Stevens, 2017. "Assessing the Expected Value of Research Studies in Reducing Uncertainty and Improving Implementation Dynamics," Medical Decision Making, , vol. 37(5), pages 523-533, July.
    9. Paula K. Lorgelly & Amanda Adler, 2020. "Impact of a Global Pandemic on Health Technology Assessment," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 339-343, June.
    10. Sabine Elisabeth Grimm & Mark Strong & Alan Brennan & Allan J. Wailoo, 2017. "The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment," PharmacoEconomics, Springer, vol. 35(12), pages 1287-1296, December.
    11. Josh Carlson & Katharine Gries & Kai Yeung & Sean Sullivan & Louis Garrison, 2014. "Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers," Applied Health Economics and Health Policy, Springer, vol. 12(3), pages 231-238, June.
    12. A. Carletto & A. Cicchetti & S. Coretti & V. Moramarco & M. Ruggeri, 2019. "Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals," Eurasian Business Review, Springer;Eurasia Business and Economics Society, vol. 9(1), pages 89-101, March.
    13. Hester V Eeren & Saskia J Schawo & Ron H J Scholte & Jan J V Busschbach & Leona Hakkaart, 2015. "Value of Information Analysis Applied to the Economic Evaluation of Interventions Aimed at Reducing Juvenile Delinquency: An Illustration," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-15, July.
    14. Sabine E. Grimm & Xavier Pouwels & Bram L. T. Ramaekers & Ben Wijnen & Thomas Otten & Janneke Grutters & Manuela A. Joore, 2021. "State of the ART? Two New Tools for Risk Communication in Health Technology Assessments," PharmacoEconomics, Springer, vol. 39(10), pages 1185-1196, October.
    15. Jeremy D. Goldhaber-Fiebert & Lauren E. Cipriano, 2023. "Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis," Medical Decision Making, , vol. 43(7-8), pages 914-929, October.
    16. Kisser, Agnes & Tüchler, Heinz & Erdös, Judit & Wild, Claudia, 2016. "Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015," Health Policy, Elsevier, vol. 120(8), pages 903-912.
    17. Fernando Antonanzas & Carmelo Juárez-Castelló & Reyes Lorente & Roberto Rodríguez-Ibeas, 2019. "The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments," PharmacoEconomics, Springer, vol. 37(12), pages 1469-1483, December.
    18. Haitham W. Tuffaha & Paul A. Scuffham, 2018. "The Australian Managed Entry Scheme: Are We Getting it Right?," PharmacoEconomics, Springer, vol. 36(5), pages 555-565, May.
    19. Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.
    20. Makady, A. & van Veelen, A. & de Boer, A. & Hillege, H. & Klungel, O.H. & Goettsch, W., 2019. "Implementing managed entry agreements in practice: The Dutch reality check," Health Policy, Elsevier, vol. 123(3), pages 267-274.
    21. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
    22. Christopher Jackson & John Stevens & Shijie Ren & Nick Latimer & Laura Bojke & Andrea Manca & Linda Sharples, 2017. "Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods," Medical Decision Making, , vol. 37(4), pages 377-390, May.
    23. Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.
    24. James Lomas & Miqdad Asaria & Laura Bojke & Chris P. Gale & Gerry Richardson & Simon Walker, 2018. "Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease," PharmacoEconomics - Open, Springer, vol. 2(4), pages 403-413, December.
    25. Reyes Lorente & Fernando Antonanzas & Roberto Rodriguez-Ibeas, 2019. "Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists," Health Economics Review, Springer, vol. 9(1), pages 1-8, December.

  6. Karl Claxton & Mark Sculpher & Stuart Carroll, 2011. "Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS," Working Papers 060cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Siciliani, Luigi & Rud Kristensen, Søren & Sutton, Matt, 2014. "Optimal Price-Setting in Pay for Performance Schemes in Health Care," CEPR Discussion Papers 9915, C.E.P.R. Discussion Papers.
    2. Karl Claxton & Mark Sculpher & Stephen Palmer & Anthony J Culyer, 2015. "Causes For Concern: Is Nice Failing To Uphold Its Responsibilities To All Nhs Patients?," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 1-7, January.
    3. Gandjour, Afschin & Chernyak, Nadja, 2011. "A new prize system for drug innovation," Health Policy, Elsevier, vol. 102(2), pages 170-177.
    4. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
    5. Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
    6. Wasem, Jürgen & Weegen, Lennart & Bauer, Cosima & Walendzik, Anke & Grande, Frederic & May, Uwe, 2015. "Regulatorische Handhabung der selektiven Erstattung von Arzneimitteln in den ausgewählten Ländern England, Niederlande, Frankreich und Schweden," IBES Diskussionsbeiträge 211, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).
    7. Levaggi, Laura & Levaggi, Rosella, 2024. "Competition, value-based prices and incentives to research personalised drugs," Socio-Economic Planning Sciences, Elsevier, vol. 93(C).
    8. Jessica Ochalek & Miqdad Asaria & Pei Fen Chuar & James Lomas & Sumit Mazumdar & Karl Claxton, 2019. "Assessing health opportunity costs for the Indian health care systems," Working Papers 161cherp, Centre for Health Economics, University of York.
    9. Rosella Levaggi & Paolo Pertile, 2020. "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 357-362, June.
    10. Karl Claxton & Stephen Palmer & Louise Longworth & Laura Bojke & Susan Griffin & Claire McKenna & Marta Soares & Eldon Spackman & Jihee Youn, 2011. "Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies," Working Papers 069cherp, Centre for Health Economics, University of York.
    11. Livio Garattini & Alessandro Curto & Nick Freemantle, 2016. "Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One?," PharmacoEconomics, Springer, vol. 34(5), pages 423-426, May.

  7. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Werner Brouwer & Samare Huls & Ayesha Sajjad & Tim Kanters & Leona Hakkaart-van Roijen & Job Exel, 2022. "In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era," PharmacoEconomics, Springer, vol. 40(1), pages 7-11, January.
    2. Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott, 2012. "Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years," PharmacoEconomics, Springer, vol. 30(11), pages 991-1004, November.
    3. Persson, Emil & Tinghög, Gustav, 2020. "Opportunity cost neglect in public policy," Journal of Economic Behavior & Organization, Elsevier, vol. 170(C), pages 301-312.
    4. Sebastian Hinde & Simon Walker & Hugues Lortie-Forgues, 2019. "Applying the three core concepts of economic evaluation in health to education in the UK," Working Papers 170cherp, Centre for Health Economics, University of York.
    5. Andrew Phillips & Valentina Cambiano & Fumiyo Nakagawa & Travor Magubu & Alec Miners & Debbie Ford & Deenan Pillay & Andrea De Luca & Jens Lundgren & Paul Revill, 2014. "Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-10, October.
    6. Robbin H Ophuis & Joran Lokkerbol & Juanita A Haagsma & Mickaël Hiligsmann & Silvia M A A Evers & Suzanne Polinder, 2018. "Value of information analysis of an early intervention for subthreshold panic disorder: Healthcare versus societal perspective," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-13, November.
    7. Walker, S. & Griffin, Susan & Asaria, Miqdad & Tsuchyia, Aki & Sculpher, Mark, 2019. "Striving for a societal perspective: a framework for economic evaluations when costs and effects fall on multiple sectors and decision-makers," LSE Research Online Documents on Economics 100541, London School of Economics and Political Science, LSE Library.
    8. Mike Paulden & Karl Claxton, 2012. "Budget allocation and the revealed social rate of time preference for health," Health Economics, John Wiley & Sons, Ltd., vol. 21(5), pages 612-618, May.
    9. Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards, 2017. "Scoping review on social care economic evaluation methods," Working Papers 150cherp, Centre for Health Economics, University of York.
    10. Karl Claxton & Mark Sculpher & Stephen Palmer & Anthony J Culyer, 2015. "Causes For Concern: Is Nice Failing To Uphold Its Responsibilities To All Nhs Patients?," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 1-7, January.
    11. Pieter van Baal & David Meltzer & Werner Brouwer, 2016. "Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost‐Effectiveness Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 237-248, February.
    12. Francesco Ramponi & Simon Walker & Susan Griffin & Steve Parrott & Colin Drummond & Paolo Deluca & Simon Coulton & Mona Kanaan & Gerry Richardson, 2021. "Cost‐effectiveness analysis of public health interventions with impacts on health and criminal justice: An applied cross‐sectoral analysis of an alcohol misuse intervention," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 972-988, May.
    13. Marieke Krol & Elly Stolk & Werner Brouwer, 2014. "Predicting productivity based on EQ-5D: an explorative study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(5), pages 465-475, June.
    14. Hareth Al-Janabi & Job van Exel & Werner Brouwer & Joanna Coast, 2016. "A Framework for Including Family Health Spillovers in Economic Evaluation," Medical Decision Making, , vol. 36(2), pages 176-186, February.
    15. Claire McKenna & Karl Claxton, 2011. "Addressing Adoption and Research Design Decisions Simultaneously," Medical Decision Making, , vol. 31(6), pages 853-865, November.
    16. Bram Wouterse & Pieter Baal & Matthijs Versteegh & Werner Brouwer, 2023. "The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice," PharmacoEconomics, Springer, vol. 41(6), pages 607-617, June.
    17. Mark Sculpher & Karl Claxton, 2012. "Real Economics Needs to Reflect Real Decisions," PharmacoEconomics, Springer, vol. 30(2), pages 133-136, February.
    18. Hareth Al‐Janabi & Job Van Exel & Werner Brouwer & Caroline Trotter & Linda Glennie & Laurie Hannigan & Joanna Coast, 2016. "Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis," Health Economics, John Wiley & Sons, Ltd., vol. 25(12), pages 1529-1544, December.
    19. Mark Sculpher & Karl Claxton, 2010. "Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1132-1136, October.
    20. Wei Zhang & Aslam Anis, 2014. "Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now," PharmacoEconomics, Springer, vol. 32(5), pages 425-427, May.
    21. Grupo de Economía de la Salud & Jairo Humberto Restrepo, 2012. "Economía de las enfermedades crónicas no transmisibles: Implicaciones para Colombia," Observatorio Seguridad Social 15579, Grupo de Economía de la Salud.
    22. Ana Bobinac & Job Exel & Frans Rutten & Werner Brouwer, 2014. "The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk," PharmacoEconomics, Springer, vol. 32(1), pages 75-86, January.
    23. Laura Vallejo-Torres, 2023. "The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework," Applied Health Economics and Health Policy, Springer, vol. 21(3), pages 373-384, May.
    24. John Brazier & Aki Tsuchiya, 2015. "Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 557-565, December.
    25. Krol, Marieke & Brouwer, Werner, 2015. "Unpaid work in health economic evaluations," Social Science & Medicine, Elsevier, vol. 144(C), pages 127-137.
    26. Bonny Parkinson & Stephen Goodall & Richard Norman, 2013. "Measuring the Loss of Consumer Choice in Mandatory Health Programmes Using Discrete Choice Experiments," Applied Health Economics and Health Policy, Springer, vol. 11(2), pages 139-150, April.
    27. Wildman, John & McMeekin, Peter & Grieve, Eleanor & Briggs, Andrew, 2016. "Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators," Social Science & Medicine, Elsevier, vol. 169(C), pages 141-148.
    28. Laura Bojke & Laetitia Schmitt & James Lomas & Gerry Richardson & Helen Weatherly, 2018. "Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments," IJERPH, MDPI, vol. 15(11), pages 1-9, November.
    29. van Baal, Pieter & Morton, Alec & Severens, Johan L., 2018. "Health care input constraints and cost effectiveness analysis decision rules," Social Science & Medicine, Elsevier, vol. 200(C), pages 59-64.
    30. Jonathan Siverskog & Martin Henriksson, 2019. "Estimating the marginal cost of a life year in Sweden’s public healthcare sector," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 751-762, July.
    31. Attema, Arthur & Krol, Marieke & van Exel, Job & Brouwer, Werner, 2014. "New findings from the TTO for income approach to elicit willingness to pay for a QALY," MPRA Paper 61197, University Library of Munich, Germany.
    32. Liesbet Wetering & Job Exel & Ana Bobinac & Werner Brouwer, 2015. "Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment," PharmacoEconomics, Springer, vol. 33(12), pages 1289-1300, December.
    33. Karl Claxton & Mark Sculpher & Stuart Carroll, 2011. "Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS," Working Papers 060cherp, Centre for Health Economics, University of York.
    34. Annie Hawton & James Shearer & Elizabeth Goodwin & Colin Green, 2013. "Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 331-341, August.
    35. Ana Bobinac & N. Job A. van Exel & Frans F. H. Rutten & Werner B. F. Brouwer, 2013. "Valuing Qaly Gains By Applying A Societal Perspective," Health Economics, John Wiley & Sons, Ltd., vol. 22(10), pages 1272-1281, October.
    36. Werner Brouwer & Pieter Baal & Job Exel & Matthijs Versteegh, 2019. "When is it too expensive? Cost-effectiveness thresholds and health care decision-making," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 175-180, March.
    37. Susanne Mayer & Aggie T. G. Paulus & Agata Łaszewska & Judit Simon & Ruben M. W. A. Drost & Dirk Ruwaard & Silvia M. A. A. Evers, 2017. "Health-Related Resource-Use Measurement Instruments for Intersectoral Costs and Benefits in the Education and Criminal Justice Sectors," PharmacoEconomics, Springer, vol. 35(9), pages 895-908, September.
    38. Hareth Al-Janabi & Nikki McCaffrey & Julie Ratcliffe, 2013. "Carer Preferences in Economic Evaluation and Healthcare Decision Making," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 6(4), pages 235-239, December.
    39. Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.
    40. David Epstein & Leticia García-Mochón & Stephen Kaptoge & Simon G. Thompson, 2016. "Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1041-1053, November.
    41. Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer, 2018. "New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 277-291, March.
    42. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
    43. Andrew N Phillips & Valentina Cambiano & Fumiyo Nakagawa & Loveleen Bansi-Matharu & Papa Salif Sow & Peter Ehrenkranz & Deborah Ford & Owen Mugurungi & Tsitsi Apollo & Joseph Murungu & David R Bangsbe, 2016. "Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-20, December.
    44. Office of Health Economics, 2010. "Innovation in Medicines: Can We Value Progress?," Seminar Briefing 000219, Office of Health Economics.
    45. Pieter van Baal & Meg Perry‐Duxbury & Pieter Bakx & Matthijs Versteegh & Eddy van Doorslaer & Werner Brouwer, 2019. "A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 87-100, January.
    46. Daniel R. Hanna & Jennifer A. Campbell & Rebekah J. Walker & Aprill Z. Dawson & Leonard E. Egede, 2021. "Association between Health and Wealth among Kenyan Adults with Hypertension," Global Journal of Health Science, Canadian Center of Science and Education, vol. 13(4), pages 1-86, April.
    47. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.

  8. Karl Claxton & Mark Sculpher & Tony Culyer, 2007. "Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions," Working Papers 031cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
    2. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
    3. Mike Paulden & Karl Claxton, 2012. "Budget allocation and the revealed social rate of time preference for health," Health Economics, John Wiley & Sons, Ltd., vol. 21(5), pages 612-618, May.
    4. Francesco Ramponi & Simon Walker & Susan Griffin & Steve Parrott & Colin Drummond & Paolo Deluca & Simon Coulton & Mona Kanaan & Gerry Richardson, 2021. "Cost‐effectiveness analysis of public health interventions with impacts on health and criminal justice: An applied cross‐sectoral analysis of an alcohol misuse intervention," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 972-988, May.
    5. Mike Paulden & James O’Mahony & Christopher McCabe, 2017. "Determinants of Change in the Cost-effectiveness Threshold," Medical Decision Making, , vol. 37(2), pages 264-276, February.
    6. Tuba Saygın Avşar & Xiaozhe Yang & Paula Lorgelly, 2023. "How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe," PharmacoEconomics, Springer, vol. 41(2), pages 123-138, February.
    7. Katherine Payne & Marion McAllister & Linda M. Davies, 2013. "Valuing The Economic Benefits Of Complex Interventions: When Maximising Health Is Not Sufficient," Health Economics, John Wiley & Sons, Ltd., vol. 22(3), pages 258-271, March.
    8. Katherine Payne, 2009. "Fish and chips all round? Regulation of DNA‐based genetic diagnostics," Health Economics, John Wiley & Sons, Ltd., vol. 18(11), pages 1233-1236, November.
    9. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
    10. David Epstein & Dolores Jiménez‐Rubio & Peter C. Smith & Marc Suhrcke, 2009. "Social determinants of health: an economic perspective," Health Economics, John Wiley & Sons, Ltd., vol. 18(5), pages 495-502, May.
    11. Daniel Howdon & Sebastian Hinde & James Lomas & Matthew Franklin, 2022. "Economic Evaluation Evidence for Resource-Allocation Decision Making: Bridging the Gap for Local Decision Makers Using English Case Studies," Applied Health Economics and Health Policy, Springer, vol. 20(6), pages 783-792, November.
    12. Coast, Joanna, 2009. "Maximisation in extra-welfarism: A critique of the current position in health economics," Social Science & Medicine, Elsevier, vol. 69(5), pages 786-792, September.
    13. Fattore, Giovanni & Federici, Carlo & Drummond, Michael & Mazzocchi, Mario & Detzel, Patrick & Hutton, Zsuzsa V & Shankar, Bhavani, 2021. "Economic evaluation of nutrition interventions: Does one size fit all?," Health Policy, Elsevier, vol. 125(9), pages 1238-1246.

  9. Laura Bojke & Karl Claxton & Stephen Palmer & Mark Sculpher, 2006. "Defining and characterising structural uncertainty in decision analytic models," Working Papers 009cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Joke Bilcke & Philippe Beutels & Marc Brisson & Mark Jit, 2011. "Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models," Medical Decision Making, , vol. 31(4), pages 675-692, July.
    2. Bas Groot Koerkamp & Milton C. Weinstein & Theo Stijnen & M.H. Heijenbrok-Kal & M.G. Myriam Hunink, 2010. "Uncertainty and Patient Heterogeneity in Medical Decision Models," Medical Decision Making, , vol. 30(2), pages 194-205, March.
    3. Lois G. Kim & Simon G. Thompson, 2010. "Uncertainty and validation of health economic decision models," Health Economics, John Wiley & Sons, Ltd., vol. 19(1), pages 43-55, January.
    4. Hossein Haji Ali Afzali & Jonathan Karnon, 2015. "Exploring Structural Uncertainty in Model-Based Economic Evaluations," PharmacoEconomics, Springer, vol. 33(5), pages 435-443, May.
    5. Sun-Young Kim & Sue J. Goldie & Joshua A. Salomon, 2010. "Exploring Model Uncertainty in Economic Evaluation of Health Interventions: The Example of Rotavirus Vaccination in Vietnam," Medical Decision Making, , vol. 30(5), pages 1-28, September.
    6. Laura Burgers & William Redekop & Johan Severens, 2014. "Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease," PharmacoEconomics, Springer, vol. 32(7), pages 627-637, July.

  10. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2005. "The value of implementation and the value of information: combined and uneven development," Working Papers 005cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Oakley, Jeremy E. & Brennan, Alan & Tappenden, Paul & Chilcott, Jim, 2010. "Simulation sample sizes for Monte Carlo partial EVPI calculations," Journal of Health Economics, Elsevier, vol. 29(3), pages 468-477, May.
    2. Andrew R. Willan & Simon Eckermann, 2010. "Optimal clinical trial design using value of information methods with imperfect implementation," Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 549-561, May.

  11. Elizabeth Fenwick & Karl Claxton & Mark Sculpher & Andrew Briggs, 2000. "Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling," Working Papers 179chedp, Centre for Health Economics, University of York.

    Cited by:

    1. Karnon, Jonathan, 2002. "Planning the efficient allocation of research funds: an adapted application of a non-parametric Bayesian value of information analysis," Health Policy, Elsevier, vol. 61(3), pages 329-347, September.
    2. Rachael L. Fleurence, 2007. "Setting priorities for research: a practical application of ‘payback’ and expected value of information," Health Economics, John Wiley & Sons, Ltd., vol. 16(12), pages 1345-1357, December.
    3. Jonathan Karnon, 2003. "Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation," Health Economics, John Wiley & Sons, Ltd., vol. 12(10), pages 837-848, October.
    4. Karl Claxton & Mark Sculpher & Tony Culyer, 2007. "Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions," Working Papers 031cherp, Centre for Health Economics, University of York.
    5. Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills, 2009. "Cost Effectiveness in Low- and Middle-Income Countries," PharmacoEconomics, Springer, vol. 27(11), pages 903-917, November.
    6. Elisabeth Fenwick & Bernie J. O'Brien & Andrew Briggs, 2004. "Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 405-415, May.
    7. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial‐based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687, July.
    8. Doug Coyle & Jeremy Oakley, 2008. "Estimating the expected value of partial perfect information: a review of methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 251-259, August.
    9. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2005. "The value of implementation and the value of information: combined and uneven development," Working Papers 005cherp, Centre for Health Economics, University of York.
    10. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost‐effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787, December.

  12. Mark Sculpher & David Torgerson & Ron Goeree & Bernie O'Brien, 1999. "A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis," Working Papers 169chedp, Centre for Health Economics, University of York.

    Cited by:

    1. Hege Urdahl & Andrea Manca & Mark Sculpher, 2006. "Assessing Generalisability in Model-Based Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 24(12), pages 1181-1197, December.

  13. Mark Sculpher & Michael Drummond & Martin Buxton, 1995. "Economic Evaluation in Health Care Research and Development: Undertake it Early and Often," Discussion Papers 12, Brunel University, Health Economics Research Group.

    Cited by:

    1. Trevor A. Sheldon, 1996. "Problems of using modelling in the economic evaluation of health care," Health Economics, John Wiley & Sons, Ltd., vol. 5(1), pages 1-11, January.
    2. Chase Hollman & Mike Paulden & Petros Pechlivanoglou & Christopher McCabe, 2017. "A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models," PharmacoEconomics, Springer, vol. 35(8), pages 817-830, August.

Articles

  1. Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.

    Cited by:

    1. Kasper Johannesen & Magnus Janzon & Tomas Jernberg & Martin Henriksson, 2020. "Subcategorizing the Expected Value of Perfect Implementation to Identify When and Where to Invest in Implementation Initiatives," Medical Decision Making, , vol. 40(3), pages 327-338, April.

  2. Karl Claxton & Mark Sculpher & Stephen Palmer & Anthony J Culyer, 2015. "Causes For Concern: Is Nice Failing To Uphold Its Responsibilities To All Nhs Patients?," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 1-7, January.

    Cited by:

    1. Elamin Elbasha & Jagpreet Chhatwal, 2016. "Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers," PharmacoEconomics, Springer, vol. 34(1), pages 13-22, January.
    2. Nadia Pillai & Mark Dusheiko & Bernard Burnand & Valérie Pittet, 2017. "A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-22, October.
    3. Anthony J Culyer, 2015. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Working Papers 121cherp, Centre for Health Economics, University of York.
    4. Matthew Franklin & Sebastian Hinde & Rachael Maree Hunter & Gerry Richardson & William Whittaker, 2024. "Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study," Applied Health Economics and Health Policy, Springer, vol. 22(4), pages 435-445, July.
    5. Freekje van Asten & Charlotte T J Michels & Carel B Hoyng & Gert Jan van der Wilt & B Jeroen Klevering & Maroeska M Rovers & Janneke P C Grutters, 2018. "The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-14, May.
    6. Martin, Stephen & Claxton, Karl & Lomas, James & Longo, Francesco, 2023. "The impact of different types of NHS expenditure on health: Marginal cost per QALY estimates for England for 2016/17," Health Policy, Elsevier, vol. 132(C).
    7. Jessica Ochalek & James Lomas & Karl Claxton, 2015. "Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data," Working Papers 122cherp, Centre for Health Economics, University of York.
    8. Matthew Franklin & Colin Angus & Tobias Welte & Guy Joos, 2023. "How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts," Applied Health Economics and Health Policy, Springer, vol. 21(4), pages 547-558, July.
    9. Huang, Li & Frijters, Paul & Dalziel, Kim & Clarke, Philip, 2018. "Life satisfaction, QALYs, and the monetary value of health," Social Science & Medicine, Elsevier, vol. 211(C), pages 131-136.
    10. Elamin H. Elbasha & Jagpreet Chhatwal, 2016. "Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers," PharmacoEconomics, Springer, vol. 34(1), pages 13-22, January.
    11. James Lomas & Jessica Ochalek & Rita Faria, 2022. "Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 13-18, January.
    12. Alec Morton & Amanda I. Adler & David Bell & Andrew Briggs & Werner Brouwer & Karl Claxton & Neil Craig & Alastair Fischer & Peter McGregor & Pieter van Baal, 2016. "Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 933-938, August.
    13. Øystein Ariansen Haaland & Frode Lindemark & Kjell Arne Johansson, 2019. "A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: Priority weights," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-12, October.
    14. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
    15. Pieter Baal & Alec Morton & David Meltzer & Werner Brouwer, 2019. "Future unrelated medical costs need to be considered in cost effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 1-5, February.
    16. Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for timing when assessing health-related policies," LSE Research Online Documents on Economics 100408, London School of Economics and Political Science, LSE Library.
    17. James Love-Koh & Richard Cookson & Karl Claxton & Susan Griffin, 2020. "Estimating Social Variation in the Health Effects of Changes in Health Care Expenditure," Medical Decision Making, , vol. 40(2), pages 170-182, February.
    18. Jessica Ochalek & Miqdad Asaria & Pei Fen Chuar & James Lomas & Sumit Mazumdar & Karl Claxton, 2019. "Assessing health opportunity costs for the Indian health care systems," Working Papers 161cherp, Centre for Health Economics, University of York.
    19. Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong, 2018. "Cost-Effectiveness Thresholds: the Past, the Present and the Future," PharmacoEconomics, Springer, vol. 36(5), pages 509-522, May.
    20. Beth Woods & James Lomas & Mark Sculpher & Helen Weatherly & Karl Claxton, 2024. "Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 804-819, April.
    21. Christopher McCabe, 2019. "Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution," PharmacoEconomics, Springer, vol. 37(4), pages 457-460, April.
    22. Lucarelli, Claudio & Nicholson, Sean & Tilipman, Nicholas, 2022. "Price Indices and the Value of Innovation with Heterogenous Patients," Journal of Health Economics, Elsevier, vol. 84(C).
    23. Pieter van Baal & Meg Perry‐Duxbury & Pieter Bakx & Matthijs Versteegh & Eddy van Doorslaer & Werner Brouwer, 2019. "A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 87-100, January.

  3. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.

    Cited by:

    1. Stefan Scholz & Thomas Mittendorf, 2014. "Modeling rheumatoid arthritis using different techniques - a review of model construction and results," Health Economics Review, Springer, vol. 4(1), pages 1-16, December.
    2. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.

  4. Mark Sculpher & Karl Claxton, 2012. "Real Economics Needs to Reflect Real Decisions," PharmacoEconomics, Springer, vol. 30(2), pages 133-136, February.

    Cited by:

    1. Lopert, Ruth & Ruiz, Francis & Chalkidou, Kalipso, 2013. "Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania," Health Policy, Elsevier, vol. 112(3), pages 202-208.
    2. Francesco Ramponi & Simon Walker & Susan Griffin & Steve Parrott & Colin Drummond & Paolo Deluca & Simon Coulton & Mona Kanaan & Gerry Richardson, 2021. "Cost‐effectiveness analysis of public health interventions with impacts on health and criminal justice: An applied cross‐sectoral analysis of an alcohol misuse intervention," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 972-988, May.
    3. Dirk Steijger & Chandrima Chatterjee & Wim Groot & Milena Pavlova, 2022. "Challenges and Limitations in Distributional Cost-Effectiveness Analysis: A Systematic Literature Review," IJERPH, MDPI, vol. 20(1), pages 1-14, December.

  5. Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian Bruce & Mark Sculpher & Nerys Woolacott, 2012. "Golimumab for the Treatment of Psoriatic Arthritis," PharmacoEconomics, Springer, vol. 30(4), pages 257-270, April.

    Cited by:

    1. Eldon Spackman & Stephen Rice & Gill Norman & Dong-Churl Suh & Alison Eastwood & Stephen Palmer, 2013. "Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer," PharmacoEconomics, Springer, vol. 31(3), pages 185-194, March.
    2. Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott, 2012. "Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years," PharmacoEconomics, Springer, vol. 30(11), pages 991-1004, November.
    3. Eleftherios Sideris & Mark Corbett & Stephen Palmer & Nerys Woolacott & Laura Bojke, 2016. "The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence," PharmacoEconomics, Springer, vol. 34(11), pages 1101-1110, November.
    4. Lesley Uttley & Ben Kearns & Shijie Ren & Matt Stevenson, 2013. "Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar I Disorder in Children and Adolescents: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(11), pages 981-990, November.
    5. Rita Faria & Eldon Spackman & Jane Burch & Belen Corbacho & Derick Todd & Chris Pepper & Nerys Woolacott & Stephen Palmer, 2013. "Dabigatran for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(7), pages 551-562, July.
    6. Ben Kearns & Myfanwy Lloyd Jones & Matt Stevenson & Chris Littlewood, 2013. "Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(6), pages 479-488, June.
    7. László Gulácsi & Fanni Rencz & Márta Péntek & Valentin Brodszky & Ruth Lopert & Noémi Hevér & Petra Baji, 2014. "Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 27-34, May.
    8. Afschin Gandjour & Dennis A. Ostwald, 2020. "Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 109-125, February.
    9. Sophie Whyte & Abdullah Pandor & Matt Stevenson, 2012. "Bevacizumab for Metastatic Colorectal Cancer," PharmacoEconomics, Springer, vol. 30(12), pages 1119-1132, December.
    10. Joanne O’Connor & Stephen Rice & Alison Smith & Mark Rodgers & Rocio Rodriguez Lopez & Dawn Craig & Nerys Woolacott, 2016. "The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence," PharmacoEconomics, Springer, vol. 34(4), pages 337-348, April.
    11. Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer, 2017. "How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 767-776, August.
    12. Rachid Rafia & Emma Simpson & Matt Stevenson & Diana Papaioannou, 2013. "Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(6), pages 471-478, June.
    13. Nicholas Latimer & Christopher Carroll & Ruth Wong & Paul Tappenden & Michael Venning & Raashid Luqmani, 2014. "Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 32(12), pages 1171-1183, December.
    14. E. Simpson & P. Fitzgerald & P. Evans & P. Tappenden & N. Kalita & J. Reckless & A. Bakhai, 2013. "Bivalirudin for the Treatment of ST-Segment Elevation Myocardial Infarction: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(4), pages 269-275, April.
    15. Jonathan Tosh & Rachel Archer & Sarah Davis & Matt Stevenson & John Stevens, 2013. "Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(8), pages 653-661, August.
    16. Bernd Schweikert & Chiara Malmberg & Örjan Åkerborg & Gayathri Kumar & Debby Nott & Sandeep Kiri & Christophe Sapin & Susanne Hartz, 2020. "Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK," PharmacoEconomics - Open, Springer, vol. 4(4), pages 635-648, December.
    17. Karen Smith & Su Golder & Abeed Sarker & Yoon Loke & Karen O’Connor & Graciela Gonzalez-Hernandez, 2018. "Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab," Drug Safety, Springer, vol. 41(12), pages 1397-1410, December.
    18. Sophie Whyte & Abdullah Pandor & Matt Stevenson, 2012. "Bevacizumab for Metastatic Colorectal Cancer," PharmacoEconomics, Springer, vol. 30(12), pages 1119-1132, December.
    19. Nigel Armstrong & Manuela Joore & Thea Asselt & Kate Misso & Nathan Manning & Florian Tomini & Jos Kleijnen & Rob Riemsma, 2013. "Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(5), pages 415-425, May.
    20. Dawn Craig & Stephen Rice & Fiona Paton & David Fox & Nerys Woolacott, 2013. "Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization," PharmacoEconomics, Springer, vol. 31(2), pages 101-110, February.
    21. Janette Greenhalgh & Adrian Bagust & Angela Boland & Michaela Blundell & James Oyee & Sophie Beale & Yenal Dundar & Juliet Hockenhull & Chris Proudlove & Patrick Chu, 2013. "Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma," PharmacoEconomics, Springer, vol. 31(5), pages 403-413, May.
    22. Mary Kilonzo & Jenni Hislop & Andrew Elders & Cynthia Fraser & Donald Bissett & Samuel McClinton & Graham Mowatt & Luke Vale, 2013. "Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma," PharmacoEconomics, Springer, vol. 31(1), pages 15-24, January.

  6. Susan C. Griffin & Karl P. Claxton & Stephen J. Palmer & Mark J. Sculpher, 2011. "Dangerous omissions: the consequences of ignoring decision uncertainty," Health Economics, John Wiley & Sons, Ltd., vol. 20(2), pages 212-224, February.

    Cited by:

    1. Bognar, Katalin & Romley, John A. & Bae, Jay P. & Murray, James & Chou, Jacquelyn W. & Lakdawalla, Darius N., 2017. "The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions," Journal of Health Economics, Elsevier, vol. 51(C), pages 1-12.
    2. Martin Forster & Paolo Pertile, 2013. "Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective," Health Economics, John Wiley & Sons, Ltd., vol. 22(12), pages 1507-1514, December.
    3. Andrija S Grustam & Nasuh Buyukkaramikli & Ron Koymans & Hubertus J M Vrijhoef & Johan L Severens, 2019. "Value of information analysis in telehealth for chronic heart failure management," PLOS ONE, Public Library of Science, vol. 14(6), pages 1-23, June.
    4. Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Institutions and Markets Papers 98047, Fondazione Eni Enrico Mattei (FEEM).
    5. Gandjour, Afschin & Chernyak, Nadja, 2011. "A new prize system for drug innovation," Health Policy, Elsevier, vol. 102(2), pages 170-177.
    6. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
    7. Anirban Basu & David Meltzer, 2018. "Decision Criterion and Value of Information Analysis: Optimal Aspirin Dosage for Secondary Prevention of Cardiovascular Events," Medical Decision Making, , vol. 38(4), pages 427-438, May.
    8. Laura Bojke & Marta O. Soares & Karl Claxton & Abigail Colson & Aimée Fox & Chris Jackson & Dina Jankovic & Alec Morton & Linda D. Sharples & Andrea Taylor, 2022. "Reference Case Methods for Expert Elicitation in Health Care Decision Making," Medical Decision Making, , vol. 42(2), pages 182-193, February.
    9. David D. Kim & Anirban Basu, 2017. "New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives," Medical Decision Making, , vol. 37(8), pages 930-941, November.
    10. Kisser, Agnes & Tüchler, Heinz & Erdös, Judit & Wild, Claudia, 2016. "Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015," Health Policy, Elsevier, vol. 120(8), pages 903-912.
    11. Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.
    12. Campillo-Artero, Carlos, 2013. "A full-fledged overhaul is needed for a risk and value-based regulation of medical devices in Europe," Health Policy, Elsevier, vol. 113(1), pages 38-44.

  7. Mark Sculpher & Karl Claxton, 2010. "Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1132-1136, October.

    Cited by:

    1. Pieter van Baal & David Meltzer & Werner Brouwer, 2016. "Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost‐Effectiveness Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 237-248, February.
    2. Christine Arentz, 2011. "Medizinisch-technischer Fortschritt im Gesundheitswesen: Zentrale Kosten-Nutzen-Bewertung ohne Alternative?," Otto-Wolff-Institut Discussion Paper Series 01/2011, Otto-Wolff-Institut für Wirtschaftsordnung, Köln, Deutschland.

  8. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.

    Cited by:

    1. Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo, 2016. "Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches," PharmacoEconomics, Springer, vol. 34(5), pages 447-461, May.
    2. Arantzazu Arrospide & Oliver Ibarrondo & Iván Castilla & Igor Larrañaga & Javier Mar, 2022. "Development and Validation of a Discrete Event Simulation Model to Evaluate the Cardiovascular Impact of Population Policies for Obesity," Medical Decision Making, , vol. 42(2), pages 241-254, February.
    3. Matthew Calver, 2016. "Measuring the Appropriate Outcomes for Better Decision-Making: A Framework to Guide the Analysis of Health Policy," CSLS Research Reports 2016-03, Centre for the Study of Living Standards.
    4. Joanna M Charles & Deirdre M Harrington & Melanie J Davies & Charlotte L Edwardson & Trish Gorely & Danielle H Bodicoat & Kamlesh Khunti & Lauren B Sherar & Thomas Yates & Rhiannon Tudor Edwards, 2019. "Micro-costing and a cost-consequence analysis of the ‘Girls Active’ programme: A cluster randomised controlled trial," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-17, August.
    5. Di Bartolomeo Giovanni & Stefano Papa, 2017. "The effects of physical activity on social interactions: The case of trust and trustworthiness," wp.comunite 00134, Department of Communication, University of Teramo.
    6. Emma Frew & Katie Breheny, 2019. "Methods for public health economic evaluation: A Delphi survey of decision makers in English and Welsh local government," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 1052-1063, August.
    7. Matthew Franklin & James Lomas & Gerry Richardson, 2020. "Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations," PharmacoEconomics, Springer, vol. 38(7), pages 665-681, July.
    8. Giulia Greco & Paula Lorgelly & Inthira Yamabhai, 2016. "Outcomes in Economic Evaluations of Public Health Interventions in Low‐ and Middle‐Income Countries: Health, Capabilities and Subjective Wellbeing," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 83-94, February.
    9. Frida Ngalesoni & George Ruhago & Mary Mayige & Tiago Cravo Oliveira & Bjarne Robberstad & Ole Frithjof Norheim & Hideki Higashi, 2017. "Cost-effectiveness analysis of population-based tobacco control strategies in the prevention of cardiovascular diseases in Tanzania," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-20, August.
    10. Goebbels, Adrienne F.G. & Lakerveld, Jeroen & Ament, André J.H.A. & Bot, Sandra D.M. & Severens, Johan L., 2012. "Exploring non-health outcomes of health promotion: The perspective of participants in a lifestyle behaviour change intervention," Health Policy, Elsevier, vol. 106(2), pages 177-186.
    11. Sebastian Himmler & Job Exel & Werner Brouwer, 2020. "Estimating the monetary value of health and capability well-being applying the well-being valuation approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1235-1244, November.
    12. Mac Giolla Phadraig, Caoimhin & Nunn, June & Guerin, Suzanne & Normand, Charles, 2016. "Should we provide oral health training for staff caring for people with intellectual disabilities in community based residential care? A cost-effectiveness analysis," Evaluation and Program Planning, Elsevier, vol. 55(C), pages 46-54.
    13. Hazel Squires & James Chilcott & Ronald Akehurst & Jennifer Burr & Michael P. Kelly, 2016. "A systematic literature review of the key challenges for developing the structure of public health economic models," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 61(3), pages 289-298, April.
    14. Thiboonboon, Kittiphong & Lourenco, Richard De Abreu & Cronin, Paula & Khoo, Terence & Goodall, Stephen, 2024. "Economic Evaluations of Obesity-Targeted Sugar-Sweetened Beverage (SSB) Taxes–A Review to Identify Methodological Issues," Health Policy, Elsevier, vol. 144(C).
    15. Cyr, Pascale Renée & Jain, Vageesh & Chalkidou, Kalipso & Ottersen, Trygve & Gopinathan, Unni, 2021. "Evaluations of public health interventions produced by health technology assessment agencies: A mapping review and analysis by type and evidence content," Health Policy, Elsevier, vol. 125(8), pages 1054-1064.
    16. Cochrane, M. & Watson, P.M. & Timpson, H. & Haycox, A. & Collins, B. & Jones, L. & Martin, A. & Graves, L.E.F., 2019. "Systematic review of the methods used in economic evaluations of targeted physical activity and sedentary behaviour interventions," Social Science & Medicine, Elsevier, vol. 232(C), pages 156-167.
    17. Den Daas, C. & Van Aar, F. & Van Benthem, B.H.B., 2019. "Evaluating the impact of health reforms in the Netherlands: Assessing the impact of an alcohol ban on sexually transmitted infections in national surveillance data," Health Policy, Elsevier, vol. 123(10), pages 992-997.
    18. Deidda, Manuela & Geue, Claudia & Kreif, Noemi & Dundas, Ruth & McIntosh, Emma, 2019. "A framework for conducting economic evaluations alongside natural experiments," Social Science & Medicine, Elsevier, vol. 220(C), pages 353-361.
    19. Anna Månsdotter & Björn Ekman & Inna Feldman & Lars Hagberg & Anna-Karin Hurtig & Lars Lindholm, 2017. "We Propose a Novel Measure for Social Welfare and Public Health: Capability-Adjusted Life-Years, CALYs," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 437-440, August.
    20. Emma Frew, 2017. "Aligning Health Economics Methods to Fit with the Changing World of Public Health," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 287-289, June.
    21. Lakerveld, Jeroen & Woods, Catherine & Hebestreit, Antje & Brenner, Hermann & Flechtner-Mors, Marion & Harrington, Janas M. & Kamphuis, Carlijn B.M. & Laxy, Michael & Luszczynska, Aleksandra & Mazzocc, 2020. "Advancing the evidence base for public policies impacting on dietary behaviour, physical activity and sedentary behaviour in Europe: The Policy Evaluation Network promoting a multidisciplinary approac," Food Policy, Elsevier, vol. 96(C).
    22. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2020. "Modelling the impact of physical activity on public health: A review and critique," Health Policy, Elsevier, vol. 124(10), pages 1155-1164.
    23. Tarik Benmarhnia & Pierre-Alexandre Dionne & Éric Tchouaket & Alvine K. Fansi & Astrid Brousselle, 2017. "Investing in a healthy lifestyle strategy: is it worth it?," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 62(1), pages 3-13, January.
    24. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2021. "Taking a local government perspective for economic evaluation of a population-level programme to promote exercise," Health Policy, Elsevier, vol. 125(5), pages 651-657.
    25. Susanne Mayer & Aggie T. G. Paulus & Agata Łaszewska & Judit Simon & Ruben M. W. A. Drost & Dirk Ruwaard & Silvia M. A. A. Evers, 2017. "Health-Related Resource-Use Measurement Instruments for Intersectoral Costs and Benefits in the Education and Criminal Justice Sectors," PharmacoEconomics, Springer, vol. 35(9), pages 895-908, September.
    26. Jain, Vageesh & Crosby, Liam & Baker, Peter & Chalkidou, Kalipso, 2020. "Distributional equity as a consideration in economic and modelling evaluations of health taxes: A systematic review," Health Policy, Elsevier, vol. 124(9), pages 919-931.
    27. Hill, Sarah R. & Vale, Luke & Hunter, David & Henderson, Emily & Oluboyede, Yemi, 2017. "Economic evaluations of alcohol prevention interventions: Is the evidence sufficient? A review of methodological challenges," Health Policy, Elsevier, vol. 121(12), pages 1249-1262.
    28. Tom L. Drake & Yoel Lubell, 2017. "Malaria and Economic Evaluation Methods: Challenges and Opportunities," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 291-297, June.

  9. Diego Ossa & Andrew Briggs & Emma McIntosh & Warren Cowell & Tim Littlewood & Mark Sculpher, 2007. "Recombinant Erythropoietin for Chemotherapy-Related Anaemia," PharmacoEconomics, Springer, vol. 25(3), pages 223-237, March.

    Cited by:

    1. Brigitte Essers & Debby Helvoort-Postulart & Martin Prins & Martino Neumann & Carmen Dirksen, 2010. "Does the Inclusion of a Cost Attribute Result in Different Preferences for the Surgical Treatment of Primary Basal Cell Carcinoma?," PharmacoEconomics, Springer, vol. 28(6), pages 507-520, June.
    2. Ruth Brown & Sean Stern & Sujith Dhanasiri & Steve Schey, 2013. "Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 507-514, June.
    3. Peasgood, T & Ward, S & Brazier, J, 2010. "A review and meta-analysis of health state utility values in breast cancer," MPRA Paper 29950, University Library of Munich, Germany.

  10. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial‐based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687, July.

    Cited by:

    1. Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo, 2016. "Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches," PharmacoEconomics, Springer, vol. 34(5), pages 447-461, May.
    2. Schulenburg J.-Matthias Graf von der & Vauth Christoph, 2007. "Nach welchen ökonomischen Methoden sollten Gesundheitsleistungen in Deutschland evaluiert werden? / According to Which Economic Methods Should Health Care Services Become Evaluated in Germany?," Journal of Economics and Statistics (Jahrbuecher fuer Nationaloekonomie und Statistik), De Gruyter, vol. 227(5-6), pages 787-806, October.
    3. Manca, A & Austin, P. C, 2008. "Using propensity score methods to analyse individual patient-level cost-effectiveness data from observational studies," Health, Econometrics and Data Group (HEDG) Working Papers 08/20, HEDG, c/o Department of Economics, University of York.
    4. Ulla Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.
    5. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Management of Dementia Patients - A Systematic Literature Review," Working Papers 2018:41, Lund University, Department of Economics.
    6. Graves, Nicholas & Clare, Gina & Haines, Mary & Bird, Robert, 2010. "A policy case study of blood in Australia," Social Science & Medicine, Elsevier, vol. 71(9), pages 1677-1682, November.
    7. Sean Docking & Lan Gao & Zanfina Ademi & Christian Bonello & Rachelle Buchbinder, 2023. "Use of Decision-Analytic Modelling to Assess the Cost-Effectiveness of Diagnostic Imaging of the Spine, Shoulder, and Knee: A Scoping Review," Applied Health Economics and Health Policy, Springer, vol. 21(3), pages 467-475, May.
    8. John W. Stevens, 2018. "Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?," PharmacoEconomics, Springer, vol. 36(10), pages 1135-1141, October.
    9. Dina Jankovic & Laura Bojke & David Marshall & Pedro Saramago Goncalves & Rachel Churchill & Hollie Melton & Sally Brabyn & Lina Gega, 2021. "Systematic Review and Critique of Methods for Economic Evaluation of Digital Mental Health Interventions," Applied Health Economics and Health Policy, Springer, vol. 19(1), pages 17-27, January.
    10. Edward Burn & Alexander D. Liddle & Thomas W. Hamilton & Sunil Pai & Hemant G. Pandit & David W. Murray & Rafael Pinedo-Villanueva, 2017. "Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(4), pages 241-253, December.
    11. Renee Lévesque & Daniele Marcelli & Héloïse Cardinal & Marie-Line Caron & Muriel Grooteman & Michiel Bots & Peter Blankestijn & Menso Nubé & Aileen Grassmann & Bernard Canaud & Afschin Gandjour, 2015. "Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 647-659, December.
    12. Marta O. Soares & Simon Walker & Stephen J. Palmer & Mark J. Sculpher, 2018. "Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment," Medical Decision Making, , vol. 38(4), pages 495-508, May.
    13. Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins, 2017. "Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(7), pages 685-695, July.
    14. Kerry Bell & Belen Corbacho & Sarah Ronaldson & Gerry Richardson & David Torgerson & Michael Robling, 2018. "The impact of pre and perinatal lifestyle factors on child long term health and social outcomes: a systematic review," Health Economics Review, Springer, vol. 8(1), pages 1-18, December.
    15. Alexander Thompson & Bruce Guthrie & Katherine Payne, 2016. "Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility," PharmacoEconomics, Springer, vol. 34(4), pages 333-336, April.
    16. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    17. Mohsen Ghaffari Darab & Lidia Engel & Dennis Henzler & Michael Lauerer & Eckhard Nagel & Vicki Brown & Cathrine Mihalopoulos, 2024. "Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment," Applied Health Economics and Health Policy, Springer, vol. 22(4), pages 503-525, July.
    18. Lois G. Kim & Simon G. Thompson, 2010. "Uncertainty and validation of health economic decision models," Health Economics, John Wiley & Sons, Ltd., vol. 19(1), pages 43-55, January.
    19. Ulla Kou Griffiths & Rosa Legood & Catherine Pitt, 2016. "Comparison of Economic Evaluation Methods Across Low‐income, Middle‐income and High‐income Countries: What are the Differences and Why?," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 29-41, February.
    20. Karl Claxton & Mark Sculpher & Tony Culyer, 2007. "Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions," Working Papers 031cherp, Centre for Health Economics, University of York.
    21. Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer, 2017. "How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 767-776, August.
    22. James A. Hall & Kika Konstantinou & Martyn Lewis & Raymond Oppong & Reuben Ogollah & Sue Jowett, 2019. "Systematic Review of Decision Analytic Modelling in Economic Evaluations of Low Back Pain and Sciatica," Applied Health Economics and Health Policy, Springer, vol. 17(4), pages 467-491, August.
    23. Takahashi, R. & Todo, Y., 2018. "When do consumers stand up for the environment? Evidence from a large-scale social experiment to promote environmentally friendly coffee," 2018 Conference, July 28-August 2, 2018, Vancouver, British Columbia 277507, International Association of Agricultural Economists.
    24. J. Caro & Jörgen Möller, 2014. "Decision-Analytic Models: Current Methodological Challenges," PharmacoEconomics, Springer, vol. 32(10), pages 943-950, October.
    25. Sanjib Saha & Katarina Steen Carlsson & Ulf-G Gerdtham & Margareta K Eriksson & Lars Hagberg & Mats Eliasson & Pia Johansson, 2013. "Are Lifestyle Interventions in Primary Care Cost-Effective? – An Analysis Based on a Markov Model, Differences-In-Differences Approach and the Swedish Björknäs Study," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-1, November.
    26. Brousselle, Astrid & Lessard, Chantale, 2011. "Economic evaluation to inform health care decision-making: Promise, pitfalls and a proposal for an alternative path," Social Science & Medicine, Elsevier, vol. 72(6), pages 832-839, March.
    27. Dixon, Padraig & Harrison, Sean & Hollingworth, William & Davies, Neil M. & Davey Smith, George, 2022. "Estimating the causal effect of liability to disease on healthcare costs using Mendelian Randomization," Economics & Human Biology, Elsevier, vol. 46(C).
    28. David Glynn & John Giardina & Julia Hatamyar & Ankur Pandya & Marta Soares & Noemi Kreif, 2024. "Integrating decision modeling and machine learning to inform treatment stratification," Health Economics, John Wiley & Sons, Ltd., vol. 33(8), pages 1772-1792, August.
    29. Gemma E. Shields & Becky Pennington & Ash Bullement & Stuart Wright & Jamie Elvidge, 2022. "Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time," PharmacoEconomics, Springer, vol. 40(3), pages 249-256, March.
    30. Zafar Zafari & Kristian Thorlund & J. FitzGerald & Carlo Marra & Mohsen Sadatsafavi, 2014. "Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes," PharmacoEconomics, Springer, vol. 32(10), pages 995-1004, October.
    31. Edward Wilson, 2015. "A Practical Guide to Value of Information Analysis," PharmacoEconomics, Springer, vol. 33(2), pages 105-121, February.
    32. Ana Sofia Oliveira Gonçalves & Dimitra Panteli & Lars Neeb & Tobias Kurth & Annette Aigner, 2022. "HIT-6 and EQ-5D-5L in patients with migraine: assessment of common latent constructs and development of a mapping algorithm," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(1), pages 47-57, February.
    33. Stavros Petrou & Joseph Kwon & Jason Madan, 2018. "A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values," PharmacoEconomics, Springer, vol. 36(9), pages 1043-1061, September.
    34. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2020. "Modelling the impact of physical activity on public health: A review and critique," Health Policy, Elsevier, vol. 124(10), pages 1155-1164.
    35. Andrew Briggs, 2012. "Statistical Methods for Cost-effectiveness Analysis Alongside Clinical Trials," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 50, Edward Elgar Publishing.
    36. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
    37. Christoffer Lilja Terjesen & Julia Kovaleva & Lars Ehlers, 2017. "Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes," PharmacoEconomics - Open, Springer, vol. 1(2), pages 133-141, June.
    38. Stuart J. Wright & Ewan Gray & Gabriel Rogers & Anna Donten & Katherine Payne, 2024. "A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening," Applied Health Economics and Health Policy, Springer, vol. 22(4), pages 527-542, July.
    39. J.- Graf v. d. Schulenburg & Christoph Vauth & Thomas Mittendorf & Wolfgang Greiner, 2007. "Methods for determining cost-benefit ratios for pharmaceuticals in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(1), pages 5-31, September.
    40. Ferrari, Giulia & Torres-Rueda, Sergio & Michaels-Igbokwe, Christine & Watts, Charlotte & Jewkes, Rachel & Vassall, Anna, 2019. "Economic evaluation of public health interventions: an application to interventions for the prevention of violence against women and girls implemented by the “what works to prevent violence against wo," LSE Research Online Documents on Economics 103639, London School of Economics and Political Science, LSE Library.
    41. Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne, 2016. "Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations," PharmacoEconomics, Springer, vol. 34(11), pages 1161-1172, November.
    42. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
    43. Rob Anderson, 2010. "Systematic reviews of economic evaluations: utility or futility?," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 350-364, March.
    44. Samantha Husbands & Susan Jowett & Pelham Barton & Joanna Coast, 2017. "How Qualitative Methods Can be Used to Inform Model Development," PharmacoEconomics, Springer, vol. 35(6), pages 607-612, June.

  11. Hege Urdahl & Andrea Manca & Mark Sculpher, 2006. "Assessing Generalisability in Model-Based Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 24(12), pages 1181-1197, December.

    Cited by:

    1. Katharina Korber, 2014. "Potential Transferability of Economic Evaluations of Programs Encouraging Physical Activity in Children and Adolescents across Different Countries—A Systematic Review of the Literature," IJERPH, MDPI, vol. 11(10), pages 1-16, October.
    2. Rachael Fleurence & Cynthia Iglesias & Jeanene Johnson, 2007. "The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis," PharmacoEconomics, Springer, vol. 25(11), pages 913-933, November.
    3. F. El Masri & E. Sapin de Brosses & K. Rhissassi & W. Skalli & D. Mitton, 2012. "Apparent Young's modulus of vertebral cortico-cancellous bone specimens," Computer Methods in Biomechanics and Biomedical Engineering, Taylor & Francis Journals, vol. 15(1), pages 23-28.

  12. Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier, 2006. "Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 1-4, January.

    Cited by:

    1. van Baal, P.H. & Feenstra, T.L. & Polder, J.J. & Hoogenveen, R.T. & Brouwer, W., 2011. "Economic evaluation and the postponement of health care costs," Other publications TiSEM ee3d1a20-234a-46d7-8acd-d, Tilburg University, School of Economics and Management.
    2. M. Parouty & H. Le & D. Krooshof & M. Postma, 2014. "Differential Time Preferences for Money and Quality of Life," PharmacoEconomics, Springer, vol. 32(4), pages 411-419, April.
    3. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
    4. van der Pol, Marjon & Cairns, John, 2008. "Comparison of two methods of eliciting time preference for future health states," Social Science & Medicine, Elsevier, vol. 67(5), pages 883-889, September.
    5. Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
    6. Paul Hanly & Michelle Ahern & Linda Sharp & Diana Ursul & Gerard Loughnane, 2022. "The cost of lost productivity due to premature mortality associated with COVID-19: a Pan-European study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 249-259, March.
    7. Mike Paulden & Anthony J Culyer, 2010. "Does cost-effectiveness analysis discriminate against patients with short life expectancy? Matters of logic and matters of context," Working Papers 055cherp, Centre for Health Economics, University of York.
    8. Mike Paulden & James F. O’Mahony & Christopher McCabe, 2017. "Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine," PharmacoEconomics, Springer, vol. 35(1), pages 5-13, January.
    9. Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe, 2014. "Some Inconsistencies in NICE’s Consideration of Social Values," PharmacoEconomics, Springer, vol. 32(11), pages 1043-1053, November.
    10. Hugh Gravelle & Werner Brouwer & Louis Niessen & Maarten Postma & Frans Rutten, 2007. "Discounting in economic evaluations: stepping forward towards optimal decision rules," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 307-317, March.
    11. Arthur E. Attema & Werner B. F. Brouwer & Karl Claxton, 2018. "Discounting in Economic Evaluations," PharmacoEconomics, Springer, vol. 36(7), pages 745-758, July.
    12. Erik Nord, 2011. "Discounting future health benefits: the poverty of consistency arguments," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 16-26, January.
    13. Karl Claxton & Mike Paulden & Hugh Gravelle & Werner Brouwer & Anthony J. Culyer, 2011. "Discounting and decision making in the economic evaluation of health‐care technologies," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 2-15, January.
    14. N. J. Welton & A. E. Ades & D. M. Caldwell & T. J. Peters, 2008. "Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 171(4), pages 807-841, October.
    15. Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.
    16. Mike Paulden & Anthony J. Culyer, 2010. "Does Cost-Effectiveness Analysis Discriminate against Patients with Short Life Expectancy?," Working Paper series 41_10, Rimini Centre for Economic Analysis.
    17. Mareike Schad & Jürgen John, 2012. "Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 127-144, April.
    18. Ana Bobinac & Werner Brouwer & Job van Exel, 2011. "Discounting future health gains: an empirical enquiry into the influence of growing life expectancy," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 111-119, January.

  13. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.

    Cited by:

    1. Joke Bilcke & Philippe Beutels & Marc Brisson & Mark Jit, 2011. "Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models," Medical Decision Making, , vol. 31(4), pages 675-692, July.
    2. Jackson Christopher H & Sharples Linda D & Thompson Simon G, 2010. "Survival Models in Health Economic Evaluations: Balancing Fit and Parsimony to Improve Prediction," The International Journal of Biostatistics, De Gruyter, vol. 6(1), pages 1-31, October.
    3. Tazio Vanni & Jonathan Karnon & Jason Madan & Richard White & W. Edmunds & Anna Foss & Rosa Legood, 2011. "Calibrating Models in Economic Evaluation," PharmacoEconomics, Springer, vol. 29(1), pages 35-49, January.
    4. Christopher H. Jackson & Mark Jit & Linda D. Sharples & Daniela De Angelis, 2015. "Calibration of Complex Models through Bayesian Evidence Synthesis," Medical Decision Making, , vol. 35(2), pages 148-161, February.
    5. Hawre Jalal & Jeremy D. Goldhaber-Fiebert & Karen M. Kuntz, 2015. "Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling," Medical Decision Making, , vol. 35(5), pages 584-595, July.
    6. Sun-Young Kim & Louise B. Russell & Anushua Sinha, 2015. "Handling Parameter Uncertainty in Cost-Effectiveness Models Simply and Responsibly," Medical Decision Making, , vol. 35(5), pages 567-569, July.
    7. C. Armero & G. García‐Donato & A. López‐Quílez, 2010. "Bayesian methods in cost–effectiveness studies: objectivity, computation and other relevant aspects," Health Economics, John Wiley & Sons, Ltd., vol. 19(6), pages 629-643, June.
    8. Testa, Riccardo & Foderà, Mario & Di Trapani, Anna Maria & Tudisca, Salvatore & Sgroi, Filippo, 2016. "Giant reed as energy crop for Southern Italy: An economic feasibility study," Renewable and Sustainable Energy Reviews, Elsevier, vol. 58(C), pages 558-564.
    9. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.
    10. Benjamin Thorpe & Orlagh Carroll & Linda Sharples, 2018. "Methods for Handling Unobserved Covariates in a Bayesian Update of a Cost-effectiveness Model," Medical Decision Making, , vol. 38(2), pages 150-162, February.
    11. Zafar Zafari & Kristian Thorlund & J. FitzGerald & Carlo Marra & Mohsen Sadatsafavi, 2014. "Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes," PharmacoEconomics, Springer, vol. 32(10), pages 995-1004, October.
    12. Denis Getsios & Kristen Migliaccio-Walle & Jaime Caro, 2007. "NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors," PharmacoEconomics, Springer, vol. 25(12), pages 997-1006, December.

  14. Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347, April.

    Cited by:

    1. Laura Bojke & Karl Claxton & Stephen Palmer & Mark Sculpher, 2006. "Defining and characterising structural uncertainty in decision analytic models," Working Papers 009cherp, Centre for Health Economics, University of York.
    2. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.
    3. Anthony J. Hatswell & Ash Bullement & Andrew Briggs & Mike Paulden & Matthew D. Stevenson, 2018. "Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models," PharmacoEconomics, Springer, vol. 36(12), pages 1421-1426, December.
    4. John W. Stevens, 2018. "Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?," PharmacoEconomics, Springer, vol. 36(10), pages 1135-1141, October.
    5. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2017. "A Review of Methods for Analysis of the Expected Value of Information," Medical Decision Making, , vol. 37(7), pages 747-758, October.
    6. Lionel Perrier & Anne Lefranc & Philippe Quittet & Philippe Moreau & Carole Siani & Hervé Ghesquières & Fabrice Jardin & Bertrand Favier & Norbert Ifrah & Séverine Lissandre & David Pérol & Catherine , 2013. "Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma," Post-Print halshs-00752571, HAL.
    7. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    8. Dominic Tilden & Segundo Mariz & Gillies O’Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos, 2007. "A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK," PharmacoEconomics, Springer, vol. 25(1), pages 39-54, January.
    9. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2019. "Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression," Medical Decision Making, , vol. 39(4), pages 347-359, May.
    10. Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi, 2019. "Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review," PharmacoEconomics, Springer, vol. 37(6), pages 777-818, June.
    11. Michelle Tew & Michael Willis & Christian Asseburg & Hayley Bennett & Alan Brennan & Talitha Feenstra & James Gahn & Alastair Gray & Laura Heathcote & William H. Herman & Deanna Isaman & Shihchen Kuo , 2022. "Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Chal," Medical Decision Making, , vol. 42(5), pages 599-611, July.
    12. Pedram Sendi & Huldrych F Günthard & Mathew Simcock & Bruno Ledergerber & Jörg Schüpbach & Manuel Battegay & for the Swiss HIV Cohort Study, 2007. "Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure," PLOS ONE, Public Library of Science, vol. 2(1), pages 1-8, January.
    13. Christopher McCabe & Mike Paulden & Isaac Awotwe & Andrew Sutton & Peter Hall, 2020. "One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit," PharmacoEconomics, Springer, vol. 38(2), pages 135-141, February.
    14. Isaac Corro Ramos & Maureen P. M. H. Rutten-van Mölken & Maiwenn J. Al, 2013. "The Role of Value-of-Information Analysis in a Health Care Research Priority Setting," Medical Decision Making, , vol. 33(4), pages 472-489, May.
    15. Mohan V. Bala & Gary A. Zarkin & Josephine Mauskopf, 2008. "Presenting results of probabilistic sensitivity analysis: the incremental benefit curve," Health Economics, John Wiley & Sons, Ltd., vol. 17(3), pages 435-440, March.
    16. Anthony O'Hagan & Matt Stevenson & Jason Madan, 2007. "Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA," Health Economics, John Wiley & Sons, Ltd., vol. 16(10), pages 1009-1023, October.
    17. Sun-Young Kim & Louise B. Russell & Anushua Sinha, 2015. "Handling Parameter Uncertainty in Cost-Effectiveness Models Simply and Responsibly," Medical Decision Making, , vol. 35(5), pages 567-569, July.
    18. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
    19. Mark Sculpher & Stephen Palmer, 2020. "After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?," PharmacoEconomics, Springer, vol. 38(3), pages 247-257, March.
    20. Adam J. N. Raymakers & John Mayo & Stephen Lam & J. Mark FitzGerald & David G. T. Whitehurst & Larry D. Lynd, 2016. "Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 409-418, August.
    21. T. I. Armina Padmasawitri & Sarah Maria Saragih & Gerardus W. Frederix & Olaf Klungel & Anke M. Hövels, 2020. "Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 4(2), pages 223-233, June.
    22. Bogdan Grigore & Oriana Ciani & Florian Dams & Carlo Federici & Saskia Groot & Meilin Möllenkamp & Stefan Rabbe & Kosta Shatrov & Antal Zemplenyi & Rod S. Taylor, 2020. "Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines," PharmacoEconomics, Springer, vol. 38(10), pages 1055-1070, October.
    23. Zoë Pieters & Mark Strong & Virginia E. Pitzer & Philippe Beutels & Joke Bilcke, 2020. "A Computationally Efficient Method for Probabilistic Parameter Threshold Analysis for Health Economic Evaluations," Medical Decision Making, , vol. 40(5), pages 669-679, July.
    24. Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp, 2014. "Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 32(6), pages 601-612, June.
    25. Mehdi Najafzadeh & Jorge A. Garces & Alejandra Maciel, 2017. "Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety," PharmacoEconomics, Springer, vol. 35(12), pages 1297-1310, December.
    26. Kurinchi Gurusamy & Edward Wilson & Andrew Burroughs & Brian Davidson, 2012. "Intra-operative vs pre-operative endoscopic sphincterotomy in patients with gallbladder and common bile duct stones," Applied Health Economics and Health Policy, Springer, vol. 10(1), pages 15-29, January.
    27. Nicky J. Welton & Jason J. Madan & Deborah M. Caldwell & Tim J. Peters & Anthony E. Ades, 2014. "Expected Value of Sample Information for Multi-Arm Cluster Randomized Trials with Binary Outcomes," Medical Decision Making, , vol. 34(3), pages 352-365, April.
    28. Xuanqian Xie & Alexis K. Schaink & Sichen Liu & Myra Wang & Andrei Volodin, 2023. "Understanding bias in probabilistic analysis in model-based health economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 307-319, March.
    29. Samer A. Kharroubi & Richard Edlin & David Meads & Chantelle Browne & Julia Brown & Christopher McCabe, 2015. "Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from EORTC QLQ Data in Myeloma for Use in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 35(3), pages 351-360, April.
    30. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial‐based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687, July.
    31. Benjamin Thorpe & Orlagh Carroll & Linda Sharples, 2018. "Methods for Handling Unobserved Covariates in a Bayesian Update of a Cost-effectiveness Model," Medical Decision Making, , vol. 38(2), pages 150-162, February.
    32. Belfiore, Alessandra & Scaletti, Alessandro & Lavorato, Domenica & Cuccurullo, Corrado, 2023. "The long process by which HTA became a paradigm: A longitudinal conceptual structure analysis," Health Policy, Elsevier, vol. 127(C), pages 74-79.
    33. Devin Incerti & Jeffrey R. Curtis & Jason Shafrin & Darius N. Lakdawalla & Jeroen P. Jansen, 2019. "A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 37(6), pages 829-843, June.
    34. Torbjørn Wisløff & Gunhild Hagen & Vida Hamidi & Espen Movik & Marianne Klemp & Jan Olsen, 2014. "Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010," PharmacoEconomics, Springer, vol. 32(4), pages 367-375, April.
    35. Laura Bojke & Marta O. Soares & Karl Claxton & Abigail Colson & Aimée Fox & Chris Jackson & Dina Jankovic & Alec Morton & Linda D. Sharples & Andrea Taylor, 2022. "Reference Case Methods for Expert Elicitation in Health Care Decision Making," Medical Decision Making, , vol. 42(2), pages 182-193, February.
    36. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
    37. Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton, 2012. "Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode," PharmacoEconomics, Springer, vol. 30(6), pages 513-530, June.
    38. Bogdan Grigore & Jaime Peters & Christopher Hyde & Ken Stein, 2013. "Methods to Elicit Probability Distributions from Experts: A Systematic Review of Reported Practice in Health Technology Assessment," PharmacoEconomics, Springer, vol. 31(11), pages 991-1003, November.
    39. Anna Heath & Mark Strong & David Glynn & Natalia Kunst & Nicky J. Welton & Jeremy D. Goldhaber-Fiebert, 2022. "Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial," Medical Decision Making, , vol. 42(2), pages 143-155, February.
    40. Sofia Dias & Alex J. Sutton & A. E. Ades & Nicky J. Welton, 2013. "Evidence Synthesis for Decision Making 2," Medical Decision Making, , vol. 33(5), pages 607-617, July.
    41. White, Nicole & Blythe, Robin, 2023. "ShinyPrior: A tool for estimating probability distributions using published evidence," OSF Preprints zf62e, Center for Open Science.
    42. Matt Stevenson & Peter Selby, 2014. "Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider," PharmacoEconomics, Springer, vol. 32(8), pages 735-743, August.
    43. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
    44. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    45. Peter J. Dodd & Debebe Shaweno & Chu-Chang Ku & Philippe Glaziou & Carel Pretorius & Richard J. Hayes & Peter MacPherson & Ted Cohen & Helen Ayles, 2023. "Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    46. Ji-Hee Youn & Matt D. Stevenson & Praveen Thokala & Katherine Payne & Maria Goddard, 2019. "Modeling the Economic Impact of Interventions for Older Populations with Multimorbidity: A Method of Linking Multiple Single-Disease Models," Medical Decision Making, , vol. 39(7), pages 842-856, October.
    47. Fernando Antonanzas & Benoit Rive & Josep Badenas & Susana Gomez-Lus & Chantal Guilhaume, 2006. "Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 137-144, June.
    48. Anthony Newall & Mark Jit & Philippe Beutels, 2012. "Economic Evaluations of Childhood Influenza Vaccination," PharmacoEconomics, Springer, vol. 30(8), pages 647-660, August.
    49. Christopher McCabe & Giovanni Tramonti & Andrew Sutton & Peter Hall & Mike Paulden, 2021. "Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier," PharmacoEconomics, Springer, vol. 39(1), pages 19-24, January.
    50. Pepijn Vemer & Lucas M. A. Goossens & Maureen P. M. H. Rutten-van Mölken, 2014. "Not Simply More of the Same," Medical Decision Making, , vol. 34(8), pages 1048-1058, November.
    51. Nicholas Graves & Katie Page & Elizabeth Martin & David Brain & Lisa Hall & Megan Campbell & Naomi Fulop & Nerina Jimmeison & Katherine White & David Paterson & Adrian G Barnett, 2016. "Cost-Effectiveness of a National Initiative to Improve Hand Hygiene Compliance Using the Outcome of Healthcare Associated Staphylococcus aureus Bacteraemia," PLOS ONE, Public Library of Science, vol. 11(2), pages 1-17, February.
    52. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310, December.
    53. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
    54. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
    55. Tiago M. de Carvalho & Eveline A. M. Heijnsdijk & Luc Coffeng & Harry J. de Koning, 2019. "Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators," Medical Decision Making, , vol. 39(4), pages 405-413, May.
    56. Yevgeniy Samyshkin & Robert Kotchie & Ann-Christin Mörk & Andrew Briggs & Eric Bateman, 2014. "Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 69-82, January.
    57. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    58. Anna Heath & Petros Pechlivanoglou, 2022. "Prioritizing Research in an Era of Personalized Medicine: The Potential Value of Unexplained Heterogeneity," Medical Decision Making, , vol. 42(5), pages 649-660, July.
    59. N. J. Welton & A. E. Ades & D. M. Caldwell & T. J. Peters, 2008. "Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 171(4), pages 807-841, October.
    60. Shijie Ren & Jonathan Minton & Sophie Whyte & Nicholas R. Latimer & Matt Stevenson, 2018. "A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis," PharmacoEconomics, Springer, vol. 36(3), pages 341-347, March.
    61. Laura Bojke & Bogdan Grigore & Dina Jankovic & Jaime Peters & Marta Soares & Ken Stein, 2017. "Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties," PharmacoEconomics, Springer, vol. 35(9), pages 867-877, September.
    62. Christopher H. Jackson & Laura Bojke & Simon G. Thompson & Karl Claxton & Linda D. Sharples, 2011. "A Framework for Addressing Structural Uncertainty in Decision Models," Medical Decision Making, , vol. 31(4), pages 662-674, July.
    63. Daniel Hill-McManus, 2024. "The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations," PharmacoEconomics, Springer, vol. 42(1), pages 11-18, January.
    64. Helen A. Dakin & José Leal & Andrew Briggs & Philip Clarke & Rury R. Holman & Alastair Gray, 2020. "Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data," Medical Decision Making, , vol. 40(4), pages 460-473, May.
    65. Steven Edwards & Sarah Wordsworth & Mike Clarke, 2012. "Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 181-192, April.
    66. Karl Claxton & Stephen Palmer & Louise Longworth & Laura Bojke & Susan Griffin & Claire McKenna & Marta Soares & Eldon Spackman & Jihee Youn, 2011. "Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies," Working Papers 069cherp, Centre for Health Economics, University of York.
    67. Jagpreet Chhatwal & Tianhua He, 2015. "Economic Evaluations with Agent-Based Modelling: An Introduction," PharmacoEconomics, Springer, vol. 33(5), pages 423-433, May.
    68. Sofia Dias & Alex J. Sutton & Nicky J. Welton & A. E. Ades, 2013. "Evidence Synthesis for Decision Making 6," Medical Decision Making, , vol. 33(5), pages 671-678, July.
    69. Joseph F. Levy & Patrick D. Meek & Marjorie A. Rosenberg, 2015. "US-Based Drug Cost Parameter Estimation for Economic Evaluations," Medical Decision Making, , vol. 35(5), pages 622-632, July.

  15. Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs, 2005. "Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 471-485, May.

    Cited by:

    1. Manca, A & Austin, P. C, 2008. "Using propensity score methods to analyse individual patient-level cost-effectiveness data from observational studies," Health, Econometrics and Data Group (HEDG) Working Papers 08/20, HEDG, c/o Department of Economics, University of York.
    2. Lange, Ian, 2008. "Contract Parameters' Impacts on Coal Prices," Stirling Economics Discussion Papers 2008-26, University of Stirling, Division of Economics.
    3. Thompson, Simon G. & Nixon, Richard M. & Grieve, Richard, 2006. "Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study," Journal of Health Economics, Elsevier, vol. 25(6), pages 1015-1028, November.
    4. Christian E. H. Boehler & Joanne Lord, 2016. "Mind the Gap! A Multilevel Analysis of Factors Related to Variation in Published Cost-Effectiveness Estimates within and between Countries," Medical Decision Making, , vol. 36(1), pages 31-47, January.
    5. Pepijn Vemer & Maureen Rutten-van Mölken, 2013. "The Road Not Taken: Transferability Issues in Multinational Trials," PharmacoEconomics, Springer, vol. 31(10), pages 863-876, October.
    6. Peter Makai & Willemijn Looman & Eddy Adang & René Melis & Elly Stolk & Isabelle Fabbricotti, 2015. "Cost-effectiveness of integrated care in frail elderly using the ICECAP-O and EQ-5D: does choice of instrument matter?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 437-450, May.
    7. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial‐based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687, July.
    8. Md Abu Manju & Math J. J. M. Candel & Gerard J. P. van Breukelen, 2019. "SamP2CeT: an interactive computer program for sample size and power calculation for two-level cost-effectiveness trials," Computational Statistics, Springer, vol. 34(1), pages 47-70, March.
    9. Manju, Md Abu & Candel, Math J.J.M. & van Breukelen, Gerard J.P., 2021. "Robustness of cost-effectiveness analyses of cluster randomized trials assuming bivariate normality against skewed cost data," Computational Statistics & Data Analysis, Elsevier, vol. 157(C).
    10. Fernando Antonanzas & Roberto Rodríguez‐Ibeas & Carmelo Juárez & Florencia Hutter & Reyes Lorente & Mariola Pinillos, 2009. "Transferability indices for health economic evaluations: methods and applications," Health Economics, John Wiley & Sons, Ltd., vol. 18(6), pages 629-643, June.
    11. Oliveira, Monica D. & Bevan, Gwyn, 2008. "Modelling hospital costs to produce evidence for policies that promote equity and efficiency," European Journal of Operational Research, Elsevier, vol. 185(3), pages 933-947, March.
    12. Adrian Gheorghe & Tracy E Roberts & Jonathan C Ives & Benjamin R Fletcher & Melanie Calvert, 2013. "Centre Selection for Clinical Trials and the Generalisability of Results: A Mixed Methods Study," PLOS ONE, Public Library of Science, vol. 8(2), pages 1-9, February.
    13. Aline Gauthier & Andrea Manca & Susan Anton, 2009. "Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials," PharmacoEconomics, Springer, vol. 27(12), pages 1017-1029, December.
    14. Moreno, Elías & Girón, F.J. & Vázquez-Polo, F.J. & Negrín, M.A., 2012. "Optimal healthcare decisions: The importance of the covariates in cost–effectiveness analysis," European Journal of Operational Research, Elsevier, vol. 218(2), pages 512-522.
    15. Jeffrey Hoch & Carolyn Dewa, 2007. "Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions," PharmacoEconomics, Springer, vol. 25(10), pages 807-816, October.
    16. Carmen Selva-Sevilla & F Dámaso Fernández-Ginés & Manuel Cortiñas-Sáenz & Manuel Gerónimo-Pardo, 2021. "Cost-effectiveness analysis of domiciliary topical sevoflurane for painful leg ulcers," PLOS ONE, Public Library of Science, vol. 16(9), pages 1-18, September.
    17. Andrew Briggs, 2012. "Statistical Methods for Cost-effectiveness Analysis Alongside Clinical Trials," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 50, Edward Elgar Publishing.
    18. Hege Urdahl & Andrea Manca & Mark Sculpher, 2006. "Assessing Generalisability in Model-Based Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 24(12), pages 1181-1197, December.
    19. Xin Sun & Thomas Faunce, 2008. "Decision-analytical modelling in health-care economic evaluations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(4), pages 313-323, November.
    20. Andrew R. Willan & Matthew E. Kowgier, 2008. "Cost‐effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 777-791, July.
    21. Richard Grieve & Richard Nixon & Simon G. Thompson & John Cairns, 2007. "Multilevel models for estimating incremental net benefits in multinational studies," Health Economics, John Wiley & Sons, Ltd., vol. 16(8), pages 815-826, August.
    22. Richard M. Nixon & Simon G. Thompson, 2005. "Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 14(12), pages 1217-1229, December.

  16. Andrea Manca & Neil Hawkins & Mark J. Sculpher, 2005. "Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 487-496, May.

    Cited by:

    1. Adrian Gheorghe & Tracy E Roberts & Thomas D Pinkney & David C Bartlett & Dion Morton & Melanie Calvert & on behalf of the West Midlands Research Collaborative and the ROSSINI Trial Investigators, 2014. "The Cost-Effectiveness of Wound-Edge Protection Devices Compared to Standard Care in Reducing Surgical Site Infection after Laparotomy: An Economic Evaluation alongside the ROSSINI Trial," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-8, April.
    2. Eldon Spackman & Stewart Richmond & Mark Sculpher & Martin Bland & Stephen Brealey & Rhian Gabe & Ann Hopton & Ada Keding & Harriet Lansdown & Sara Perren & David Torgerson & Ian Watt & Hugh MacPherso, 2014. "Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-12, November.
    3. Melina Dritsaki & Felix Achana & James Mason & Stavros Petrou, 2017. "Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Sys," PharmacoEconomics, Springer, vol. 35(5), pages 501-515, May.
    4. Ilias Goranitis & Joanna Coast & Ed Day & Alex Copello & Nick Freemantle & Emma Frew, 2017. "Maximizing Health or Sufficient Capability in Economic Evaluation? A Methodological Experiment of Treatment for Drug Addiction," Medical Decision Making, , vol. 37(5), pages 498-511, July.
    5. Nadia YAKHELEF & Martine AUDIBERT & Bruno PEIRERA & Antoine MONS & Emmanuel CHABERT, 2015. "Cost-utility Analysis of Vertebroplasty versus Thoracolumbosacral Orthosis in the Treatment of Traumatic Vertebral Fractures," Working Papers 201534, CERDI.
    6. Iftekhar Khan & Stavros Petrou & Kamran Khan & Dipesh Mistry & Ranjit Lall & Bart Sheehan & Sarah Lamb, 2019. "Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical," PharmacoEconomics - Open, Springer, vol. 3(2), pages 215-227, June.
    7. Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind, 2017. "Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial," PharmacoEconomics - Open, Springer, vol. 1(3), pages 175-184, September.
    8. Francisco Jódar-Sánchez & Amaia Malet-Larrea & José Martín & Leticia García-Mochón & M. López del Amo & Fernando Martínez-Martínez & Miguel Gastelurrutia-Garralda & Victoria García-Cárdenas & Daniel S, 2015. "Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program," PharmacoEconomics, Springer, vol. 33(6), pages 599-610, June.
    9. Sabrina Storgaard Sørensen & Kjeld Møller Pedersen & Ulla Møller Weinreich & Lars Ehlers, 2017. "Economic Evaluation of Community-Based Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 413-424, June.
    10. Theodoros Mantopoulos & Paul M. Mitchell & Nicky J. Welton & Richard McManus & Lazaros Andronis, 2016. "Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 927-938, November.
    11. Danielle Brunenberg & Gwenn Wetzels & Patricia Nelemans & Carmen Dirksen & Johan Severens & Henri Stoffers & Jan Schouten & Martin Prins & Peter Leeuw & Manuela Joore, 2007. "Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients," PharmacoEconomics, Springer, vol. 25(3), pages 239-251, March.
    12. Rachael Hunter & Gianluca Baio & Thomas Butt & Stephen Morris & Jeff Round & Nick Freemantle, 2015. "An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 33(4), pages 355-366, April.
    13. Wanrudee Isaranuwatchai & Maureen Markle-Reid & Jeffrey Hoch, 2015. "Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters," PharmacoEconomics, Springer, vol. 33(10), pages 1083-1090, October.
    14. Paddy Gillespie & Eamon O’Shea & Andrew Murphy & Susan Smith & Mary Byrne & Molly Byrne & Margaret Cupples, 2012. "Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 429-443, August.
    15. David Meads & Andrea Marshall & Claire Hulme & Janet Dunn & Hugo Ford, 2016. "The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial," PharmacoEconomics, Springer, vol. 34(1), pages 33-42, January.
    16. Wen Wan & M. Reza Skandari & Alexa Minc & Aviva G. Nathan & Parmida Zarei & Aaron N. Winn & Michael O’Grady & Elbert S. Huang, 2018. "Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial," Medical Decision Making, , vol. 38(8), pages 942-953, November.
    17. Andrew H. Briggs & Patrick S. Parfrey & Nasreen Khan & Spring Tseng & Bastian Dehmel & Yumi Kubo & Glenn M. Chertow & Vasily Belozeroff, 2016. "Analyzing Health-Related Quality of Life in the EVOLVE Trial," Medical Decision Making, , vol. 36(8), pages 965-972, November.
    18. Sabrina Gabrielle Anjara & Chiara Bonetto & Poushali Ganguli & Diana Setiyawati & Yodi Mahendradhata & Bambang Hastha Yoga & Laksono Trisnantoro & Carol Brayne & Tine Van Bortel, 2019. "Can General Practitioners manage mental disorders in primary care? A partially randomised, pragmatic, cluster trial," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-26, November.
    19. Alex J. Turner & Matt Sutton & Mark Harrison & Alexandra Hennessey & Neil Humphrey, 2020. "Cost-Effectiveness of a School-Based Social and Emotional Learning Intervention: Evidence from a Cluster-Randomised Controlled Trial of the Promoting Alternative Thinking Strategies Curriculum," Applied Health Economics and Health Policy, Springer, vol. 18(2), pages 271-285, April.
    20. Nadia Yakhelef & Martine Audibert & Bruno Peirera & Antoine Mons & Emmanuel Chabert, 2015. "Cost-utility Analysis of Vertebroplasty versus Thoracolumbosacral Orthosis in the Treatment of Traumatic Vertebral Fractures," CERDI Working papers halshs-01241824, HAL.
    21. McCarthy, Ian M., 2016. "Eliminating composite bias in treatment effects estimates: Applications to quality of life assessment," Journal of Health Economics, Elsevier, vol. 50(C), pages 47-58.
    22. Matthew Franklin & Sarah Davis & Michelle Horspool & Wei Sun Kua & Steven Julious, 2017. "Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study," PharmacoEconomics, Springer, vol. 35(5), pages 561-573, May.
    23. Nadia Yakhelef & Martine Audibert & Bruno Peirera & Antoine Mons & Emmanuel Chabert, 2015. "Cost-utility Analysis of Vertebroplasty versus Thoracolumbosacral Orthosis in the Treatment of Traumatic Vertebral Fractures," Working Papers halshs-01241824, HAL.
    24. Catharine Ward Thompson & Aldo Elizalde & Steven Cummins & Alastair H. Leyland & Willings Botha & Andrew Briggs & Sara Tilley & Eva Silveirinha de Oliveira & Jenny Roe & Peter Aspinall & Richard Mitch, 2019. "Enhancing Health Through Access to Nature: How Effective are Interventions in Woodlands in Deprived Urban Communities? A Quasi-experimental Study in Scotland, UK," Sustainability, MDPI, vol. 11(12), pages 1-21, June.
    25. Lukasz Tanajewski & Matthew Franklin & Georgios Gkountouras & Vladislav Berdunov & Rowan H Harwood & Sarah E Goldberg & Lucy E Bradshaw & John R F Gladman & Rachel A Elliott, 2015. "Economic Evaluation of a General Hospital Unit for Older People with Delirium and Dementia (TEAM Randomised Controlled Trial)," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-20, December.
    26. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
    27. Henderson, Catherine & Knapp, Martin & Fernández, José-Luis & Beecham, Jennifer & Hirani, Shashivadan P. & Beynon, Michelle & Cartwright, Martin & Rixon, Lorna & Doll, Helen & Bower, Peter & Steventon, 2014. "Cost-effectiveness of telecare for people with social care needs: the Whole Systems Demonstrator cluster randomised trial," LSE Research Online Documents on Economics 57270, London School of Economics and Political Science, LSE Library.
    28. Helen A. Dakin & José Leal & Andrew Briggs & Philip Clarke & Rury R. Holman & Alastair Gray, 2020. "Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data," Medical Decision Making, , vol. 40(4), pages 460-473, May.

  17. Louise Longworth & Martin Buxton & Mark Sculpher & David Smith, 2005. "Estimating utility data from clinical indicators for patients with stable angina," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 347-353, December.

    Cited by:

    1. Agota Szende & Caroline Schaefer, 2006. "A taxonomy of health utility assessment methods and the role for uncertainty analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 147-151, June.
    2. India Flint & Jasmina Medjedovic & Ewa Drogon O’Flaherty & Elena Alvarez-Baron & Karthinathan Thangavelu & Natasa Savic & Aurelie Meunier & Louise Longworth, 2023. "Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1061-1072, September.
    3. Brazier, JE & Yang, Y & Tsuchiya, A, 2008. "A review of studies mapping (or cross walking) from non-preference based measures of health to generic preference-based measures," MPRA Paper 29808, University Library of Munich, Germany.
    4. L. T. Burgers & W. K. Redekop & M. J. Al & S. K. Lhachimi & N. Armstrong & S. Walker & C. Rothery & M. Westwood & J. L. Severens, 2017. "Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 731-742, July.
    5. John Brazier & Yaling Yang & Aki Tsuchiya & Donna Rowen, 2010. "A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 215-225, April.
    6. Álvaro Hidalgo-Vega & Juan Ramos-Goñi & Renata Villoro, 2014. "Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 917-925, December.
    7. Nick Kontodimopoulos & Panagiotis Bozios & John Yfantopoulos & Dimitris Niakas, 2013. "Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 307-314, April.

  18. Sculpher, Mark & Gafni, Amiram & Watt, Ian, 2002. "Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions," Social Science & Medicine, Elsevier, vol. 54(9), pages 1369-1377, May.

    Cited by:

    1. Manuel Antonio Espinoza & Andrea Manca & Karl Claxton & Mark Sculpher, 2018. "Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 28-40, February.
    2. Margier, Jennifer & Gafni, Amiram & Moumjid, Nora, 2021. "Cancer care at home or in local health centres versus in hospital: Public policy goals and patients’ preferences in the Rhône-Alps region in France," Health Policy, Elsevier, vol. 125(2), pages 213-220.
    3. Doyeon Lee & Keunhwan Kim, 2022. "National Investment Framework for Revitalizing the R&D Collaborative Ecosystem of Sustainable Smart Agriculture," Sustainability, MDPI, vol. 14(11), pages 1-30, May.
    4. Wirtz, Veronika & Cribb, Alan & Barber, Nick, 2006. "Patient-doctor decision-making about treatment within the consultation--A critical analysis of models," Social Science & Medicine, Elsevier, vol. 62(1), pages 116-124, January.
    5. Nora Moumjid & Amiram Gafni & Alain Brémond & Marie-Odile Carrère, 2007. "Shared Decision Making in the Medical Encounter: Are We All Talking about the Same Thing?," Medical Decision Making, , vol. 27(5), pages 539-546, September.

  19. Mark Sculpher & Amiram Gafni, 2001. "Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 10(4), pages 317-324, June.

    Cited by:

    1. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294, November.
    2. Siciliani, Luigi & Kifmann, Mathias, 2014. "Average-cost Pricing and Dynamic Selection Incentives in the Hospital Sector," CEPR Discussion Papers 10155, C.E.P.R. Discussion Papers.
    3. Jennifer Roberts & Paul Dolan, 2004. "To what extent do people prefer health states with higher values? A note on evidence from the EQ‐5D valuation set," Health Economics, John Wiley & Sons, Ltd., vol. 13(7), pages 733-737, July.
    4. Siciliani, Luigi & Straume, Odd Rune, 2019. "Competition and equity in health care markets," Journal of Health Economics, Elsevier, vol. 64(C), pages 1-14.
    5. Angela Robinson & David Parkin, 2002. "Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. A response to Sculpher and Gafni," Health Economics, John Wiley & Sons, Ltd., vol. 11(7), pages 649-651, October.
    6. Gemma E. Shields & Paul Clarkson & Ash Bullement & Warren Stevens & Mark Wilberforce & Tracey Farragher & Arpana Verma & Linda M. Davies, 2024. "Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature," PharmacoEconomics, Springer, vol. 42(7), pages 737-749, July.
    7. Ian M. McCarthy, 2015. "Putting the Patient in Patient Reported Outcomes: A Robust Methodology for Health Outcomes Assessment," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1588-1603, December.
    8. Stephen Birch & Amiram Gafni, 2002. "On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales," Health Economics, John Wiley & Sons, Ltd., vol. 11(3), pages 185-191, April.
    9. Gemma E. Shields & Mark Wilberforce & Paul Clarkson & Tracey Farragher & Arpana Verma & Linda M. Davies, 2022. "Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency," PharmacoEconomics, Springer, vol. 40(2), pages 149-156, February.
    10. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.
    11. Moreno, E. & Girón, F.J. & Martínez, M.L. & Vázquez-Polo, F.J. & Negrín, M.A., 2013. "Optimal treatments in cost-effectiveness analysis in the presence of covariates: Improving patient subgroup definition," European Journal of Operational Research, Elsevier, vol. 226(1), pages 173-182.
    12. Werner B.F. Brouwer & Frans F.H. Rutten, 2003. "The missing link: on the line between C and E," Health Economics, John Wiley & Sons, Ltd., vol. 12(8), pages 629-636, August.
    13. Clazien Bouwmans & Annemarie Kolk & Mark Oppe & Saskia Schawo & Elly Stolk & Michel Agthoven & Jan Buitelaar & LeonaHakkaart Roijen, 2014. "Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 967-977, December.

  20. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost‐effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787, December.

    Cited by:

    1. Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs, 2005. "Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 471-485, May.
    2. Bas Groot Koerkamp & Milton C. Weinstein & Theo Stijnen & M.H. Heijenbrok-Kal & M.G. Myriam Hunink, 2010. "Uncertainty and Patient Heterogeneity in Medical Decision Models," Medical Decision Making, , vol. 30(2), pages 194-205, March.
    3. Manca, A & Austin, P. C, 2008. "Using propensity score methods to analyse individual patient-level cost-effectiveness data from observational studies," Health, Econometrics and Data Group (HEDG) Working Papers 08/20, HEDG, c/o Department of Economics, University of York.
    4. Richard T. Meenan & Somnath Saha & Roger Chou & Karleen Swarztrauber & Kathryn Pyle Krages & Maureen C. O'Keeffe-Rosetti & Marian McDonagh & Benjamin K. S. Chan & Mark C. Hornbrook & Mark Helfand, 2007. "Cost-Effectiveness of Echocardiography to Identify Intracardiac Thrombus among Patients with First Stroke or Transient Ischemic Attack," Medical Decision Making, , vol. 27(2), pages 161-177, March.
    5. Marije E. Hagendijk & Simon Schans & Cornelis Boersma & Maarten J. Postma & Simon Pol, 2021. "Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(6), pages 991-999, August.
    6. Simon Eckermann & Andrew Willan, 2011. "Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies," PharmacoEconomics, Springer, vol. 29(7), pages 563-577, July.
    7. Raymond C. W. Hutubessy & Louis W. Niessen & Rob F. Dijkstra & Ton F. Casparie & Frans F. Rutten, 2005. "Stochastic league tables: an application to diabetes interventions in the Netherlands," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 445-455, May.
    8. Ifigeneia Mavranezouli & Joran Lokkerbol, 2017. "A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder," PharmacoEconomics, Springer, vol. 35(3), pages 271-296, March.
    9. Nadja Chernyak & Heribert Sattel & Marsel Scheer & Christina Baechle & Johannes Kruse & Peter Henningsen & Andrea Icks, 2014. "Economic Evaluation of Brief Psychodynamic Interpersonal Therapy in Patients with Multisomatoform Disorder," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-4, January.
    10. M D Stevenson & J E Brazier & N W Calvert & M Lloyd-Jones & J E Oakley & J A Kanis, 2005. "Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 56(2), pages 214-221, February.
    11. Jill Bindels & Bram Ramaekers & Isaac Corro Ramos & Leyla Mohseninejad & Saskia Knies & Janneke Grutters & Maarten Postma & Maiwenn Al & Talitha Feenstra & Manuela Joore, 2016. "Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives," PharmacoEconomics, Springer, vol. 34(3), pages 315-322, March.
    12. Ernst, Richard, 2017. "Theories of Health Care Cost-Effectiveness Analysis," SocArXiv gjbcp, Center for Open Science.
    13. Rob M.P.M. Baltussen & Raymond C.W. Hutubessy & Jan J. Barendregt & David B. Evans & Christopher J.L. Murray, 2003. "Formal response to ‘Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues’," Health Economics, John Wiley & Sons, Ltd., vol. 12(2), pages 163-164, February.
    14. M D Stevenson & J E Oakley & S E Chick & K Chalkidou, 2009. "The cost-effectiveness of surgical instrument management policies to reduce the risk of vCJD transmission to humans," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 60(4), pages 506-518, April.
    15. Lisa Nagy & Terho Heikkinen & Alfred Sackeyfio & Richard Pitman, 2016. "The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland," PharmacoEconomics, Springer, vol. 34(9), pages 939-951, September.
    16. Andrija S Grustam & Nasuh Buyukkaramikli & Ron Koymans & Hubertus J M Vrijhoef & Johan L Severens, 2019. "Value of information analysis in telehealth for chronic heart failure management," PLOS ONE, Public Library of Science, vol. 14(6), pages 1-23, June.
    17. E. Remák & J. Hutton & M. Price & K. Peeters & I. Adriaenssen, 2003. "A Markov model of treatment of newly diagnosed epilepsy in the UK," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(4), pages 271-278, December.
    18. Nicholas Graves & Adrian G Barnett & Kate A Halton & Jacob L Veerman & Elisabeth Winkler & Neville Owen & Marina M Reeves & Alison Marshall & Elizabeth Eakin, 2009. "Cost-Effectiveness of a Telephone-Delivered Intervention for Physical Activity and Diet," PLOS ONE, Public Library of Science, vol. 4(9), pages 1-8, September.
    19. Yates, Brian T., 2021. "Toward collaborative cost-inclusive evaluation: Adaptations and transformations for evaluators and economists," Evaluation and Program Planning, Elsevier, vol. 89(C).
    20. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.
    21. Mohsen Sadatsafavi; & Carlo Marra; & Lawrence McCandless & Stirling Bryan, 2012. "The challenge of incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods," Health, Econometrics and Data Group (HEDG) Working Papers 12/24, HEDG, c/o Department of Economics, University of York.
    22. Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347, April.
    23. Lagarde, Mylene & Blaauw, Duane & Cairns, John, 2012. "Cost-effectiveness analysis of human resources policy interventions to address the shortage of nurses in rural South Africa," Social Science & Medicine, Elsevier, vol. 75(5), pages 801-806.
    24. Stefano Conti & Karl Claxton, 2009. "Dimensions of Design Space: A Decision-Theoretic Approach to Optimal Research Design," Medical Decision Making, , vol. 29(6), pages 643-660, November.
    25. Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012. "Decision-making with Uncertainty: The Value of Information," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 51, Edward Elgar Publishing.
    26. Mohan V. Bala & Gary A. Zarkin & Josephine Mauskopf, 2008. "Presenting results of probabilistic sensitivity analysis: the incremental benefit curve," Health Economics, John Wiley & Sons, Ltd., vol. 17(3), pages 435-440, March.
    27. Rachael L. Fleurence, 2007. "Setting priorities for research: a practical application of ‘payback’ and expected value of information," Health Economics, John Wiley & Sons, Ltd., vol. 16(12), pages 1345-1357, December.
    28. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    29. Neil Hawkins & Mark Sculpher & David Epstein, 2005. "Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response," Medical Decision Making, , vol. 25(5), pages 511-519, September.
    30. Pedram Sendi, 2021. "Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve," PharmacoEconomics, Springer, vol. 39(2), pages 161-169, February.
    31. Vining Aidan & Weimer David L, 2010. "An Assessment of Important Issues Concerning the Application of Benefit-Cost Analysis to Social Policy," Journal of Benefit-Cost Analysis, De Gruyter, vol. 1(1), pages 1-40, July.
    32. Sennen Hounton & David Newlands, 2012. "Applying the Net-Benefit Framework for Analyzing and Presenting Cost-Effectiveness Analysis of a Maternal and Newborn Health Intervention," PLOS ONE, Public Library of Science, vol. 7(7), pages 1-8, July.
    33. Rachel A. Elliott & Lukasz Tanajewski & Georgios Gkountouras & Anthony J. Avery & Nick Barber & Rajnikant Mehta & Matthew J. Boyd & Asam Latif & Antony Chuter & Justin Waring, 2017. "Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal," PharmacoEconomics, Springer, vol. 35(12), pages 1237-1255, December.
    34. Miguel A. Negrín & Francisco J. Vázquez‐Polo, 2006. "Bayesian cost‐effectiveness analysis with two measures of effectiveness: the cost‐effectiveness acceptability plane," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 363-372, April.
    35. Elamin H. Elbasha, 2005. "Risk aversion and uncertainty in cost‐effectiveness analysis: the expected‐utility, moment‐generating function approach," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 457-470, May.
    36. Elisabeth Fenwick & Bernie J. O'Brien & Andrew Briggs, 2004. "Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 405-415, May.
    37. Torbjørn Wisløff & Richard White & Olav Dalgard & Ellen J. Amundsen & Hinta Meijerink & Astrid Louise Løvlie & Hilde Kløvstad, 2018. "Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway," PharmacoEconomics, Springer, vol. 36(5), pages 591-601, May.
    38. Andrea Manca & Neil Hawkins & Mark J. Sculpher, 2005. "Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 487-496, May.
    39. Jeroen P. Jansen & Devin Incerti & Mark T. Linthicum, 2019. "Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project," PharmacoEconomics, Springer, vol. 37(11), pages 1313-1320, November.
    40. Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp, 2014. "Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 32(6), pages 601-612, June.
    41. Hester V Eeren & Saskia J Schawo & Ron H J Scholte & Jan J V Busschbach & Leona Hakkaart, 2015. "Value of Information Analysis Applied to the Economic Evaluation of Interventions Aimed at Reducing Juvenile Delinquency: An Illustration," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-15, July.
    42. Stefano Conti & Karl Claxton, 2008. "Dimensions of design space: a decision-theoretic approach to optimal research design," Working Papers 038cherp, Centre for Health Economics, University of York.
    43. Michał Jakubczyk & Bogumił Kamiński, 2017. "Fuzzy approach to decision analysis with multiple criteria and uncertainty in health technology assessment," Annals of Operations Research, Springer, vol. 251(1), pages 301-324, April.
    44. Klemen Naveršnik, 2015. "Output correlations in probabilistic models with multiple alternatives," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 133-139, March.
    45. Simon Eckermann & Andrew Briggs & Andrew R. Willan, 2008. "Health Technology Assessment in the Cost-Disutility Plane," Medical Decision Making, , vol. 28(2), pages 172-181, March.
    46. Sylvain Druais & Agathe Doutriaux & Magali Cognet & Annabelle Godet & Christophe Lançon & Pierre Levy & Ludovic Samalin & Pascal Guillon, 2016. "Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France," PharmacoEconomics, Springer, vol. 34(4), pages 363-391, April.
    47. Elisabeth Fenwick & Andrew Briggs, 2007. "Cost-Effectiveness Acceptability Curves in the Dock," Medical Decision Making, , vol. 27(2), pages 93-95, March.
    48. Shiell, Alan & Rush, Bonnie, 2003. "Can willingness to pay capture the value of altruism? An exploration of Sen's notion of commitment," Journal of Behavioral and Experimental Economics (formerly The Journal of Socio-Economics), Elsevier, vol. 32(6), pages 647-660, December.
    49. Jill Bindels & Bram Ramaekers & Isaac Ramos & Leyla Mohseninejad & Saskia Knies & Janneke Grutters & Maarten Postma & Maiwenn Al & Talitha Feenstra & Manuela Joore, 2016. "Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives," PharmacoEconomics, Springer, vol. 34(3), pages 315-322, March.
    50. David B. Evans & Dan Chisholm & Tessa Tan-Torres Edejer, 2012. "Generalized Cost-effectiveness Analysis: Principles and Practice," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 48, Edward Elgar Publishing.
    51. Tzeyu L. Michaud & Robert L. Kane & J. Riley McCarten & Joseph E. Gaugler & John A. Nyman & Karen M. Kuntz, 2018. "Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis," PharmacoEconomics - Open, Springer, vol. 2(3), pages 309-323, September.
    52. Maureen Rutten-van Mölken & Jan Oostenbrink & Marc Miravitlles & Brigitta Monz, 2007. "Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 123-135, June.
    53. José Leal & Stefania Manetti & James Buchanan, 2018. "The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study," PharmacoEconomics, Springer, vol. 36(10), pages 1263-1272, October.
    54. Alejandro Arrieta & Timothy F Page & Emir Veledar & Khurram Nasir, 2017. "Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives," PLOS ONE, Public Library of Science, vol. 12(1), pages 1-14, January.
    55. Yingyan Ma & Xiaohua Ying & Haidong Zou & Xiaocheng Xu & Haiyun Liu & Lin Bai & Xun Xu & Xi Zhang, 2014. "Rhegmatogenous Retinal Detachment Surgery in Elderly People over 70 Years Old: Visual Acuity, Quality of Life, and Cost-Utility Values," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-8, October.
    56. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
    57. Erik J. Dasbach & Elamin H. Elbasha, 2017. "Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview," PharmacoEconomics, Springer, vol. 35(7), pages 673-683, July.
    58. Rachael Maree Hunter & Rob Anderson & Tim Kirkpatrick & Charlotte Lennox & Fiona Warren & Rod S. Taylor & Jenny Shaw & Mark Haddad & Alex Stirzaker & Mike Maguire & Richard Byng, 2022. "Economic evaluation of a complex intervention (Engager) for prisoners with common mental health problems, near to and after release: a cost-utility and cost-consequences analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 193-210, March.
    59. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2005. "The value of implementation and the value of information: combined and uneven development," Working Papers 005cherp, Centre for Health Economics, University of York.
    60. J. Brown & N. J. Welton & C. Bankhead & S. H. Richards & L. Roberts & C. Tydeman & T. J. Peters, 2006. "A Bayesian approach to analysing the cost‐effectiveness of two primary care interventions aimed at improving attendance for breast screening," Health Economics, John Wiley & Sons, Ltd., vol. 15(5), pages 435-445, May.
    61. Jennifer Prah Ruger & Arbi Ben Abdallah & Craig Luekens & Linda Cottler, 2012. "Cost-Effectiveness of Peer-Delivered Interventions for Cocaine and Alcohol Abuse among Women: A Randomized Controlled Trial," PLOS ONE, Public Library of Science, vol. 7(3), pages 1-12, March.
    62. Baumann, Florian & Friehe, Tim, 2016. "Learning-by-doing in torts: Liability and information about accident technology," Economics Letters, Elsevier, vol. 138(C), pages 1-4.
    63. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
    64. Francisco-José Polo & Miguel Negrín & Xavier Badía & Montse Roset, 2005. "Bayesian regression models for cost-effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 45-52, March.
    65. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
    66. Michal Jakubczyk, 2016. "Choosing from multiple alternatives in cost-effectiveness analysis with fuzzy willingness-to-pay/accept and uncertainty," KAE Working Papers 2016-006, Warsaw School of Economics, Collegium of Economic Analysis.
    67. Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery, 2014. "Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)," PharmacoEconomics, Springer, vol. 32(6), pages 573-590, June.
    68. Hoch, Jeffrey S. & Blume, Jeffrey D., 2008. "Measuring and illustrating statistical evidence in a cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(2), pages 476-495, March.
    69. Lukasz Tanajewski & Matthew Franklin & Georgios Gkountouras & Vladislav Berdunov & Rowan H Harwood & Sarah E Goldberg & Lucy E Bradshaw & John R F Gladman & Rachel A Elliott, 2015. "Economic Evaluation of a General Hospital Unit for Older People with Delirium and Dementia (TEAM Randomised Controlled Trial)," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-20, December.
    70. Martin Henriksson & Fredrik Lundgren & Per Carlsson, 2006. "Informing the efficient use of health care and health care research resources ‐ the case of screening for abdominal aortic aneurysm in Sweden," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1311-1322, December.
    71. Douglas Coyle, 2003. "Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues," Health Economics, John Wiley & Sons, Ltd., vol. 12(2), pages 159-162, February.
    72. Douwe Postmus & Tommi Tervonen & Gert Valkenhoef & Hans Hillege & Erik Buskens, 2014. "A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(7), pages 709-716, September.
    73. Lukasz Tanajewski & Matthew Franklin & Georgios Gkountouras & Vladislav Berdunov & Judi Edmans & Simon Conroy & Lucy E Bradshaw & John R F Gladman & Rachel A Elliott, 2015. "Cost-Effectiveness of a Specialist Geriatric Medical Intervention for Frail Older People Discharged from Acute Medical Units: Economic Evaluation in a Two-Centre Randomised Controlled Trial (AMIGOS)," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-18, May.
    74. N. J. Welton & A. E. Ades & D. M. Caldwell & T. J. Peters, 2008. "Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 171(4), pages 807-841, October.
    75. Casey Quinn, 2005. "Generalisable regression methods for costeffectiveness using copulas," Health, Econometrics and Data Group (HEDG) Working Papers 05/13, HEDG, c/o Department of Economics, University of York.
    76. Lemoine, Coralie & Loubière, Sandrine & Boucekine, Mohamed & Girard, Vincent & Tinland, Aurélie & Auquier, Pascal, 2021. "Cost-effectiveness analysis of housing first intervention with an independent housing and team support for homeless people with severe mental illness: A Markov model informed by a randomized controlle," Social Science & Medicine, Elsevier, vol. 272(C).
    77. David M. Meads & Adam Martin & Alys Griffiths & Rachael Kelley & Byron Creese & Louise Robinson & Joanne McDermid & Rebecca Walwyn & Clive Ballard & Claire A. Surr, 2020. "Cost-Effectiveness of Dementia Care Mapping in Care-Home Settings: Evaluation of a Randomised Controlled Trial," Applied Health Economics and Health Policy, Springer, vol. 18(2), pages 237-247, April.

  21. Mark Sculpher & Michael Palmer & Anne Heyes, 2000. "Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy," PharmacoEconomics, Springer, vol. 17(4), pages 361-370, April.

    Cited by:

    1. Daniel E. Jonas & Louise B. Russell & Jon Chou & Michael Pignone, 2010. "Willingness‐to‐pay to avoid the time spent and discomfort associated with screening colonoscopy," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1193-1211, October.

  22. Mark Sculpher, 1998. "The cost‐effectiveness of preference‐based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia," Health Economics, John Wiley & Sons, Ltd., vol. 7(2), pages 129-142, March.

    Cited by:

    1. Peter Zweifel & H. E. Frech, 2016. "Why ‘Optimal’ Payment for Healthcare Providers Can Never be Optimal Under Community Rating," Applied Health Economics and Health Policy, Springer, vol. 14(1), pages 9-20, February.
    2. Mark Sculpher & Amiram Gafni, 2001. "Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 10(4), pages 317-324, June.

  23. Andrew Briggs & Mark Sculpher, 1995. "Sensitivity analysis in economic evaluation: A review of published studies," Health Economics, John Wiley & Sons, Ltd., vol. 4(5), pages 355-371, September.

    Cited by:

    1. Joanne Lord & Maxwell A. Asante, 1999. "Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 8(4), pages 323-333, June.
    2. K. Cooper & S. Brailsford & R. Davies & J. Raftery, 2006. "A review of health care models for coronary heart disease interventions," Health Care Management Science, Springer, vol. 9(4), pages 311-324, November.
    3. Mark J. C. Nuijten & Pieter H. A. J. M. Van Gelder, 2011. "A Concise Equation That Captures the Essential Elements of One-Way Sensitivity Analyses in Health Economic Models," Medical Decision Making, , vol. 31(4), pages 642-649, July.
    4. Damian Walker & Julia A. Fox‐Rushby, 2000. "Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature," Health Economics, John Wiley & Sons, Ltd., vol. 9(8), pages 681-698, December.
    5. Isaac Corro Ramos & Maureen P. M. H. Rutten-van Mölken & Maiwenn J. Al, 2013. "The Role of Value-of-Information Analysis in a Health Care Research Priority Setting," Medical Decision Making, , vol. 33(4), pages 472-489, May.
    6. Trevor A. Sheldon, 1996. "Problems of using modelling in the economic evaluation of health care," Health Economics, John Wiley & Sons, Ltd., vol. 5(1), pages 1-11, January.
    7. Nancy Wolff & Thomas W. Helminiak, 1996. "Nonsampling measurement error in administrative data: Implications for economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 5(6), pages 501-512, November.
    8. K Cooper & S C Brailsford & R Davies, 2007. "Choice of modelling technique for evaluating health care interventions," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 58(2), pages 168-176, February.
    9. Alan M. Garber, 1999. "Advances in Cost-Effectiveness Analysis of Health Interventions," NBER Working Papers 7198, National Bureau of Economic Research, Inc.
    10. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
    11. David J. Vanness & W. Ray Kim, 2002. "Bayesian estimation, simulation and uncertainty analysis: the cost‐effectiveness of ganciclovir prophylaxis in liver transplantation," Health Economics, John Wiley & Sons, Ltd., vol. 11(6), pages 551-566, September.
    12. Clive Pritchard, 1998. "Trends in Economic Evaluation," Briefing 000444, Office of Health Economics.

Chapters

    Sorry, no citations of chapters recorded.

Books

  1. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629.

    Cited by:

    1. Chiranjeev Sanyal & Don Husereau, 2020. "Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 375-392, June.
    2. Kristian Schultz Hansen & Siân E Clarke & Sham Lal & Pascal Magnussen & Anthony K Mbonye, 2017. "Cost-effectiveness analysis of introducing malaria diagnostic testing in drug shops: A cluster-randomised trial in Uganda," PLOS ONE, Public Library of Science, vol. 12(12), pages 1-18, December.
    3. Verin Lertjanyakun & Nathorn Chaiyakunapruk & Susumu Kunisawa & Yuichi Imanaka, 2018. "Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor–positive and Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in Japan," PharmacoEconomics, Springer, vol. 36(9), pages 1113-1124, September.
    4. Joke Bilcke & Philippe Beutels & Marc Brisson & Mark Jit, 2011. "Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models," Medical Decision Making, , vol. 31(4), pages 675-692, July.
    5. Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis, 2012. "Economic Evaluation of Clopidogrel in Acute Coronary Syndrome Patients without ST-Segment Elevation in Greece," Applied Health Economics and Health Policy, Springer, vol. 10(4), pages 261-271, July.
    6. Arantzazu Arrospide & Oliver Ibarrondo & Iván Castilla & Igor Larrañaga & Javier Mar, 2022. "Development and Validation of a Discrete Event Simulation Model to Evaluate the Cardiovascular Impact of Population Policies for Obesity," Medical Decision Making, , vol. 42(2), pages 241-254, February.
    7. Charlotte Deogan & Natalie Zarabi & Nils Stenström & Pi Högberg & Eva Skärstrand & Edison Manrique-Garcia & Kristian Neovius & Anna Månsdotter, 2015. "Cost-Effectiveness of School-Based Prevention of Cannabis Use," Applied Health Economics and Health Policy, Springer, vol. 13(5), pages 525-542, October.
    8. Elamin Elbasha & Jagpreet Chhatwal, 2016. "Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers," PharmacoEconomics, Springer, vol. 34(1), pages 13-22, January.
    9. Lara J Wolfson & Vincent J Daniels & Matthew Pillsbury & Zafer Kurugöl & Cuneyt Yardimci & Jeffrey Kyle & Ener Cagri Dinleyici, 2019. "Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-26, August.
    10. Tom L. Drake & Angela Devine & Shunmay Yeung & Nicholas P. J. Day & Lisa J. White & Yoel Lubell, 2016. "Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low‐ and Middle‐Income Countries: A Systematic Literature Review," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 124-139, February.
    11. Geke Romijn & Neeltje Batelaan & Jeroen Koning & Anton van Balkom & Aart de Leeuw & Friederike Benning & Leona Hakkaart van Roijen & Heleen Riper, 2021. "Acceptability, effectiveness and cost-effectiveness of blended cognitive-behavioural therapy (bCBT) versus face-to-face CBT (ftfCBT) for anxiety disorders in specialised mental health care: A 15-week ," PLOS ONE, Public Library of Science, vol. 16(11), pages 1-20, November.
    12. Jackson Christopher H & Sharples Linda D & Thompson Simon G, 2010. "Survival Models in Health Economic Evaluations: Balancing Fit and Parsimony to Improve Prediction," The International Journal of Biostatistics, De Gruyter, vol. 6(1), pages 1-31, October.
    13. Waranya Rattanavipapong & Chittawan Poonsiri & Wanrudee Isaranuwatchai & Sopon Iamsirithaworn & Jutarat Apakupakul & Chaninan Sonthichai & Rungrueng Kitphati & Yot Teerawattananon, 2023. "Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand," Applied Health Economics and Health Policy, Springer, vol. 21(3), pages 511-522, May.
    14. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    15. Kaitlyn Hastings & Clara Marquina & Jedidiah Morton & Dina Abushanab & Danielle Berkovic & Stella Talic & Ella Zomer & Danny Liew & Zanfina Ademi, 2022. "Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia," PharmacoEconomics, Springer, vol. 40(4), pages 449-460, April.
    16. Naiyana Praditsitthikorn & Yot Teerawattananon & Sripen Tantivess & Supon Limwattananon & Arthorn Riewpaiboon & Saibua Chichareon & Nantakan Ieumwananonthachai & Viroj Tangcharoensathien, 2011. "Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand," PharmacoEconomics, Springer, vol. 29(9), pages 781-806, September.
    17. Ulla Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.
    18. Gordon Hazen, 2011. "Cohort Decomposition for Markov Cost-Effectiveness Models," Medical Decision Making, , vol. 31(1), pages 19-34, January.
    19. Siin Kim & Sola Han & Hyungtae Kim & Hae Sun Suh, 2021. "Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea," Applied Health Economics and Health Policy, Springer, vol. 19(4), pages 545-555, July.
    20. Beth Woods & Claire Rothery & Paul Revill & Timothy Hallett & Andrew Phillips & Karl Claxton., 2018. "Setting research priorities in Global Health:Appraising the value of evidence generation activities to support decision-making in health care," Working Papers 155cherp, Centre for Health Economics, University of York.
    21. Ifigeneia Mavranezouli & Odette Megnin-Viggars & Nick Grey & Gita Bhutani & Jonathan Leach & Caitlin Daly & Sofia Dias & Nicky J Welton & Cornelius Katona & Sharif El-Leithy & Neil Greenberg & Sarah S, 2020. "Cost-effectiveness of psychological treatments for post-traumatic stress disorder in adults," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-22, April.
    22. Christine Nguyen & Mark Bounthavong & Margaret Mendes & Melissa Christopher & Josephine Tran & Rashid Kazerooni & Anthony Morreale, 2012. "Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 30(7), pages 575-593, July.
    23. Paul Tappenden & Sue Harnan & Lesley Uttley & Matthew Mildred & Martin Walshaw & Christopher Taylor & Keith Brownlee, 2014. "The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis," PharmacoEconomics, Springer, vol. 32(2), pages 159-172, February.
    24. Ifigeneia Mavranezouli & Joran Lokkerbol, 2017. "A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder," PharmacoEconomics, Springer, vol. 35(3), pages 271-296, March.
    25. Elamin Elbasha & Jagpreet Chhatwal, 2015. "Characterizing Heterogeneity Bias in Cohort-Based Models," PharmacoEconomics, Springer, vol. 33(8), pages 857-865, August.
    26. Christopher H. Jackson & Mark Jit & Linda D. Sharples & Daniela De Angelis, 2015. "Calibration of Complex Models through Bayesian Evidence Synthesis," Medical Decision Making, , vol. 35(2), pages 148-161, February.
    27. David Brain & Jonathan Mitchell & James O’Beirne, 2020. "Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care," PLOS ONE, Public Library of Science, vol. 15(6), pages 1-13, June.
    28. Prajakta P. Masurkar & Haluk Damgacioglu & Ashish A. Deshmukh & Meghana V. Trivedi, 2023. "Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA," PharmacoEconomics, Springer, vol. 41(6), pages 709-718, June.
    29. Mario J. N. M. Ouwens & Pralay Mukhopadhyay & Yiduo Zhang & Min Huang & Nicholas Latimer & Andrew Briggs, 2019. "Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations," PharmacoEconomics, Springer, vol. 37(9), pages 1129-1138, September.
    30. Rebekah Fong Soe Khioe & Chris Skedgel & Andrew Hart & Michael Philip Nelson Lewis & Leo Alexandre, 2018. "Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 36(3), pages 349-358, March.
    31. Angelis, A. & Montibeller, G. & Kanavos, P., 2023. "A structured methodology for essential medicines lists and health emergency stockpiles: Experience with the Emergency Medicines Buffer Stock in the United Kingdom," Social Science & Medicine, Elsevier, vol. 337(C).
    32. Xiao Zang & Emanuel Krebs & Jeong E. Min & Ankur Pandya & Brandon D. L. Marshall & Bruce R. Schackman & Czarina N. Behrends & Daniel J. Feaster & Bohdan Nosyk, 2020. "Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities," Medical Decision Making, , vol. 40(1), pages 3-16, January.
    33. Mandeville, Kate L. & Hanson, Kara & Muula, Adamson S. & Dzowela, Titha & Ulaya, Godwin & Lagarde, Mylène, 2017. "Specialty training for the retention of Malawian doctors: A cost-effectiveness analysis," Social Science & Medicine, Elsevier, vol. 194(C), pages 87-95.
    34. Charlotte Davies & Andrew Briggs & Paula Lorgelly & Göran Garellick & Henrik Malchau, 2013. "The “Hazards†of Extrapolating Survival Curves," Medical Decision Making, , vol. 33(3), pages 369-380, April.
    35. Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini, 2019. "Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data," PharmacoEconomics, Springer, vol. 37(2), pages 255-266, February.
    36. Candio, Paolo & Violato, Mara & Luengo-Fernandez, Ramon & Leal, Jose, 2022. "Cost-effectiveness of home-based stroke rehabilitation across Europe: A modelling study," Health Policy, Elsevier, vol. 126(3), pages 183-189.
    37. Risha Gidwani & Louise B. Russell, 2020. "Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers," PharmacoEconomics, Springer, vol. 38(11), pages 1153-1164, November.
    38. Deirdre B. Blissett & Joerg S. Steier & Yakubu G. Karagama & Rob S. Blissett, 2021. "Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Per," PharmacoEconomics - Open, Springer, vol. 5(3), pages 475-489, September.
    39. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2017. "A Review of Methods for Analysis of the Expected Value of Information," Medical Decision Making, , vol. 37(7), pages 747-758, October.
    40. Conti, Gabriella & Pizzo, Elena & Morris, Steve & Melnychuk, Mariya, 2021. "The Economic Costs of Child Maltreatment in UK," CEPR Discussion Papers 16397, C.E.P.R. Discussion Papers.
    41. Elizaveta Sopina & Jan Sørensen, 2018. "Decision modelling of non-pharmacological interventions for individuals with dementia: a systematic review of methodologies," Health Economics Review, Springer, vol. 8(1), pages 1-12, December.
    42. Bogumił Kamiński & Michał Jakubczyk & Przemysław Szufel, 2018. "A framework for sensitivity analysis of decision trees," Central European Journal of Operations Research, Springer;Slovak Society for Operations Research;Hungarian Operational Research Society;Czech Society for Operations Research;Österr. Gesellschaft für Operations Research (ÖGOR);Slovenian Society Informatika - Section for Operational Research;Croatian Operational Research Society, vol. 26(1), pages 135-159, March.
    43. Round, Jeff, 2012. "Is a QALY still a QALY at the end of life?," Journal of Health Economics, Elsevier, vol. 31(3), pages 521-527.
    44. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    45. Matthew Franklin & Sebastian Hinde & Rachael Maree Hunter & Gerry Richardson & William Whittaker, 2024. "Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study," Applied Health Economics and Health Policy, Springer, vol. 22(4), pages 435-445, July.
    46. Jill Bindels & Bram Ramaekers & Isaac Corro Ramos & Leyla Mohseninejad & Saskia Knies & Janneke Grutters & Maarten Postma & Maiwenn Al & Talitha Feenstra & Manuela Joore, 2016. "Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives," PharmacoEconomics, Springer, vol. 34(3), pages 315-322, March.
    47. Anne Neumann & Lars Lindholm & Margareta Norberg & Olaf Schoffer & Stefanie J. Klug & Fredrik Norström, 2017. "The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 905-919, September.
    48. Matthew Franklin & James Lomas & Gerry Richardson, 2020. "Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations," PharmacoEconomics, Springer, vol. 38(7), pages 665-681, July.
    49. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
    50. Francisco J. Díez & Mar Yebra & Iñigo Bermejo & Miguel A. Palacios-Alonso & Manuel Arias Calleja & Manuel Luque & Jorge Pérez-Martín, 2017. "Markov Influence Diagrams," Medical Decision Making, , vol. 37(2), pages 183-195, February.
    51. Ties Hoomans & Johan L. Severens & Silvia M. A. A. Evers & Andre J. H. A. Ament, 2009. "Value for Money in Changing Clinical Practice: Should Decisions about Guidelines and Implementation Strategies Be Made Sequentially or Simultaneously?," Medical Decision Making, , vol. 29(2), pages 207-216, March.
    52. Christopher G Fawsitt & Jane Bourke & Richard A Greene & Claire M Everard & Aileen Murphy & Jennifer E Lutomski, 2013. "At What Price? A Cost-Effectiveness Analysis Comparing Trial of Labour after Previous Caesarean versus Elective Repeat Caesarean Delivery," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-8, March.
    53. Mathyn Vervaart & Eline Aas & Karl P. Claxton & Mark Strong & Nicky J. Welton & Torbjørn Wisløff & Anna Heath, 2023. "General-Purpose Methods for Simulating Survival Data for Expected Value of Sample Information Calculations," Medical Decision Making, , vol. 43(5), pages 595-609, July.
    54. Manal H. El-Hamamsy & Gihan H. Elsisi & Randa Eldessouki & Mohamed M. Elmazar & Ahmed S. Taha & Basma F. Awad & Hossam Elmansy, 2016. "Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 431-440, August.
    55. Yesim Tozan & Pitcha Ratanawong & Valérie R Louis & Pattamaporn Kittayapong & Annelies Wilder-Smith, 2014. "Use of Insecticide-Treated School Uniforms for Prevention of Dengue in Schoolchildren: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 9(9), pages 1-9, September.
    56. Xinyue Dong & Xiaoning He & Jing Wu, 2022. "Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting," PharmacoEconomics, Springer, vol. 40(12), pages 1187-1205, December.
    57. Charles E. Okafor, 2021. "Management of Chest Indrawing Pneumonia in Children Under Five Years at the Outpatient Health Facilities in Nigeria: An Economic Evaluation," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 429-437, May.
    58. Joseph F. Levy & Marjorie A. Rosenberg, 2019. "A Latent Class Approach to Modeling Trajectories of Health Care Cost in Pediatric Cystic Fibrosis," Medical Decision Making, , vol. 39(5), pages 593-604, July.
    59. Jonathan D. Campbell & R. Brett McQueen & Anne M. Libby & D. Eldon Spackman & Joshua J. Carlson & Andrew Briggs, 2015. "Cost-Effectiveness Uncertainty Analysis Methods," Medical Decision Making, , vol. 35(5), pages 596-607, July.
    60. Mattias Neyt & Chris Laet & Annemieke Ridder & Hans Brabandt, 2009. "Cost Effectiveness of Drug-Eluting Stents In Belgian Practice," PharmacoEconomics, Springer, vol. 27(4), pages 313-327, April.
    61. Hawre Jalal & Jeremy D. Goldhaber-Fiebert & Karen M. Kuntz, 2015. "Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling," Medical Decision Making, , vol. 35(5), pages 584-595, July.
    62. Thomas Michael Otten & Sabine E. Grimm & Bram Ramaekers & Manuela A. Joore, 2023. "Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations," PharmacoEconomics, Springer, vol. 41(6), pages 619-632, June.
    63. Jisoo A Kwon & Georgina M Chambers & Fabio Luciani & Lei Zhang & Shamin Kinathil & Dennis Kim & Hla-Hla Thein & Willings Botha & Sandra Thompson & Andrew Lloyd & Lorraine Yap & Richard T Gray & Tony B, 2021. "Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis," PLOS ONE, Public Library of Science, vol. 16(2), pages 1-13, February.
    64. Pepijn Vemer & Maureen Rutten-van Mölken, 2013. "The Road Not Taken: Transferability Issues in Multinational Trials," PharmacoEconomics, Springer, vol. 31(10), pages 863-876, October.
    65. Andrea Marcellusi & Claudia Simonelli & Francesco S. Mennini & Loreta A. Kondili, 2022. "Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 133-143, January.
    66. Christopher H. Jackson & Linda D. Sharples & Simon G. Thompson, 2010. "Structural and parameter uncertainty in Bayesian cost‐effectiveness models," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 59(2), pages 233-253, March.
    67. Joanna Thorn & Joanna Coast & Lazaros Andronis, 2016. "Interpretation of the Expected Value of Perfect Information and Research Recommendations," Medical Decision Making, , vol. 36(3), pages 285-295, April.
    68. Robbin H Ophuis & Joran Lokkerbol & Juanita A Haagsma & Mickaël Hiligsmann & Silvia M A A Evers & Suzanne Polinder, 2018. "Value of information analysis of an early intervention for subthreshold panic disorder: Healthcare versus societal perspective," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-13, November.
    69. Yong Yi Lee & Long Khanh-Dao Le & Emily A. Stockings & Phillipa Hay & Harvey A. Whiteford & Jan J. Barendregt & Cathrine Mihalopoulos, 2018. "Estimation of a Relative Risk Effect Size when Using Continuous Outcomes Data: An Application of Methods in the Prevention of Major Depression and Eating Disorders," Medical Decision Making, , vol. 38(7), pages 866-880, October.
    70. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    71. Deirdre B. Blissett & Rob S. Blissett & Matthew P. Newton Ede & Philip M. Stott & Daniel J. Cher & W. Carlton Reckling, 2021. "Minimally Invasive Sacroiliac Joint Fusion with Triangular Titanium Implants: Cost-Utility Analysis from NHS Perspective," PharmacoEconomics - Open, Springer, vol. 5(2), pages 197-209, June.
    72. Mehdi Javanbakht & Atefeh Mashayekhi & Hamid R Baradaran & AliAkbar Haghdoost & Ashkan Afshin, 2015. "Projection of Diabetes Population Size and Associated Economic Burden through 2030 in Iran: Evidence from Micro-Simulation Markov Model and Bayesian Meta-Analysis," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-17, July.
    73. Edward Cox & Simon Walker & Charlotte L. Edwardson & Stuart J. H. Biddle & Alexandra M. Clarke-Cornwell & Stacy A. Clemes & Melanie J. Davies & David W. Dunstan & Helen Eborall & Malcolm H. Granat & L, 2022. "The Cost-Effectiveness of the SMART Work & Life Intervention for Reducing Sitting Time," IJERPH, MDPI, vol. 19(22), pages 1-14, November.
    74. Rosarin Sruamsiri & Piyameth Dilokthornsakul & Chayanin Pratoomsoot & Nathorn Chaiyakunapruk, 2014. "A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding," PharmacoEconomics, Springer, vol. 32(8), pages 801-813, August.
    75. Jorge Pérez-Martín & Iñigo Bermejo & Francisco J. Díez, 2019. "Evaluation of Markov Models with Discontinuities," Medical Decision Making, , vol. 39(4), pages 414-420, May.
    76. Qiushi Chen & Turgay Ayer & Jagpreet Chhatwal, 2017. "Sensitivity Analysis in Sequential Decision Models," Medical Decision Making, , vol. 37(2), pages 243-252, February.
    77. Pankaj Bahuguna & Shankar Prinja & Chandrakant Lahariya & Radha Krishan Dhiman & Madhumita Prem Kumar & Vineeta Sharma & Arun Kumar Aggarwal & Rajesh Bhaskar & Hilde Graeve & Henk Bekedam, 2020. "Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 393-411, June.
    78. Andrew Yu & Scott Johnson & Si-Tien Wang & Pavel Atanasov & Jackson Tang & Eric Wu & Jingdong Chao & Parvez Mulani, 2009. "Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease," PharmacoEconomics, Springer, vol. 27(7), pages 609-621, July.
    79. Jorge Luis García & James J. Heckman, 2020. "Early Childhood Education and Life-cycle Health," NBER Working Papers 26880, National Bureau of Economic Research, Inc.
    80. Inigo Bermejo & Paul Tappenden & Ji-Hee Youn, 2017. "Replicating Health Economic Models: Firm Foundations or a House of Cards?," PharmacoEconomics, Springer, vol. 35(11), pages 1113-1121, November.
    81. Andrija S Grustam & Nasuh Buyukkaramikli & Ron Koymans & Hubertus J M Vrijhoef & Johan L Severens, 2019. "Value of information analysis in telehealth for chronic heart failure management," PLOS ONE, Public Library of Science, vol. 14(6), pages 1-23, June.
    82. Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards, 2017. "Scoping review on social care economic evaluation methods," Working Papers 150cherp, Centre for Health Economics, University of York.
    83. Marta O. Soares & Simon Walker & Stephen J. Palmer & Mark J. Sculpher, 2018. "Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment," Medical Decision Making, , vol. 38(4), pages 495-508, May.
    84. Moritz Hadwiger & Fabian-Simon Frielitz & Nora Eisemann & Christian Elsner & Nikolaos Dagres & Gerhard Hindricks & Alexander Katalinic, 2021. "Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator," Applied Health Economics and Health Policy, Springer, vol. 19(1), pages 57-68, January.
    85. Nicholas Graves & Adrian G Barnett & Kate A Halton & Jacob L Veerman & Elisabeth Winkler & Neville Owen & Marina M Reeves & Alison Marshall & Elizabeth Eakin, 2009. "Cost-Effectiveness of a Telephone-Delivered Intervention for Physical Activity and Diet," PLOS ONE, Public Library of Science, vol. 4(9), pages 1-8, September.
    86. Fernando Alarid-Escudero & Karen M. Kuntz, 2020. "Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio," PharmacoEconomics, Springer, vol. 38(3), pages 285-296, March.
    87. A. Ramírez de Arellano & A. Coca & M. de la Figuera & C. Rubio-Terrés & D. Rubio-Rodríguez & A. Gracia & A. Boldeanu & J. Puig-Gilberte & E. Salas, 2013. "Economic Evaluation of Cardio inCode ® , a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment," Applied Health Economics and Health Policy, Springer, vol. 11(5), pages 531-542, October.
    88. Matthew Franklin & Colin Angus & Tobias Welte & Guy Joos, 2023. "How Much Should be Invested in Lung Care Across the WHO European Region? Applying a Monetary Value to Disability-Adjusted Life-Years Within the International Respiratory Coalition’s Lung Facts," Applied Health Economics and Health Policy, Springer, vol. 21(4), pages 547-558, July.
    89. Stephen Morris & Kurinchi S Gurusamy & Jessica Sheringham & Brian R Davidson, 2015. "Cost-Effectiveness Analysis of Endoscopic Ultrasound versus Magnetic Resonance Cholangiopancreatography in Patients with Suspected Common Bile Duct Stones," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-12, March.
    90. Svenn Alexander Hansen & Eline Aas & Oddvar Solli, 2020. "A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 73-84, February.
    91. C. Rubio-Terrés & J. Soria & P. Morange & J. Souto & P. Suchon & J. Mateo & N. Saut & D. Rubio-Rodríguez & J. Sala & A. Gracia & S. Pich & E. Salas, 2015. "Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 233-242, April.
    92. Xudong Du & Mier Li & Ping Zhu & Ju Wang & Lisha Hou & Jijie Li & Hongdao Meng & Muke Zhou & Cairong Zhu, 2018. "Comparison of the flexible parametric survival model and Cox model in estimating Markov transition probabilities using real-world data," PLOS ONE, Public Library of Science, vol. 13(8), pages 1-13, August.
    93. Tushar Srivastava & Nicholas R. Latimer & Paul Tappenden, 2021. "Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals," PharmacoEconomics, Springer, vol. 39(8), pages 869-878, August.
    94. Mathias Baumann & Tom Stargardt & Simon Frey, 2020. "Cost–Utility of Internet-Based Cognitive Behavioral Therapy in Unipolar Depression: A Markov Model Simulation," Applied Health Economics and Health Policy, Springer, vol. 18(4), pages 567-578, August.
    95. Biddle, Louise & Miners, Alec & Bozorgmehr, Kayvan, 2019. "Cost-utility of screening for depression among asylum seekers: a modelling study in Germany," Health Policy, Elsevier, vol. 123(9), pages 873-881.
    96. Mark Bounthavong & Javed Butler & Chantal M. Dolan & Jeffrey D. Dunn & Kathryn A. Fisher & Nina Oestreicher & Bertram Pitt & Paul J. Hauptman & David L. Veenstra, 2018. "Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia," PharmacoEconomics, Springer, vol. 36(12), pages 1463-1473, December.
    97. Eleanor Heather & Katherine Payne & Mark Harrison & Deborah Symmons, 2014. "Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models," PharmacoEconomics, Springer, vol. 32(2), pages 109-134, February.
    98. Shepherd, Keith D. & Shepherd, Gemma & Walsh, Markus G., 2015. "Land health surveillance and response: A framework for evidence-informed land management," Agricultural Systems, Elsevier, vol. 132(C), pages 93-106.
    99. Carmen Selva-Sevilla & Elena Conde-Montero & Manuel Gerónimo-Pardo, 2020. "Bayesian Regression Model for a Cost-Utility and Cost-Effectiveness Analysis Comparing Punch Grafting Versus Usual Care for the Treatment of Chronic Wounds," IJERPH, MDPI, vol. 17(11), pages 1-21, May.
    100. Aneeka Hafeez & Lauren E. Cipriano & Richard B. Kim & Gregory S. Zaric & Ute I. Schwarz & Sisira Sarma, 2024. "Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada," PharmacoEconomics, Springer, vol. 42(1), pages 69-90, January.
    101. Han-I. Wang & Alexandra Smith & Eline Aas & Eve Roman & Simon Crouch & Cathy Burton & Russell Patmore, 2017. "Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(2), pages 255-267, March.
    102. John Graves & Shawn Garbett & Zilu Zhou & Jonathan S. Schildcrout & Josh Peterson, 2021. "Comparison of Decision Modeling Approaches for Health Technology and Policy Evaluation," Medical Decision Making, , vol. 41(4), pages 453-464, May.
    103. Steven Simoens, 2009. "Health Economic Assessment: A Methodological Primer," IJERPH, MDPI, vol. 6(12), pages 1-17, November.
    104. Vakaramoko Diaby & Georges Adunlin & Alberto Montero, 2014. "Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial," PharmacoEconomics, Springer, vol. 32(2), pages 101-108, February.
    105. Zoe Philips & Karl Claxton & Stephen Palmer, 2008. "The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions?," Medical Decision Making, , vol. 28(3), pages 287-299, May.
    106. Manuel Gomes & Robert Aldridge & Peter Wylie & James Bell & Owen Epstein, 2013. "Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography Versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients," Applied Health Economics and Health Policy, Springer, vol. 11(2), pages 107-117, April.
    107. Ruth Pulikottil-Jacob & Martin Connock & Ngianga-Bakwin Kandala & Hema Mistry & Amy Grove & Karoline Freeman & Matthew Costa & Paul Sutcliffe & Aileen Clarke, 2016. "Has Metal-On-Metal Resurfacing Been a Cost-Effective Intervention for Health Care Providers?—A Registry Based Study," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-13, November.
    108. Charles E Okafor & Obinna I Ekwunife, 2017. "Cost-effectiveness analysis of diarrhoea management approaches in Nigeria: A decision analytical model," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 11(12), pages 1-14, December.
    109. Marina Antoniou & Céu Mateus & Bruce Hollingsworth & Andrew Titman, 2024. "A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus," PharmacoEconomics, Springer, vol. 42(1), pages 19-40, January.
    110. Isaac Corro Ramos & Maureen P. M. H. Rutten-van Mölken & Maiwenn J. Al, 2013. "The Role of Value-of-Information Analysis in a Health Care Research Priority Setting," Medical Decision Making, , vol. 33(4), pages 472-489, May.
    111. Mathyn Vervaart & Mark Strong & Karl P. Claxton & Nicky J. Welton & Torbjørn Wisløff & Eline Aas, 2022. "An Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trial," Medical Decision Making, , vol. 42(5), pages 612-625, July.
    112. Nicky J. Welton & Marta O. Soares & Stephen Palmer & Anthony E. Ades & David Harrison & Manu Shankar-Hari & Kathy M. Rowan, 2015. "Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses," Medical Decision Making, , vol. 35(5), pages 608-621, July.
    113. Andrea Gabrio & Michael J. Daniels & Gianluca Baio, 2020. "A Bayesian parametric approach to handle missing longitudinal outcome data in trial‐based health economic evaluations," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 183(2), pages 607-629, February.
    114. David Brain & Ruth Tulleners & Xing Lee & Qinglu Cheng & Nicholas Graves & Rosana Pacella, 2019. "Cost-effectiveness analysis of an innovative model of care for chronic wounds patients," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-13, March.
    115. Andrew Ying & Eric J. Tchetgen Tchetgen, 2023. "Structural cumulative survival models for estimation of treatment effects accounting for treatment switching in randomized experiments," Biometrics, The International Biometric Society, vol. 79(3), pages 1597-1609, September.
    116. Saskia Schawo & Annemarie Kolk & Clazien Bouwmans & Lieven Annemans & Maarten Postma & Jan Buitelaar & Michel Agthoven & Leona Hakkaart-van Roijen, 2015. "Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Neede," PharmacoEconomics, Springer, vol. 33(5), pages 489-509, May.
    117. David Brain & David Johnson & Julia Hocking & Angela T Chang, 2021. "The economic impact of rostering junior doctors to triage to assist nursing staff in the early part of the patient journey through the emergency department," PLOS ONE, Public Library of Science, vol. 16(12), pages 1-10, December.
    118. Stefano Conti & Karl Claxton, 2009. "Dimensions of Design Space: A Decision-Theoretic Approach to Optimal Research Design," Medical Decision Making, , vol. 29(6), pages 643-660, November.
    119. Claire McKenna & Karl Claxton, 2011. "Addressing Adoption and Research Design Decisions Simultaneously," Medical Decision Making, , vol. 31(6), pages 853-865, November.
    120. Chantal Guilhaume & Delphine Saragoussi & John Cochran & Clément François & Mondher Toumi, 2010. "Modeling stroke management: a qualitative review of cost-effectiveness analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(4), pages 419-426, August.
    121. Claire Rothery & Karl Claxton & Stephen Palmer & David Epstein & Rosanna Tarricone & Mark Sculpher, 2017. "Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs," Health Economics, John Wiley & Sons, Ltd., vol. 26(S1), pages 109-123, February.
    122. Lisa Meckley & James Gudgeon & Jeffrey Anderson & Marc Williams & David Veenstra, 2010. "A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing," PharmacoEconomics, Springer, vol. 28(1), pages 61-74, January.
    123. Theresa Tawiah & Kristian Schultz Hansen & Frank Baiden & Jane Bruce & Mathilda Tivura & Rupert Delimini & Seeba Amengo-Etego & Daniel Chandramohan & Seth Owusu-Agyei & Jayne Webster, 2016. "Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-18, October.
    124. Wolf H. Rogowski, 2009. "The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study," Medical Decision Making, , vol. 29(2), pages 224-238, March.
    125. Paolo Candio, 2023. "On the role of cost-effectiveness in accounting," MANAGEMENT CONTROL, FrancoAngeli Editore, vol. 2023(2 Suppl.), pages 215-225.
    126. Martin Hoyle & Rob Anderson, 2010. "Whose Costs and Benefits? Why Economic Evaluations Should Simulate Both Prevalent and All Future Incident Patient Cohorts," Medical Decision Making, , vol. 30(4), pages 426-437, July.
    127. William Herring & Isobel Pearson & Molly Purser & Hamid Reza Nakhaipour & Amin Haiderali & Sorrel Wolowacz & Kavisha Jayasundara, 2016. "Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada," PharmacoEconomics, Springer, vol. 34(1), pages 77-90, January.
    128. Tom Bromilow & Hayden Holmes & Laura Coote & Sam Woods & Joshua Pink, 2023. "Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England," PharmacoEconomics - Open, Springer, vol. 7(5), pages 739-750, September.
    129. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.
    130. David McDaid & A-La Park, 2021. "Modelling the Economic Impact of Reducing Loneliness in Community Dwelling Older People in England," IJERPH, MDPI, vol. 18(4), pages 1-16, February.
    131. Eric Jutkowitz & Fernando Alarid-Escudero & Karen M. Kuntz & Hawre Jalal, 2019. "The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis," PharmacoEconomics, Springer, vol. 37(7), pages 871-877, July.
    132. Hiral Anil Shah & Tim Baker & Carl Otto Schell & August Kuwawenaruwa & Khamis Awadh & Karima Khalid & Angela Kairu & Vincent Were & Edwine Barasa & Peter Baker & Lorna Guinness, 2023. "Cost Effectiveness of Strategies for Caring for Critically Ill Patients with COVID-19 in Tanzania," PharmacoEconomics - Open, Springer, vol. 7(4), pages 537-552, July.
    133. Elamin H. Elbasha & Jagpreet Chhatwal, 2016. "Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers," PharmacoEconomics, Springer, vol. 34(1), pages 13-22, January.
    134. Salah Ghabri & Erwan Autin & Anne-Isabelle Poullié & Jean Michel Josselin, 2018. "The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)," PharmacoEconomics, Springer, vol. 36(4), pages 407-417, April.
    135. Sabine E. Grimm & Xavier Pouwels & Bram L. T. Ramaekers & Ben Wijnen & Saskia Knies & Janneke Grutters & Manuela A. Joore, 2020. "Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models," PharmacoEconomics, Springer, vol. 38(2), pages 205-216, February.
    136. Harold P. Lehmann & Nkossi Dambita & George R. Buchanan & James F. Casella, 2011. "Decision Modeling of Disagreements," Medical Decision Making, , vol. 31(6), pages 805-815, November.
    137. Ghayoori, Arash & Nagi, Rakesh, 2022. "A Markov model examining intervention effects on the HIV prevalence/incidence amongst the overall population," Socio-Economic Planning Sciences, Elsevier, vol. 79(C).
    138. Anna Heath, 2022. "Calculating Expected Value of Sample Information Adjusting for Imperfect Implementation," Medical Decision Making, , vol. 42(5), pages 626-636, July.
    139. G. Ramos & Antoinette Asselt & Sandra Kuiper & Johan Severens & Tanja Maas & Edward Dompeling & J. Knottnerus & Onno Schayck, 2014. "Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 869-883, November.
    140. Xiaomin Wan & Liubao Peng & Yuanjian Li, 2015. "A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-21, March.
    141. Henry Glick, 2011. "Sample Size and Power for Cost-Effectiveness Analysis (Part 1)," PharmacoEconomics, Springer, vol. 29(3), pages 189-198, March.
    142. Timothy Spelman & William L. Herring & Yuanhui Zhang & Michael Tempest & Isobel Pearson & Ulrich Freudensprung & Carlos Acosta & Thibaut Dort & Robert Hyde & Eva Havrdova & Dana Horakova & Maria Troja, 2022. "Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the Unit," PharmacoEconomics, Springer, vol. 40(3), pages 323-339, March.
    143. Sun-Young Kim & Louise B. Russell & Anushua Sinha, 2015. "Handling Parameter Uncertainty in Cost-Effectiveness Models Simply and Responsibly," Medical Decision Making, , vol. 35(5), pages 567-569, July.
    144. Naruemon Bamrungsawad & Nathorn Chaiyakunapruk & Nilawan Upakdee & Chayanin Pratoomsoot & Rosarin Sruamsiri & Piyameth Dilokthornsakul, 2015. "Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand," PharmacoEconomics, Springer, vol. 33(5), pages 521-531, May.
    145. Andre Verhoek & Parneet Cheema & Barbara Melosky & Benoit Samson & Frances A. Shepherd & Filippo Marinis & Thomas John & Yi-Long Wu & Bart Heeg & Nadia Dalfsen & Benjamin Bracke & Miguel Miranda & Sim, 2023. "Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer," PharmacoEconomics - Open, Springer, vol. 7(3), pages 455-467, May.
    146. Michael Willis & Christian Asseburg & April Slee & Andreas Nilsson & Cheryl Neslusan, 2021. "Macrovascular Risk Equations Based on the CANVAS Program," PharmacoEconomics, Springer, vol. 39(4), pages 447-461, April.
    147. Elamin H. Elbasha & Jagpreet Chhatwal, 2016. "Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods," Medical Decision Making, , vol. 36(1), pages 115-131, January.
    148. Ezeofor Victory & Edwards T. Rhiannon & Burnside Girvan & Adair Pauline & Pine M. Cynthia, 2022. "Cost-effectiveness Analysis of the Dental RECUR Pragmatic Randomized Controlled Trial: Evaluating a Goal-oriented Talking Intervention to Prevent Reoccurrence of Dental Caries in Children," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 431-445, May.
    149. Sameera Senanayake & Nicholas Graves & Helen Healy & Keshwar Baboolal & Adrian Barnett & Sanjeewa Kularatna, 2021. "Time-to-event analysis in economic evaluations: a comparison of modelling methods to assess the cost-effectiveness of transplanting a marginal quality kidney," Health Economics Review, Springer, vol. 11(1), pages 1-12, December.
    150. Paolo Candio & Andrew J. Hill & Stavros Poupakis & Anni-Maria Pulkki-Brännström & Chris Bojke & Manuel Gomes, 2021. "Copula Models for Addressing Sample Selection in the Evaluation of Public Health Programmes: An Application to the Leeds Let’s Get Active Study," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 305-312, May.
    151. F. S. Mennini & Gianluca Fabiano & G. Favato & P. Sciattella & P. Bonanni & C. Pinto & A. Marcellusi, 2019. "Economic burden of HPV9-related diseases: a real-world cost analysis from Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 829-840, August.
    152. Yiqiao Xin & Ewan Gray & Jose Antonio Robles-Zurita & Houra Haghpanahan & Robert Heggie & Ciaran Kohli-Lynch & Andrew Briggs & David A. McAllister & Kenny D. Lawson & Jim Lewsey, 2022. "From Spreadsheets to Script: Experiences From Converting a Scottish Cardiovascular Disease Policy Model into R," Applied Health Economics and Health Policy, Springer, vol. 20(2), pages 149-158, March.
    153. Mariano Giorgi & Christian Caroli & Norberto Giglio & Paula Micone & Eleonora Aiello & Cristina Vulcano & Julia Blanco & Bonnie Donato & Joaquin Quevedo, 2015. "Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina," Health Economics Review, Springer, vol. 5(1), pages 1-10, December.
    154. Astrid Van Muylder & Thomas D’Hooghe & Jeroen Luyten, 2023. "Economic Evaluation of Medically Assisted Reproduction: A Methodological Systematic Review," Medical Decision Making, , vol. 43(7-8), pages 973-991, October.
    155. Kevin Marsh & Ceri Phillips & Richard Fordham & Evelina Bertranou & Janine Hale, 2012. "Estimating cost-effectiveness in public health: a summary of modelling and valuation methods," Health Economics Review, Springer, vol. 2(1), pages 1-6, December.
    156. Alison Pearce & Marion Haas & Rosalie Viney, 2013. "Are the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 11(6), pages 619-637, December.
    157. Simon van der Pol & Paula Rojas Garcia & Maarten J. Postma & Fernando Antoñanzas Villar & Antoinette D. I. Asselt, 2021. "Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review," PharmacoEconomics, Springer, vol. 39(12), pages 1411-1427, December.
    158. Sabine E. Grimm & Simon Dixon & John W. Stevens, 2017. "Assessing the Expected Value of Research Studies in Reducing Uncertainty and Improving Implementation Dynamics," Medical Decision Making, , vol. 37(5), pages 523-533, July.
    159. Torbjørn Wisløff & Richard White & Olav Dalgard & Ellen J. Amundsen & Hinta Meijerink & Astrid Louise Løvlie & Hilde Kløvstad, 2018. "Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway," PharmacoEconomics, Springer, vol. 36(5), pages 591-601, May.
    160. Wei Fang & Zhenru Wang & Michael B. Giles & Chris H. Jackson & Nicky J. Welton & Christophe Andrieu & Howard Thom, 2022. "Multilevel and Quasi Monte Carlo Methods for the Calculation of the Expected Value of Partial Perfect Information," Medical Decision Making, , vol. 42(2), pages 168-181, February.
    161. Michelle Tew & Kim Dalziel & Michelle Dowsey & Peter F. Choong & Philip Clarke, 2020. "Exploring the Impact of Quality of Life on Survival: A Case Study in Total Knee Replacement Surgery," Medical Decision Making, , vol. 40(3), pages 302-313, April.
    162. Zoë Pieters & Mark Strong & Virginia E. Pitzer & Philippe Beutels & Joke Bilcke, 2020. "A Computationally Efficient Method for Probabilistic Parameter Threshold Analysis for Health Economic Evaluations," Medical Decision Making, , vol. 40(5), pages 669-679, July.
    163. Caroline S. Clarke & Mariya Melnychuk & Angus I. G. Ramsay & Cecilia Vindrola-Padros & Claire Levermore & Ravi Barod & Axel Bex & John Hines & Muntzer M. Mughal & Kathy Pritchard-Jones & Maxine Tran &, 2022. "Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences Analysis," Applied Health Economics and Health Policy, Springer, vol. 20(6), pages 905-917, November.
    164. Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas, 2017. "The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(1), pages 1-12, March.
    165. Elisabetta Fenu & Vasily Lukyanov & Annabel Acs & Xenia Radu & Stephanie Stypa & Aren Fischer & John K. Marshall & Mark Oppe, 2022. "Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada," PharmacoEconomics - Open, Springer, vol. 6(4), pages 519-537, July.
    166. Gouveia, Catarina & Kalakou, Sofia & Cardoso-Grilo, Teresa, 2023. "How to forecast mental healthcare needs? Distinguishing between perceived and unperceived needs and their impact on capacity requirements," Socio-Economic Planning Sciences, Elsevier, vol. 87(PA).
    167. Charles Ebuka Okafor, 2021. "Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications," PharmacoEconomics - Open, Springer, vol. 5(3), pages 545-557, September.
    168. Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp, 2014. "Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 32(6), pages 601-612, June.
    169. Rachael Maree Hunter & Charles Davie & Anthony Rudd & Alan Thompson & Hilary Walker & Neil Thomson & James Mountford & Lee Schwamm & John Deanfield & Kerry Thompson & Bikash Dewan & Minesh Mistry & Sa, 2013. "Impact on Clinical and Cost Outcomes of a Centralized Approach to Acute Stroke Care in London: A Comparative Effectiveness Before and After Model," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-9, August.
    170. Fabienne Abadie & Christian Boehler, 2015. "Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing (MAFEIP) - Conceptual description of the Monitoring and Assessment Framework for the EIP on AHA," JRC Research Reports JRC96205, Joint Research Centre.
    171. Tomoyuki Takura & Akira Yuasa & Naohiro Yonemoto & Sven Demiya & Hiroyuki Matsuda & Nozomi Ebata & Koichi Fujii & Muneaki Ishijima, 2022. "Cost-Effectiveness Analysis of the Treatment Strategies with or without Opioid Medications in Surgery-Eligible Patients with Osteoarthritis in Japan," PharmacoEconomics - Open, Springer, vol. 6(1), pages 33-45, January.
    172. Fan Yang & Ana Duarte & Simon Walker & Susan Griffin, 2021. "Uncertainty Analysis in Intervention Impact on Health Inequality for Resource Allocation Decisions," Medical Decision Making, , vol. 41(6), pages 653-666, August.
    173. Carolina Barbosa & William N. Dowd & Arnie P. Aldridge & Christine Timko & Gary A. Zarkin, 2019. "Estimating Long-Term Drinking Patterns for People with Lifetime Alcohol Use Disorder," Medical Decision Making, , vol. 39(7), pages 765-780, October.
    174. Joris Kleintjens & Xiao Li & Steven Simoens & Vincent Thijs & Marnix Goethals & Ernst Rietzschel & Yumi Asukai & Ömer Saka & Thomas Evers & Petra Faes & Stefaan Vansieleghem & Mimi Ruyck, 2013. "Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting," PharmacoEconomics, Springer, vol. 31(10), pages 909-918, October.
    175. Sabine Elisabeth Grimm & Mark Strong & Alan Brennan & Allan J. Wailoo, 2017. "The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment," PharmacoEconomics, Springer, vol. 35(12), pages 1287-1296, December.
    176. Intira Jeannie Collins & John Cairns & Nicole Ngo-Giang-Huong & Wasna Sirirungsi & Pranee Leechanachai & Sophie Le Coeur & Tanawan Samleerat & Nareerat Kamonpakorn & Jutarat Mekmullica & Gonzague Jour, 2014. "Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in Thailand," Post-Print hal-02087678, HAL.
    177. Kurinchi Gurusamy & Edward Wilson & Andrew Burroughs & Brian Davidson, 2012. "Intra-operative vs pre-operative endoscopic sphincterotomy in patients with gallbladder and common bile duct stones," Applied Health Economics and Health Policy, Springer, vol. 10(1), pages 15-29, January.
    178. Lazaros Andronis & Lucinda J. Billingham & Stirling Bryan & Nicholas D. James & Pelham M. Barton, 2016. "A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research," Medical Decision Making, , vol. 36(3), pages 321-334, April.
    179. Eric Jutkowitz & Fernando Alarid-Escudero & Hyon K. Choi & Karen M. Kuntz & Hawre Jalal, 2017. "Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis," PharmacoEconomics, Springer, vol. 35(10), pages 1073-1085, October.
    180. Renée Else Michels & Maria Fransesco & Koshu Mahajan & Gerald J. D. Hengstman & Krijn M. H. Schiffers & Sangeeta Budhia & Gerard Harty & Marieke Krol, 2019. "Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands," Applied Health Economics and Health Policy, Springer, vol. 17(6), pages 857-873, December.
    181. Jonas Steel & Lode Godderis & Jeroen Luyten, 2018. "Methodological Challenges in the Economic Evaluation of Occupational Health and Safety Programmes," IJERPH, MDPI, vol. 15(11), pages 1-12, November.
    182. Martin Hoyle, 2008. "Future Drug Prices and Cost-Effectiveness Analyses," PharmacoEconomics, Springer, vol. 26(7), pages 589-602, July.
    183. Magnus Zingmark & Fredrik Norström & Lars Lindholm & Synneve Dahlin-Ivanoff & Susanne Gustafsson, 2019. "Modelling long-term cost-effectiveness of health promotion for community-dwelling older people," European Journal of Ageing, Springer, vol. 16(4), pages 395-404, December.
    184. Qi Cao & Erik Buskens & Talitha Feenstra & Tiny Jaarsma & Hans Hillege & Douwe Postmus, 2016. "Continuous-Time Semi-Markov Models in Health Economic Decision Making," Medical Decision Making, , vol. 36(1), pages 59-71, January.
    185. Gordon B. Hazen, 2022. "Augmenting Markov Cohort Analysis to Compute (Co)Variances: Implications for Strength of Cost-Effectiveness," INFORMS Journal on Computing, INFORMS, vol. 34(6), pages 3170-3180, November.
    186. Andrew H. Briggs & Timothy Baker & Nancy A. Risebrough & Mike Chambers & Sebastian Gonzalez-McQuire & Afisi S. Ismaila & Alex Exuzides & Chris Colby & Maggie Tabberer & Hana Muellerova & Nicholas Loca, 2017. "Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model," Medical Decision Making, , vol. 37(4), pages 469-480, May.
    187. Bauer, Annette & Knapp, Martin & Alvi, Mohsin & Chaudhry, Nasim & Gregoire, Alain & Malik, Abid & Sikander, Siham & Tayyaba, Kiran & Wagas, Ahmed & Husain, Nusrat, 2024. "Economic costs of perinatal depression and anxiety in a lower-middle income country: Pakistan," LSE Research Online Documents on Economics 122650, London School of Economics and Political Science, LSE Library.
    188. Elena Losina & Elizabeth E Dervan & A David Paltiel & Yan Dong & R John Wright & Kurt P Spindler & Lisa A Mandl & Morgan H Jones & Robert G Marx & Clare E Safran-Norton & Jeffrey N Katz, 2015. "Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-17, June.
    189. Hossein Haji Ali Afzali & Laura Bojke & Jonathan Karnon, 2018. "Model Structuring for Economic Evaluations of New Health Technologies," PharmacoEconomics, Springer, vol. 36(11), pages 1309-1319, November.
    190. Tae Yoon Lee & Paul Gustafson & Mohsen Sadatsafavi, 2023. "Closed-Form Solution of the Unit Normal Loss Integral in 2 Dimensions, with Application in Value-of-Information Analysis," Medical Decision Making, , vol. 43(5), pages 621-626, July.
    191. Hu, Bo & Cartagena-Farias, Javiera & Brimblecombe, Nicola & Jadoolal, Shari & Wittenberg, Raphael, 2023. "Projected costs of informal care for older people in England," LSE Research Online Documents on Economics 121157, London School of Economics and Political Science, LSE Library.
    192. Gemma E. Shields & Paul Clarkson & Ash Bullement & Warren Stevens & Mark Wilberforce & Tracey Farragher & Arpana Verma & Linda M. Davies, 2024. "Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature," PharmacoEconomics, Springer, vol. 42(7), pages 737-749, July.
    193. Mickaël Hiligsmann & Stuart S. Silverman & Andrea J. Singer & Leny Pearman & Jake Mathew & Yamei Wang & John Caminis & Jean-Yves Reginster, 2023. "Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States," PharmacoEconomics, Springer, vol. 41(7), pages 819-830, July.
    194. Arantzazu Arrospide & Oliver Ibarrondo & Rubén Blasco-Aguado & Igor Larrañaga & Fernando Alarid-Escudero & Javier Mar, 2024. "Using Age-Specific Rates for Parametric Survival Function Estimation in Simulation Models," Medical Decision Making, , vol. 44(4), pages 359-364, May.
    195. Aris Angelis & Huseyin Naci & Allan Hackshaw, 2020. "Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies," PharmacoEconomics, Springer, vol. 38(12), pages 1297-1308, December.
    196. Jennifer Uyei & R. Scott Braithwaite, 2016. "Are There Scenarios When the Use of Non–Placebo-Control Groups in Experimental Trial Designs Increase Expected Value to Society?," Medical Decision Making, , vol. 36(1), pages 20-30, January.
    197. Ingrid Zechmeister-Koss & Petra Schnell-Inderst & Günther Zauner, 2014. "Appropriate Evidence Sources for Populating Decision Analytic Models within Health Technology Assessment (HTA)," Medical Decision Making, , vol. 34(3), pages 288-299, April.
    198. Kittiphong Thiboonboon & Pattara Leelahavarong & Duangrurdee Wattanasirichaigoon & Nithiwat Vatanavicharn & Pornswan Wasant & Vorasuk Shotelersuk & Suthipong Pangkanon & Chulaluck Kuptanon & Sumonta C, 2015. "An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-25, August.
    199. Asakawa, Keiko & Senthilselvan, Ambikaipakan & Feeny, David & Johnson, Jeffrey & Rolfson, Darryl, 2012. "Trajectories of health-related quality of life differ by age among adults: Results from an eight-year longitudinal study," Journal of Health Economics, Elsevier, vol. 31(1), pages 207-218.
    200. Christopher H. Jackson & Simon G. Thompson & Linda D. Sharples, 2009. "Accounting for uncertainty in health economic decision models by using model averaging," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 172(2), pages 383-404, April.
    201. Rachel Song & Varinder Jeet & Rajan Sharma & Martin Hoyle & Bonny Parkinson, 2022. "Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia," PharmacoEconomics, Springer, vol. 40(8), pages 807-821, August.
    202. Manuel A. Espinoza & Andrea Manca & Karl Claxton & Mark J. Sculpher, 2014. "The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis," Medical Decision Making, , vol. 34(8), pages 951-964, November.
    203. Salah Ghabri & Françoise F. Hamers & Jean Michel Josselin, 2016. "Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health," PharmacoEconomics, Springer, vol. 34(6), pages 617-624, June.
    204. Andrew H. Briggs & Milton C. Weinstein & Elisabeth A. L. Fenwick & Jonathan Karnon & Mark J. Sculpher & A. David Paltiel, 2012. "Model Parameter Estimation and Uncertainty Analysis," Medical Decision Making, , vol. 32(5), pages 722-732, September.
    205. Yasuhiro Hagiwara & Takeru Shiroiwa, 2022. "Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches," Medical Decision Making, , vol. 42(5), pages 672-683, July.
    206. M. Ruggeri & M. Basile & C. Drago & F. R. Rolli & A. Cicchetti, 2018. "Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy," PharmacoEconomics, Springer, vol. 36(5), pages 625-636, May.
    207. Paal Joranger & Arild Nesbakken & Geir Hoff & Halfdan Sorbye & Arne Oshaug & Eline Aas, 2015. "Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer," Medical Decision Making, , vol. 35(2), pages 255-265, February.
    208. Hester V Eeren & Saskia J Schawo & Ron H J Scholte & Jan J V Busschbach & Leona Hakkaart, 2015. "Value of Information Analysis Applied to the Economic Evaluation of Interventions Aimed at Reducing Juvenile Delinquency: An Illustration," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-15, July.
    209. Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.
    210. Kelly Fust & Xiaoyan Li & Michael Maschio & Guillermo Villa & Anju Parthan & Richard Barron & Milton C. Weinstein & Luc Somers & Caroline Hoefkens & Gary H. Lyman, 2017. "Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma," PharmacoEconomics, Springer, vol. 35(4), pages 425-438, April.
    211. Xuanqian Xie & Alexis K. Schaink & Sichen Liu & Myra Wang & Andrei Volodin, 2023. "Understanding bias in probabilistic analysis in model-based health economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 307-319, March.
    212. Petra Menn & Reiner Leidl & Rolf Holle, 2012. "A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease," PharmacoEconomics, Springer, vol. 30(9), pages 825-840, September.
    213. Ilias Goranitis & Pelham Barton & Lee J Middleton & Jonathan J Deeks & Jane P Daniels & Pallavi Latthe & Arri Coomarasamy & Suneetha Rachaneni & Shanteela McCooty & Tina S Verghese & Tracy E Roberts, 2016. "Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-18, August.
    214. Aurea Duran & Nishan Sengupta & Alexander Diamantopoulos & Fiona Forster & Louis Kwong & Michael Lees, 2012. "Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective," PharmacoEconomics, Springer, vol. 30(2), pages 87-101, February.
    215. Sarah J Iribarren & Kenrick Cato & Louise Falzon & Patricia W Stone, 2017. "What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-20, February.
    216. Michał Jakubczyk & Bogumił Kamiński, 2017. "Fuzzy approach to decision analysis with multiple criteria and uncertainty in health technology assessment," Annals of Operations Research, Springer, vol. 251(1), pages 301-324, April.
    217. Shweta Mital & Hai V. Nguyen, 2020. "Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups," PharmacoEconomics, Springer, vol. 38(12), pages 1359-1372, December.
    218. Asaria, Miqdad & Walker, Simon & Palmer, Stephen & Gale, Chris P & Shah, Anoop D & Abrams, Keith R & Crowther, Michael & Manca, Andrea & Timmis, Adam & Hemingway, Harry & Sculpher, Mark, 2016. "Using electronic health records to predict costs and outcomes in stable coronary artery disease," LSE Research Online Documents on Economics 101257, London School of Economics and Political Science, LSE Library.
    219. Karen Pickering & Ioannis D. Gallos & Helen Williams & Malcolm J. Price & Abi Merriel & David Lissauer & Aurelio Tobias & G. Justus Hofmeyr & Arri Coomarasamy & Tracy E. Roberts, 2019. "Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis," PharmacoEconomics - Open, Springer, vol. 3(2), pages 163-176, June.
    220. Kristian Bolin, 2012. "Economic Evaluation of Smoking-Cessation Therapies," PharmacoEconomics, Springer, vol. 30(7), pages 551-564, July.
    221. Ifigeneia Mavranezouli & Nick Meader & John Cape & Tim Kendall, 2013. "The Cost Effectiveness of Pharmacological Treatments for Generalized Anxiety Disorder," PharmacoEconomics, Springer, vol. 31(4), pages 317-333, April.
    222. Salvatore Russo & Stefano Landi & Paolo Landa, 2017. "Management of knee osteoarthritis in Italy. A cost-utility analysis of Platelet-Rich-Plasma dedicated kit versus Hyaluronic acid for the intra-articular treatment of knee OA," Working Papers 08, Venice School of Management - Department of Management, Università Ca' Foscari Venezia.
    223. Padraig Dixon & George Davey Smith & Stephanie von Hinke & Neil M. Davies & William Hollingworth, 2016. "Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation," PharmacoEconomics, Springer, vol. 34(11), pages 1075-1086, November.
    224. William Herring & Isobel Pearson & Molly Purser & Hamid Nakhaipour & Amin Haiderali & Sorrel Wolowacz & Kavisha Jayasundara, 2016. "Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada," PharmacoEconomics, Springer, vol. 34(1), pages 77-90, January.
    225. Kangho Suh & Brian J. Cole & Andreas Gomoll & Seung-Mi Lee & Hangseok Choi & Chul-Won Ha & Hong Chul Lim & Myung Ku Kim & Gwi-Yeom Ha & Dong-Churl Suh, 2023. "Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 141-152, January.
    226. Rashidah T Uthman & Andrew J Sutton & Louise J Jackson & Olalekan A Uthman, 2018. "Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-15, January.
    227. Devin Incerti & Jeffrey R. Curtis & Jason Shafrin & Darius N. Lakdawalla & Jeroen P. Jansen, 2019. "A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 37(6), pages 829-843, June.
    228. Magnus Zingmark & Ingeborg Nilsson & Fredrik Norström & Klas Göran Sahlén & Lars Lindholm, 2017. "Cost effectiveness of an intervention focused on reducing bathing disability," European Journal of Ageing, Springer, vol. 14(3), pages 233-241, September.
    229. Judith Dams & Bernhard Bornschein & Jens Reese & Annette Conrads-Frank & Wolfgang Oertel & Uwe Siebert & Richard Dodel, 2011. "Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease," PharmacoEconomics, Springer, vol. 29(12), pages 1025-1049, December.
    230. Neily Zakiyah & Antoinette D I van Asselt & Frank Roijmans & Maarten J Postma, 2016. "Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-19, December.
    231. David Lee & Dominic Muston & Alison Sweet & Chris Cunningham & Andrew Slater & Kevin Lock, 2010. "Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60–69 years," Applied Health Economics and Health Policy, Springer, vol. 8(3), pages 141-154, May.
    232. Jill Bindels & Bram Ramaekers & Isaac Ramos & Leyla Mohseninejad & Saskia Knies & Janneke Grutters & Maarten Postma & Maiwenn Al & Talitha Feenstra & Manuela Joore, 2016. "Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives," PharmacoEconomics, Springer, vol. 34(3), pages 315-322, March.
    233. Deidda, Manuela & Geue, Claudia & Kreif, Noemi & Dundas, Ruth & McIntosh, Emma, 2019. "A framework for conducting economic evaluations alongside natural experiments," Social Science & Medicine, Elsevier, vol. 220(C), pages 353-361.
    234. Dixon, Padraig & Harrison, Sean & Hollingworth, William & Davies, Neil M. & Davey Smith, George, 2022. "Estimating the causal effect of liability to disease on healthcare costs using Mendelian Randomization," Economics & Human Biology, Elsevier, vol. 46(C).
    235. Gemma E. Shields & Mark Wilberforce & Paul Clarkson & Tracey Farragher & Arpana Verma & Linda M. Davies, 2022. "Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency," PharmacoEconomics, Springer, vol. 40(2), pages 149-156, February.
    236. Koen Degeling & Martin Vu & Hendrik Koffijberg & Hui-Li Wong & Miriam Koopman & Peter Gibbs & Maarten IJzerman, 2020. "Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review," PharmacoEconomics, Springer, vol. 38(7), pages 683-713, July.
    237. Alec Morton & Amanda I. Adler & David Bell & Andrew Briggs & Werner Brouwer & Karl Claxton & Neil Craig & Alastair Fischer & Peter McGregor & Pieter van Baal, 2016. "Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 933-938, August.
    238. Kathryn Coyle & Doug Coyle & Julie Blouin & Karen Lee & Mohammed F. Jabr & Khai Tran & Lisa Mielniczuk & John Swiston & Mike Innes, 2016. "Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study," PharmacoEconomics, Springer, vol. 34(5), pages 509-520, May.
    239. Mathilda L. Bongers & Dirk de Ruysscher & Cary Oberije & Philippe Lambin & Carin A. Uyl–de Groot & V. M. H. Coupé, 2016. "Multistate Statistical Modeling," Medical Decision Making, , vol. 36(1), pages 86-100, January.
    240. Jose Robles-Zurita, 2023. "Reducing the basic reproduction number of COVID-19: a model simulation focused on QALYs, hospitalisation, productivity costs and optimal (soft) lockdown," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(4), pages 647-659, June.
    241. David Glynn & John Giardina & Julia Hatamyar & Ankur Pandya & Marta Soares & Noemi Kreif, 2024. "Integrating decision modeling and machine learning to inform treatment stratification," Health Economics, John Wiley & Sons, Ltd., vol. 33(8), pages 1772-1792, August.
    242. Caroline S Clarke & Rachael M Hunter & Ian Shemilt & Victoria Serra-Sastre, 2017. "Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-19, March.
    243. Billingsley Kaambwa & Julie Ratcliffe, 2018. "Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People’s Quality of Life Brief Questionnaire (OPQoL-Brief) Scores," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(1), pages 39-54, February.
    244. Peter C. Smith & Andrew D. Street, 2013. "On The Uses Of Routine Patient‐Reported Health Outcome Data," Health Economics, John Wiley & Sons, Ltd., vol. 22(2), pages 119-131, February.
    245. Marta O. Soares & Jo C. Dumville & Rebecca L. Ashby & Cynthia P. Iglesias & Laura Bojke & Una Adderley & Elizabeth McGinnis & Nikki Stubbs & David J. Torgerson & Karl Claxton & Nicky Cullum, 2013. "Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse," Medical Decision Making, , vol. 33(3), pages 415-436, April.
    246. Ray Gani & Gavin Giovannoni & David Bates & Belinda Kemball & Steve Hughes & John Kerrigan, 2008. "Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK," PharmacoEconomics, Springer, vol. 26(7), pages 617-627, July.
    247. Graeme Ball & Mitch Levine & Lehana Thabane & Jean-Eric Tarride, 2021. "Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology," PharmacoEconomics - Open, Springer, vol. 5(3), pages 397-410, September.
    248. Helen Bell Gorrod & Ben Kearns & John Stevens & Praveen Thokala & Alexander Labeit & Nicholas Latimer & David Tyas & Ahmed Sowdani, 2019. "A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement," Medical Decision Making, , vol. 39(8), pages 899-909, November.
    249. Stephen G. Pauker, 2013. "Probability Distributions," Medical Decision Making, , vol. 33(2), pages 133-135, February.
    250. C. Elizabeth McCarron & Eleanor M. Pullenayegum & Lehana Thabane & Ron Goeree & Jean-Eric Tarride, 2013. "The Impact of Using Informative Priors in a Bayesian Cost-Effectiveness Analysis," Medical Decision Making, , vol. 33(3), pages 437-450, April.
    251. Edward Wilson, 2015. "A Practical Guide to Value of Information Analysis," PharmacoEconomics, Springer, vol. 33(2), pages 105-121, February.
    252. Mylene Lagarde & John Cairns, 2012. "Modelling human resources policies with Markov models: an illustration with the South African nursing labour market," Health Care Management Science, Springer, vol. 15(3), pages 270-282, September.
    253. Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton, 2012. "Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode," PharmacoEconomics, Springer, vol. 30(6), pages 513-530, June.
    254. Erik J. Dasbach & Elamin H. Elbasha, 2017. "Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview," PharmacoEconomics, Springer, vol. 35(7), pages 673-683, July.
    255. Dmitrij Achelrod & Tom Stargardt, 2014. "Cost-Utility Analysis Comparing Heavy-Weight and Light-Weight Mesh in Laparoscopic Surgery for Unilateral Inguinal Hernias," Applied Health Economics and Health Policy, Springer, vol. 12(2), pages 151-163, April.
    256. Massimo Bilancia & Giuseppe Pasculli & Danilo Di Bona, 2020. "A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-33, May.
    257. Teresa Cardoso & Mónica Oliveira & Ana Barbosa-Póvoa & Stefan Nickel, 2012. "Modeling the demand for long-term care services under uncertain information," Health Care Management Science, Springer, vol. 15(4), pages 385-412, December.
    258. Anna Heath & Mark Strong & David Glynn & Natalia Kunst & Nicky J. Welton & Jeremy D. Goldhaber-Fiebert, 2022. "Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial," Medical Decision Making, , vol. 42(2), pages 143-155, February.
    259. Yanara Marks & Jeffrey S. Hoch & Anna Heath & Petros Pechlivanoglou, 2024. "Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results," PharmacoEconomics, Springer, vol. 42(7), pages 783-795, July.
    260. Simon Dickinson & Huey Yi Chong & Toby Leslie & Mark Rowland & Kristian Schultz Hansen & Dwayne Boyers, 2021. "Cost-effectiveness of point-of-care C-Reactive Protein test compared to current clinical practice as an intervention to improve antibiotic prescription in malaria-negative patients in Afghanistan," PLOS ONE, Public Library of Science, vol. 16(11), pages 1-20, November.
    261. José Rodríguez Barrios & Ferran Pérez Alcántara & Carlos Crespo Palomo & Paloma González García & Enrique Antón De Las Heras & Max Brosa Riestra, 2012. "The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(6), pages 723-740, December.
    262. Rudolf T. Hoogenveen & Hendriek C. Boshuizen & Peter M. Engelfriet & Pieter H. M. van Baal, 2017. "You Only Die Once: Accounting for Multi-Attributable Mortality Risks in Multi-Disease Models for Health-Economic Analyses," Medical Decision Making, , vol. 37(4), pages 403-414, May.
    263. Alison Bray & Emmanouela Kampouraki & Amanda Winter & Aaron Jesuthasan & Ben Messer & Sara Graziadio, 2020. "High Variability in Sepsis Guidelines in UK: Why Does It Matter?," IJERPH, MDPI, vol. 17(6), pages 1-18, March.
    264. David D. Kim & Gregory F. Guzauskas & Caroline S. Bennette & Anirban Basu & David L. Veenstra & Scott D. Ramsey & Josh J. Carlson, 2020. "Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment," PharmacoEconomics, Springer, vol. 38(2), pages 171-179, February.
    265. Koen Degeling & Maarten J. IJzerman & Mariel S. Lavieri & Mark Strong & Hendrik Koffijberg, 2020. "Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process," Medical Decision Making, , vol. 40(3), pages 348-363, April.
    266. Susan Griffin & Nicky J. Welton & Karl Claxton, 2010. "Exploring the Research Decision Space: The Expected Value of Information for Sequential Research Designs," Medical Decision Making, , vol. 30(2), pages 155-162, March.
    267. Michelle Tew & Philip Clarke & Karin Thursky & Kim Dalziel, 2019. "Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients," PharmacoEconomics, Springer, vol. 37(7), pages 931-941, July.
    268. Ian Wadsworth & Lisa V. Hampson & Thomas Jaki & Graeme J. Sills & Anthony G. Marson & Richard Appleton, 2020. "A quantitative framework to inform extrapolation decisions in children," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 183(2), pages 515-534, February.
    269. Eric Kaun Santos Silva & June Alisson Westarb Cruz & Maria Alexandra Viegas Cortez Cunha & Thyago Proença Moraes & Sandro Marques & Eduardo Damião Silva, 2021. "Cost-effectiveness in health: consolidated research and contemporary challenges," Palgrave Communications, Palgrave Macmillan, vol. 8(1), pages 1-10, December.
    270. Paolo Candio & Koen B. Pouwels & David Meads & Andrew J. Hill & Laura Bojke & Claire Williams, 2022. "Modelling decay in effectiveness for evaluation of behaviour change interventions: a tutorial for public health economists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(7), pages 1151-1157, September.
    271. Chris Cameron & Emmanuel Ewara & Florence R. Wilson & Abhishek Varu & Peter Dyrda & Brian Hutton & Michael Ingham, 2017. "The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis," Medical Decision Making, , vol. 37(8), pages 894-904, November.
    272. Bart M. Heeg & Ben A. van Hout, 2014. "Assessing Uncertainties Surrounding Combined Endpoints for Use in Economic Models," Medical Decision Making, , vol. 34(3), pages 300-310, April.
    273. Álvaro Hidalgo-Vega & Juan Ramos-Goñi & Renata Villoro, 2014. "Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 917-925, December.
    274. Howard Thom, 2022. "Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 447-449, May.
    275. David Glynn & Georgios Nikolaidis & Dina Jankovic & Nicky J. Welton, 2023. "Constructing Relative Effect Priors for Research Prioritization and Trial Design: A Meta-epidemiological Analysis," Medical Decision Making, , vol. 43(5), pages 553-563, July.
    276. Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson, 2017. "Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)," PharmacoEconomics, Springer, vol. 35(1), pages 111-124, January.
    277. Tobias Sydendal Grand & Hasan Basarir & Louise J Jackson, 2019. "The cost-effectiveness of oral contraceptives compared to ‘no hormonal treatment’ for endometriosis-related pain: An economic evaluation," PLOS ONE, Public Library of Science, vol. 14(1), pages 1-16, January.
    278. Patricia J. Rodriguez & Zachary J. Ward & Michael W. Long & S. Bryn Austin & Davene R. Wright, 2021. "Applied Methods for Estimating Transition Probabilities from Electronic Health Record Data," Medical Decision Making, , vol. 41(2), pages 143-152, February.
    279. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2020. "Modelling the impact of physical activity on public health: A review and critique," Health Policy, Elsevier, vol. 124(10), pages 1155-1164.
    280. Brandon S Walker & Richard E Nelson & Brian R Jackson & David G Grenache & Edward R Ashwood & Robert L Schmidt, 2015. "A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-20, July.
    281. Intira Jeannie Collins & John Cairns & Nicole Ngo-Giang-Huong & Wasna Sirirungsi & Pranee Leechanachai & Sophie Le Coeur & Tanawan Samleerat & Nareerat Kamonpakorn & Jutarat Mekmullica & Gonzague Jour, 2014. "Cost-Effectiveness of Early Infant HIV Diagnosis of HIV-Exposed Infants and Immediate Antiretroviral Therapy in HIV-Infected Children under 24 Months in Thailand," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    282. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    283. Francis Fatoye & Carol Haigh, 2016. "The cost‐effectiveness of semi‐rigid ankle brace to facilitate return to work following first‐time acute ankle sprains," Journal of Clinical Nursing, John Wiley & Sons, vol. 25(9-10), pages 1435-1443, May.
    284. Ji-Hee Youn & Matt D. Stevenson & Praveen Thokala & Katherine Payne & Maria Goddard, 2019. "Modeling the Economic Impact of Interventions for Older Populations with Multimorbidity: A Method of Linking Multiple Single-Disease Models," Medical Decision Making, , vol. 39(7), pages 842-856, October.
    285. Florian Hofer & Dmitrij Achelrod & Tom Stargardt, 2016. "Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 691-701, December.
    286. Thi-Phuong-Lan Nguyen & E Pamela Wright & Thanh-Trung Nguyen & C C M Schuiling-Veninga & M J Bijlsma & Thi-Bach-Yen Nguyen & M J Postma, 2016. "Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam," PLOS ONE, Public Library of Science, vol. 11(5), pages 1-17, May.
    287. Carmen Selva-Sevilla & F Dámaso Fernández-Ginés & Manuel Cortiñas-Sáenz & Manuel Gerónimo-Pardo, 2021. "Cost-effectiveness analysis of domiciliary topical sevoflurane for painful leg ulcers," PLOS ONE, Public Library of Science, vol. 16(9), pages 1-18, September.
    288. Brown, Vicki & Diomedi, Belen Zapata & Moodie, Marj & Veerman, J. Lennert & Carter, Rob, 2016. "A systematic review of economic analyses of active transport interventions that include physical activity benefits," Transport Policy, Elsevier, vol. 45(C), pages 190-208.
    289. Amr Makady & Ard Veelen & Páll Jonsson & Owen Moseley & Anne D’Andon & Anthonius Boer & Hans Hillege & Olaf Klungel & Wim Goettsch, 2018. "Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies," PharmacoEconomics, Springer, vol. 36(3), pages 359-368, March.
    290. Ashley Layer & Emma McManus & N. J. Levell, 2020. "A Systematic Review of Model-Based Economic Evaluations of Treatments for Venous Leg Ulcers," PharmacoEconomics - Open, Springer, vol. 4(2), pages 211-222, June.
    291. Wei Yang & Heather Gage & Daniel Jackson & Monique Raats, 2018. "The effectiveness and cost-effectiveness of plant sterol or stanol-enriched functional foods as a primary prevention strategy for people with cardiovascular disease risk in England: a modeling study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(7), pages 909-922, September.
    292. Sun-Young Kim & Sue Goldie, 2008. "Cost-Effectiveness Analyses of Vaccination Programmes," PharmacoEconomics, Springer, vol. 26(3), pages 191-215, March.
    293. A C Bouman & A J ten Cate-Hoek & B L T Ramaekers & M A Joore, 2015. "Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
    294. Nicholas R. Latimer, 2013. "Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data," Medical Decision Making, , vol. 33(6), pages 743-754, August.
    295. Björn Stollenwerk & Stephanie Stock & Uwe Siebert & Karl W. Lauterbach & Rolf Holle, 2010. "Uncertainty Assessment of Input Parameters for Economic Evaluation: Gauss’s Error Propagation, an Alternative to Established Methods," Medical Decision Making, , vol. 30(3), pages 304-313, May.
    296. Josh J. Carlson & Kangho Suh & Panos Orfanos & William Wong, 2018. "Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer," PharmacoEconomics, Springer, vol. 36(4), pages 495-504, April.
    297. Leyla Mohseninejad & Talitha Feenstra & Henriëtte Horst & Hèlen Woutersen-Koch & Erik Buskens, 2013. "Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 947-957, December.
    298. Björn Stollenwerk & Afschin Gandjour & Markus Lüngen & Uwe Siebert, 2013. "Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 1035-1048, December.
    299. F. Tomini & F. Prinzen & A. D. I. Asselt, 2016. "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1159-1172, December.
    300. Merlijn W J van Leent & Jelena Stevanović & Frank G Jansman & Maarten J Beinema & Jacobus R B J Brouwers & Maarten J Postma, 2015. "Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-15, August.
    301. Ulla K. Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.
    302. Pepijn Vemer & Lucas M. A. Goossens & Maureen P. M. H. Rutten-van Mölken, 2014. "Not Simply More of the Same," Medical Decision Making, , vol. 34(8), pages 1048-1058, November.
    303. Nicholas R. Latimer & Keith R. Abrams & Paul C. Lambert & Michael J. Crowther & Allan J. Wailoo & James P. Morden & Ron L. Akehurst & Michael J. Campbell, 2014. "Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context," Medical Decision Making, , vol. 34(3), pages 387-402, April.
    304. Josh J. Carlson & Rahber Thariani & Josh Roth & Julie Gralow & N. Lynn Henry & Laura Esmail & Pat Deverka & Scott D. Ramsey & Laurence Baker & David L. Veenstra, 2013. "Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics," Medical Decision Making, , vol. 33(4), pages 463-471, May.
    305. Thananan Rattanachotphanit & Chulaporn Limwattananon & Onanong Waleekhachonloet & Phumtham Limwattananon & Kittisak Sawanyawisuth, 2019. "Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding," PharmacoEconomics, Springer, vol. 37(2), pages 279-289, February.
    306. Paul Tappenden & James Chilcott, 2014. "Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models," PharmacoEconomics, Springer, vol. 32(10), pages 967-979, October.
    307. Dong-Jin Kim & Ho-Sook Kim & Minkyung Oh & Eun-Young Kim & Jae-Gook Shin, 2017. "Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System," Applied Health Economics and Health Policy, Springer, vol. 15(5), pages 657-667, October.
    308. Astrid Ledgaard Holm & Lennert Veerman & Linda Cobiac & Ola Ekholm & Finn Diderichsen, 2014. "Cost-Effectiveness of Preventive Interventions to Reduce Alcohol Consumption in Denmark," PLOS ONE, Public Library of Science, vol. 9(2), pages 1-9, February.
    309. Edna Keeney & Dalia Dawoud & Sofia Dias, 2018. "Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities," PharmacoEconomics, Springer, vol. 36(5), pages 523-532, May.
    310. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2021. "Taking a local government perspective for economic evaluation of a population-level programme to promote exercise," Health Policy, Elsevier, vol. 125(5), pages 651-657.
    311. Emma McManus & Tracey Sach & Nick Levell, 2018. "The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal," PharmacoEconomics, Springer, vol. 36(1), pages 51-66, January.
    312. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2018. "Efficient Monte Carlo Estimation of the Expected Value of Sample Information Using Moment Matching," Medical Decision Making, , vol. 38(2), pages 163-173, February.
    313. Osvaldo Ulises Garay & Marie Libérée Nishimwe & Marwân-al-Qays Bousmah & Asmaa Janah & Pierre-Marie Girard & Geneviève Chêne & Laetitia Moinot & Luis Sagaon-Teyssier & Jean-Luc Meynard & Bruno Spire &, 2019. "Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)," PharmacoEconomics - Open, Springer, vol. 3(4), pages 505-515, December.
    314. Baudouin Standaert & Ilse Van Vlaenderen & Laure-Anne Van Bellinghen & Sandra Talbird & Katherine Hicks & Justin Carrico & Philip O. Buck, 2020. "Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project," Applied Health Economics and Health Policy, Springer, vol. 18(4), pages 519-531, August.
    315. Björn Stollenwerk & Stefan K. Lhachimi & Andrew Briggs & Elisabeth Fenwick & Jaime J. Caro & Uwe Siebert & Marion Danner & Andreas Gerber‐Grote, 2015. "Communicating the Parameter Uncertainty in the IQWiG Efficiency Frontier to Decision‐Makers," Health Economics, John Wiley & Sons, Ltd., vol. 24(4), pages 481-490, April.
    316. Marwân-Al-Qays Bousmah & Marie Libérée Nishimwe & Tamara Tovar-Sanchez & Martial Lantche Wandji & Mireille Mpoudi-Etame & Gwenaëlle Maradan & Pierrette Omgba Bassega & Marie Varloteaux & Alice Montoyo, 2021. "Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)," Post-Print hal-03174666, HAL.
    317. Fredrik Salvesen Haukaas & Trude Margrete Arnesen & Brita Askeland Winje & Eline Aas, 2017. "Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(4), pages 405-415, May.
    318. Zhi Qu & Shanshan Zhang & Christian Krauth & Xuenan Liu, 2019. "A systematic review of decision analytic modeling techniques for the economic evaluation of dental caries interventions," PLOS ONE, Public Library of Science, vol. 14(5), pages 1-17, May.
    319. Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis, 2012. "Clopidogrel versus Aspirin in Patients with Atherothrombosis," Applied Health Economics and Health Policy, Springer, vol. 10(5), pages 331-342, September.
    320. Jeremy D. Goldhaber-Fiebert & Hawre J. Jalal, 2016. "Some Health States Are Better Than Others," Medical Decision Making, , vol. 36(8), pages 927-940, November.
    321. Colin Green & David A Richards & Jacqueline J Hill & Linda Gask & Karina Lovell & Carolyn Chew-Graham & Peter Bower & John Cape & Stephen Pilling & Ricardo Araya & David Kessler & J Martin Bland & Sim, 2014. "Cost-Effectiveness of Collaborative Care for Depression in UK Primary Care: Economic Evaluation of a Randomised Controlled Trial (CADET)," PLOS ONE, Public Library of Science, vol. 9(8), pages 1-12, August.
    322. Hardik Goswami & Adnan Alsumali & Yiling Jiang & Matthias Schindler & Elizabeth R. Duke & Joshua Cohen & Andrew Briggs & Amy Puenpatom, 2022. "Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US," PharmacoEconomics, Springer, vol. 40(7), pages 699-714, July.
    323. An Tran-Duy & Annelies Boonen & Wietske Kievit & Piet Riel & Mart Laar & Johan Severens, 2014. "Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 32(10), pages 1015-1028, October.
    324. Francesca Pierotti & Ilaria Palla & Maarten Treur & Lara Pippo & Giuseppe Turchetti, 2015. "Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-18, October.
    325. J. Jaime Caro & Andrew H. Briggs & Uwe Siebert & Karen M. Kuntz, 2012. "Modeling Good Research Practices—Overview," Medical Decision Making, , vol. 32(5), pages 667-677, September.
    326. Ifigeneia Mavranezouli & Evan Mayo-Wilson & Sofia Dias & Kayleigh Kew & David M Clark & A E Ades & Stephen Pilling, 2015. "The Cost Effectiveness of Psychological and Pharmacological Interventions for Social Anxiety Disorder: A Model-Based Economic Analysis," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-21, October.
    327. Beate Jahn & Christina Kurzthaler & Jagpreet Chhatwal & Elamin H. Elbasha & Annette Conrads-Frank & Ursula Rochau & Gaby Sroczynski & Christoph Urach & Marvin Bundo & Niki Popper & Uwe Siebert, 2019. "Alternative Conversion Methods for Transition Probabilities in State-Transition Models: Validity and Impact on Comparative Effectiveness and Cost-Effectiveness," Medical Decision Making, , vol. 39(5), pages 509-522, July.
    328. Sampson, Christopher & James, Marilyn & Huband, Nick & Geelan, Steve & McMurran, Mary, 2013. "Cost implications of treatment non-completion in a forensic personality disorder service," MPRA Paper 48757, University Library of Munich, Germany.
    329. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    330. Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.
    331. Matthew I Smith & Simon de Lusignan & David Mullett & Ana Correa & Jermaine Tickner & Simon Jones, 2016. "Predicting Falls and When to Intervene in Older People: A Multilevel Logistical Regression Model and Cost Analysis," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-13, July.
    332. Douwe Postmus & Tommi Tervonen & Gert Valkenhoef & Hans Hillege & Erik Buskens, 2014. "A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(7), pages 709-716, September.
    333. Amarzaya Jadambaa & Nicholas Graves & Donna Cross & Rosana Pacella & Hannah J. Thomas & James G. Scott & Qinglu Cheng & David Brain, 2022. "Economic Evaluation of an Intervention Designed to Reduce Bullying in Australian Schools," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 79-89, January.
    334. Gerardus Frederix & Hossein Haji Ali Afzali & Erik Dasbach & Robyn Ward, 2015. "Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions," PharmacoEconomics, Springer, vol. 33(8), pages 777-781, August.
    335. Carlo Lazzaro & Cecile van Steen & Florent Aptel & Cedric Schweitzer & Luigi Angelillo, 2022. "Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in Fr," Post-Print hal-03696350, HAL.
    336. Lieven Annemans & Mélanie Brignone & Sylvain Druais & Ann Pauw & Aline Gauthier & Koen Demyttenaere, 2014. "Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium," PharmacoEconomics, Springer, vol. 32(5), pages 479-493, May.
    337. McDaid, David & Park, A-La, 2021. "Modelling the economic impact of reducing loneliness in community dwelling older people in England," LSE Research Online Documents on Economics 108594, London School of Economics and Political Science, LSE Library.
    338. Jagpreet Chhatwal & Suren Jayasuriya & Elamin H. Elbasha, 2016. "Changing Cycle Lengths in State-Transition Models," Medical Decision Making, , vol. 36(8), pages 952-964, November.
    339. Nichola R. Naylor & Jack Williams & Nathan Green & Felicity Lamrock & Andrew Briggs, 2023. "Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses," PharmacoEconomics, Springer, vol. 41(1), pages 21-32, January.
    340. Savvas S. Ioannou & Yiola Marcou & Eleni Kakouri & Michael A. Talias, 2020. "Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective," IJERPH, MDPI, vol. 17(12), pages 1-20, June.
    341. Michelle M.A. Kip & Maarten J. IJzerman & Martin Henriksson & Tracy Merlin & Milton C. Weinstein & Charles E. Phelps & Ron Kusters & Hendrik Koffijberg, 2018. "Toward Alignment in the Reporting of Economic Evaluations of Diagnostic Tests and Biomarkers: The AGREEDT Checklist," Medical Decision Making, , vol. 38(7), pages 778-788, October.
    342. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
    343. Neily Zakiyah & A. D. I. Asselt & D. Setiawan & Q. Cao & F. Roijmans & M. J. Postma, 2019. "Cost-Effectiveness of Scaling Up Modern Family Planning Interventions in Low- and Middle-Income Countries: An Economic Modeling Analysis in Indonesia and Uganda," Applied Health Economics and Health Policy, Springer, vol. 17(1), pages 65-76, February.
    344. Ning Kam & Kanila Perera & Ella Zomer & Danny Liew & Zanfina Ademi, 2020. "Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 38(9), pages 1007-1020, September.
    345. Simone A. Huygens & Isaac Corro Ramos & Carlijn V. C. Bouten & Jolanda Kluin & Shih Ting Chiu & Gary L. Grunkemeier & Johanna J. M. Takkenberg & Maureen P. M. H. Rutten-van Mölken, 2020. "Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 557-572, June.
    346. Tan Chongqing & Peng Liubao & Zeng Xiaohui & Li Jianhe & Wan Xiaomin & Chen Gannong & Wang Siying & Ouyang Lihui & Zhao Ziying, 2014. "Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline," PharmacoEconomics, Springer, vol. 32(3), pages 235-243, March.
    347. Steffen Flessa & Dominik Dietz & Elisabete Weiderpass, 2016. "Health policy support under extreme uncertainty: the case of cervical cancer in Cambodia," EURO Journal on Decision Processes, Springer;EURO - The Association of European Operational Research Societies, vol. 4(3), pages 183-218, November.
    348. Antonio Blázquez-Pérez & Ramón San Miguel & Javier Mar, 2013. "Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients," PharmacoEconomics, Springer, vol. 31(10), pages 919-931, October.
    349. Emanuel Krebs & Jeong E. Min & Elizabeth Evans & Libo Li & Lei Liu & David Huang & Darren Urada & Thomas Kerr & Yih-Ing Hser & Bohdan Nosyk, 2017. "Estimating State Transitions for Opioid Use Disorders," Medical Decision Making, , vol. 37(5), pages 483-497, July.
    350. Xiao Zang & Emanuel Krebs & Linwei Wang & Brandon D. L. Marshall & Reuben Granich & Bruce R. Schackman & Julio S. G. Montaner & Bohdan Nosyk, 2019. "Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review," PharmacoEconomics, Springer, vol. 37(10), pages 1219-1239, October.
    351. Nikki H. Yang & Madan Dharmar & Byung-Kwang Yoo & J. Paul Leigh & Nathan Kuppermann & Patrick S. Romano & Thomas S. Nesbitt & James P. Marcin, 2015. "Economic Evaluation of Pediatric Telemedicine Consultations to Rural Emergency Departments," Medical Decision Making, , vol. 35(6), pages 773-783, August.
    352. Laura Burgers & William Redekop & Johan Severens, 2014. "Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease," PharmacoEconomics, Springer, vol. 32(7), pages 627-637, July.
    353. Joke Bilcke & Philippe Beutels, 2009. "Reviewing the Cost Effectiveness of Rotavirus Vaccination," PharmacoEconomics, Springer, vol. 27(4), pages 281-297, April.
    354. Edward C. F. Wilson, 2021. "Methodological Note: Reporting Deterministic versus Probabilistic Results of Markov, Partitioned Survival and Other Non-Linear Models," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 789-795, November.
    355. Christine Mpundu-Kaambwa & Gang Chen & Remo Russo & Katherine Stevens & Karin Dam Petersen & Julie Ratcliffe, 2017. "Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15," PharmacoEconomics, Springer, vol. 35(4), pages 453-467, April.
    356. Simone Rivolo & Manuela Di Fusco & Carlos Polanco & Amiee Kang & Devender Dhanda & Mirko Savone & Aristeidis Skandamis & Thitima Kongnakorn & Javier Soto, 2021. "Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention," PLOS ONE, Public Library of Science, vol. 16(11), pages 1-17, November.
    357. Christopher H. Jackson & Laura Bojke & Simon G. Thompson & Karl Claxton & Linda D. Sharples, 2011. "A Framework for Addressing Structural Uncertainty in Decision Models," Medical Decision Making, , vol. 31(4), pages 662-674, July.
    358. Samuel N. Frempong & Clare Davenport & Andrew J. Sutton & Justice Nonvignon & Pelham Barton, 2018. "Integrating Qualitative Techniques in Model Development: A Case Study Using the Framework Approach," Applied Health Economics and Health Policy, Springer, vol. 16(5), pages 723-733, October.
    359. Nathan Bray & Paul Burns & Alice Jones & Eira Winrow & Rhiannon Tudor Edwards, 2017. "Costs and outcomes of improving population health through better social housing: a cohort study and economic analysis," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 62(9), pages 1039-1050, December.
    360. Ben Kearns & Roberta Ara & Allan Wailoo & Andrea Manca & Monica Alava & Keith Abrams & Mike Campbell, 2013. "Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations," PharmacoEconomics, Springer, vol. 31(8), pages 643-652, August.
    361. Wren, Maev-Ann & Gillespie, Paddy & Smith, Samantha & Kearns, Karen & Crichton,Siobhan & Parkin, David & Hickey, Anne & Horgan, Frances & Wiley, Miriam, 2014. "Towards Earlier Discharge, Better Outcomes, Lower Cost: Stroke Rehabilitation in Ireland," Research Series, Economic and Social Research Institute (ESRI), number BKMNEXT277.
    362. Michael J Sorich & Michael Coory & Brita A K Pekarsky, 2013. "Indirect Estimation of the Comparative Treatment Effect in Pharmacogenomic Subgroups," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-6, August.
    363. Yumi Asukai & Michael Baldwin & Tiago Fonseca & Alastair Gray & Laura Mungapen & David Price, 2013. "Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling," PharmacoEconomics, Springer, vol. 31(2), pages 151-161, February.
    364. Maximilian Hatz & Reiner Leidl & Nichola Yates & Björn Stollenwerk, 2014. "A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention," PharmacoEconomics, Springer, vol. 32(4), pages 377-393, April.
    365. Rajan Sharma & Yuanyuan Gu & Teresa Y. C. Ching & Vivienne Marnane & Bonny Parkinson, 2019. "Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique," Applied Health Economics and Health Policy, Springer, vol. 17(3), pages 331-357, June.
    366. Richard E Nelson & Makoto Jones & Molly Leecaster & Matthew H Samore & William Ray & Angela Huttner & Benedikt Huttner & Karim Khader & Vanessa W Stevens & Dale Gerding & Marin L Schweizer & Michael A, 2016. "An Economic Analysis of Strategies to Control Clostridium Difficile Transmission and Infection Using an Agent-Based Simulation Model," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-16, March.
    367. Lazaros Andronis & Pelham M. Barton, 2016. "Adjusting Estimates of the Expected Value of Information for Implementation," Medical Decision Making, , vol. 36(3), pages 296-307, April.
    368. Steven Alberts & Tiffany Yu & Robert Behrens & Lindsay Renfro & Geetika Srivastava & Gamini Soori & Shaker Dakhil & Rex Mowat & John Kuebler & George Kim & Miroslaw Mazurczak & John Hornberger, 2014. "Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer," PharmacoEconomics, Springer, vol. 32(12), pages 1231-1243, December.
    369. Hill, Sarah R. & Vale, Luke & Hunter, David & Henderson, Emily & Oluboyede, Yemi, 2017. "Economic evaluations of alcohol prevention interventions: Is the evidence sufficient? A review of methodological challenges," Health Policy, Elsevier, vol. 121(12), pages 1249-1262.
    370. A Morton & L D Phillips, 2009. "Fifty years of probabilistic decision analysis: a view from the UK," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 60(1), pages 33-40, May.
    371. Tristan M Snowsill & Neil A J Ryan & Emma J Crosbie & Ian M Frayling & D Gareth Evans & Chris J Hyde, 2019. "Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-18, August.
    372. Haitham Tuffaha & Claire Rothery & Natalia Kunst & Chris Jackson & Mark Strong & Stephen Birch, 2021. "A Review of Web-Based Tools for Value-of-Information Analysis," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 645-651, September.
    373. James Shearer & Colin Green & Carl Counsell & John Zajicek, 2011. "The use of decision-analytic models in Parkinson’s disease," Applied Health Economics and Health Policy, Springer, vol. 9(4), pages 243-258, July.
    374. Tom L. Drake & Yoel Lubell, 2017. "Malaria and Economic Evaluation Methods: Challenges and Opportunities," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 291-297, June.
    375. WH Rogowski, 2013. "An Economic Theory Of The Fourth Hurdle," Health Economics, John Wiley & Sons, Ltd., vol. 22(5), pages 600-610, May.
    376. Adnan Alsumali & Laurence M Djatche & Andrew Briggs & Rongzhe Liu & Ibrahim Diakite & Dipen Patel & Yufei Wang & Dominik Lautsch, 2021. "Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective," PharmacoEconomics, Springer, vol. 39(11), pages 1343-1354, November.
    377. Mikyung Kelly Seo & Mark Strong, 2021. "A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper," PharmacoEconomics, Springer, vol. 39(12), pages 1373-1381, December.
    378. Joseph F. Levy & Patrick D. Meek & Marjorie A. Rosenberg, 2015. "US-Based Drug Cost Parameter Estimation for Economic Evaluations," Medical Decision Making, , vol. 35(5), pages 622-632, July.

  2. Clive Pritchard;Martin Sculpher, 2000. "Productivity Costs: Principles and Practice in Economic Evaluation," Monograph 000464, Office of Health Economics.

    Cited by:

    1. Zhang, Wei & Bansback, Nick & Anis, Aslam H., 2011. "Measuring and valuing productivity loss due to poor health: A critical review," Social Science & Medicine, Elsevier, vol. 72(2), pages 185-192, January.
    2. Werner Brouwer & Samare Huls & Ayesha Sajjad & Tim Kanters & Leona Hakkaart-van Roijen & Job Exel, 2022. "In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era," PharmacoEconomics, Springer, vol. 40(1), pages 7-11, January.
    3. Marco Hafner & Erez Yerushalmi & Fredrik L. Andersson & Teodor Burtea, 2023. "Partially different? The importance of general equilibrium in health economic evaluations: An application to nocturia," Health Economics, John Wiley & Sons, Ltd., vol. 32(3), pages 654-674, March.
    4. Gravelle, Hugh & Schroyen, Fred, 2020. "Optimal hospital payment rules under rationing by waiting," Journal of Health Economics, Elsevier, vol. 70(C).
    5. Riewpaiboon, Arthorn & Riewpaiboon, Wachara & Ponsoongnern, Kanyarat & Van den Berg, Bernard, 2009. "Economic valuation of informal care in Asia: A case study of care for disabled stroke survivors in Thailand," Social Science & Medicine, Elsevier, vol. 69(4), pages 648-653, August.
    6. Krol, Marieke & Brouwer, Werner, 2015. "Unpaid work in health economic evaluations," Social Science & Medicine, Elsevier, vol. 144(C), pages 127-137.
    7. Brigitte Wolkinger & Willi Haas & Gabriel Bachner & Ulli Weisz & Karl W. Steininger & Hans-Peter Hutter & Jennifer Delcour & Robert Griebler & Bernhard Mittelbach & Philipp Maier & Raphael Reifeltsham, 2018. "Evaluating Health Co-Benefits of Climate Change Mitigation in Urban Mobility," IJERPH, MDPI, vol. 15(5), pages 1-27, April.
    8. Marieke Krol & Werner Brouwer, 2014. "How to Estimate Productivity Costs in Economic Evaluations," PharmacoEconomics, Springer, vol. 32(4), pages 335-344, April.
    9. Carmen Herrero & Juan D. Moreno‐Ternero, 2009. "Estimating production costs in the economic evaluation of health‐care programs," Health Economics, John Wiley & Sons, Ltd., vol. 18(1), pages 21-35, January.
    10. Hendramoorthy Maheswaran & Stavros Petrou & Danielle Cohen & Peter MacPherson & Felistas Kumwenda & David G Lalloo & Elizabeth L Corbett & Aileen Clarke, 2018. "Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: A prospective hospital cohort study in Malawi," PLOS ONE, Public Library of Science, vol. 13(3), pages 1-21, March.
    11. Mennini, Francesco Saverio & Gitto, Lara, 2022. "Approaches to Estimating Indirect Costs in Healthcare: Motivations for Choice," MPRA Paper 112129, University Library of Munich, Germany.
    12. Krol, Marieke & Brouwer, Werner B.F. & Severens, Johan L. & Kaper, Janneke & Evers, Silvia M.A.A., 2012. "Productivity cost calculations in health economic evaluations: Correcting for compensation mechanisms and multiplier effects," Social Science & Medicine, Elsevier, vol. 75(11), pages 1981-1988.
    13. Hanly, Paul & Ortega Ortega, Marta & Pearce, Alison & Soerjomataram, Isabelle & Sharp, Linda, 2020. "Advances in the methodological approach to friction period estimation: A European perspective," Social Science & Medicine, Elsevier, vol. 264(C).

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.